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ABSTRACT 
The renin-angiotensin-aldosterone system (RAAS) is one of the major 
regulators of blood pressure. The actions and generation of RA AS components at the 
tissue level are less well appreciated. This work was designed to investigate the 
vascular wall not only as a target of the RAAS, but also as one of its sources. 
Immunocytochemical and immunoblotting analysis revealed positive renin 
immunoreactivity in the cytoplasm of cultured bovine aortic endothelial cells. Two 
immunoreactive bands of molecular mass approximately 37,000 and 40,000 dalton 
were identified. In situ hybridization confirmed that renin mRNA was localized in the 
same cells. Reverse transcriptase-polymerase chain reaction (RT-PCR) using primers 
specific for human renin gave a clear single band with the predicted size for 
(pro)renin. These findings suggest that these vascular endothelial cells are a source of 
local synthesised renin. 
Conditioned medium from cultured bovine aortic endothelial cells (BAECCM) 
and rat aortic smooth muscle cells (RASMCCM) were shown to contain 
immunoreactive angiotensin II (Ang II) equivalent to 15.05 ± 4.67 pg/106 cells and 
1 1.16 ± 1.8 pg/ 106 cells, respectively. Tritiated thymidine incorporation into aortic 
smooth muscle cells (ASMC) was increased by Ang II and by BAECCM. In both 
cases, this stimulated proliferation was inhibited by the Ang II type I (AT, ) receptor 
selective antagonist, losartan. Although tritiated thymidine uptake by rat aortic 
smooth muscle cells (RASMC) was not significantly enhanced by RASMCCM, it was 
significantly decreased by losartan in the presence of RASMCCM or of serum-free 
medium. Assay of RASMC proliferation by cell counting showed that the number of 
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cells in the presence of Ang II (10'6M) were nearly twice that in control cultures after r 
2 days. These findings suggest that Ang II produced by ASMC locally may regulate 
ASMC growth in an autocrine or/and paracrine fashion, via the AT, receptor. 
RASMC was also shown to produce immunoreactive aldosterone. Ang II 
significantly enhanced aldosterone formation by RASMC. but not in the presence of 
losartan. Ang II stimulated 3H-thymidine uptake into RASMC was further enhanced 
by aldosterone, but inhibited by the aldosterone antagonist. spironolactone. and the 
3ß-hydroxysteroid-dehydogenase inhibitor trilostane. These results suggest that the 
presence of locally generated aldosterone is essential for the stimulatory effects of 
Ang II, acting via the AT, receptor. on RASMC proliferation. 
Amplified products corresponding to transcripts of the CYP 11 BI gene were 
obtained by RT-PCR on RNA extracted from RASMC, using primers chosen from 
homologous parts of the exon I and exon 2 regions of CYP IIBI and CYP II B2 
genes. Sequencing showed the presence of CYP 11 B1 transcript, but gave no evidence 
for CYP 11 B2 gene transcription. 
RT-PCR also gave a band corresponding to the 770 bp fragment from bases - 
486 (upstream) to + 284 (exon 2) bp of the CYP 1lB1 gene. Furthermore, the present 
experiments demonstrated the transcription of the sequences 183-480 bp upstream 
from the CYP 11 B1 gene, and the use of competitive RT-PCR showed this was 
regulated by Ang 11. Thus. cultured RASMC may be the site of Ang 11 regulated 
transcription of a longer fragment of the CYP 11 B1 gene than generally expected. 
Finally, use of immunofluorescence and immunoblotting demonstrated the 
presence of an apparent binding carrier for 18-OH-DOC in cultured RASMC similar 
to that found in the rat adrenal. 
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MAP Mitogen-activated protein 
mCi, µm Millicurie, microcurie 
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mRNA Messenger ribonucleic acid 
NBS New-born bovine serum 
NO Nitric oxide 
NPY Neuropeptide Y 
OD Optical density 
18-OH-DOC 18-hydroxydeoxycorticosterone 
PBS Phosphate buffered saline 
PBS-T Phosphate buffered saline-"Teen-20 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PGE2 Prostaglandin E2 
PGF2 Prostaglandin F2 
PG! 2 
Prostaglandin 12 
PKC Protein kinase C 
PLA2 Phospholipase A2 
PLC Phospholipase C 
PLD Phospholipase D 
RAAS Renin-angiotensin-aldosterone system 
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RNase Ribonuclease 
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RT Reverse transcription 
RT-PCR Reverse transcriptase polymerase chain 
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SAPK Stress-activated protein kinase 
SDS Sodium dodecyl sulphate 
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SUR Spontaneously hypertensive rats 
SMC Smooth muscle cell 
SMG Submandibular gland 
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StAR Steroidogenic acute regulatory 
STAT Signal transducers and activators of 
transcription 
TE Tris- Ethylenediaminetetraacetate 
TEMED N, N. N', N'-tetramethylethylenediamine 
TGF-ß Transforming growth factor-beta 
TNF Tumor necrosis factor 
t-PA Tissue plasminogen activator 
TRE Thyroid hormone responsive element 
UM Unconditioned medium 
VSMC Vascular smooth muscle cell 
WKR Wistar-Kyoto rats 
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1. Anatomic and functional characteristics of blood vessels 
1.1. Anatomy and histology 
Blood entering the aorta is distributed throughout the body by repeatedly 
branching systemic arteries (Figure I-1) (Rogers 1992). In man, the aorta runs at first 
superiorly from the left ventricle and ends in front of the body of 1 (the fourth 
lumbar vertebra) where it divides into the two common iliac arteries (Snell 1995). 
The normal arterial wall consists of endothelial cells, smooth muscle cells 
(SMCs) and extracellular matrix (ECM) that vary in relative amounts within the 
different layers of the vessel wall reviewed by Wight (1996). The concentric layers 
are: (1) the intima, which consists of the lining endothelial cells with a sparse 
subendothelial ECM enriched in proteoglycans and hyaluronic acid (11A), (2) the 
media, which is separated from the intima by a dense elastic membrane (internal 
elastic lamina), and is composed of spindle-shaped circularly arranged smooth muscle 
cells embedded in ECM containing elastic elements, collagen and proteoglycans; and 
(3) the adventitia, which is separated from the media by the external elastic lamina, 
and is composed of fibrillar collagen, fibroblasts, and vasa vasora that nourish the 
vascular wall (Figure I-1) (Kessel 1998a, Raines 2000). 
Arteries are classified into three types on the basis of size and the 
characteristics of the media. These are: (1) elastic arteries (diameter 1 cm in man), 
including the major arteries. pulmonary. and aorta and its major branches. which 
contain mainly elastic fibres in the media: (2) muscular arteries (diameter 2-10 mm in 
ii n), which include most of the named arteries, such as renal, coronary and cerebral 
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Figure 1-1. Diagrammatic representation of the 
malll components of the vascular wall. l-rom 
Contran ei a!. 1994. 
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arteries, that contain chiefly smooth muscle in the media; (3) small arteries (diameter 
0.1-2 mm in man) and arterioles (diameter 10-100µm in man) (Ross er al. 19-5). 
These are confer the main resistance to blood flow (Levick 2000). 
Each of the three types of arteries tends to be involved in specific disease 
processes and has its own pattern of pathological lesions. Thus arteriosclerosis is a 
disease largely of elastic and muscular arteries, whereas hypertension is associated 
with functional and structural changes in resistance vessels (Cotran et al. 1994. 
Rizzoni et a!. 2000). 
1.2. Morphology of endothelial cells (ECs) 
Typically ECs are 25-50 µrn long and 10-15 . tm wide, and are oriented 
parallel to the long axis of the blood vessel (Kessel 1998a). They uniquely contain 
Weibel-Palade bodies, 0.1 µm wide, 3 µm long membrane-bound structures that 
represent the storage organelle for von Willebrand's factor (vWF) (Kessel 1998a). 
This factor serves as a carrier for factor VIII and is involved in platelet adhesion to the 
subendothelial extracellular matrix (Kessel 1998a, Spadafora-lHerreira et al. 2000). 
1.3. The physiological functions of ECs 
ECs play numerous physiological roles including (Ross 1993. Toborek & 
Kaiser 1999, Sica 2000): (1) provision of a nonthrombogenic surface: (2) a 
permeability barrier through which there 
is exchange and active transport of 
substances into the artery wall: (3) maintenance of vascular tone (the active tension 
exerted by vascular smooth muscle in a segment of wall) (Levick 
2000) by release of 
small molecules such as prostacyclin (PGI2). and endothelin that modulate 27 
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vasodilation or vasoconstriction respectively. by affecting the active tension exerted 
by VSMC; (4) formation and secretion of growth-regulator molecules 0 Hancock 
1997); (5) maintenance of the basement membrane collagen and proteoglycans upon 
which the cells rest; (6) ability to modify (oxidize) lipoproteins as the` are transported 
into the artery wall. To fulfill these functions, the endothelial cell itself is a 
metabolically active endocrine, paracrine and autocrine organ (Pearson & Vanhoutte 
1993, Drexler 1997, Anderson 1999. Stehouwer 1999). In general. the normal 
endothelial cell functions in an inhibitory mode - inhibiting contraction, thrombosis. 
white cell adhesion, and vascular smooth muscle growth (Schlant & Alexander 1994. 
Contreras et al. 2000). 
Endothelial dysfunction may take various forms (Pober & Cotran 1990, 
Simionescu 1992, Contreras et al. 2000). The endothelial cell may lose its regulatory 
role in vasoconstriction, or become prothrombotic or less thrombolytic, begin to 
support leukocyte adherence. or stimulate rather than inhibit smooth muscle migration 
and proliferation (Schiart & Alexander 1994). 
1.4. Morphology and physiological functions of vascular smooth muscle cells 
(VSMCs) 
The SMC is a spindle-shaped cell whose orientation is helical in elastic 
arteries and concentric in muscular arteries. VSMCs range 
in length from 20 µm in 
K. 
the walls of small blood vessels to as much as 200 µm and wide 
5-8 µm (Schiant 
Alexander 1994. Kessel 1998a). The contractile function of SMCs is mediated 
by 
three classes of cytoplasmic filament (muscle proteins): actin 
(thin) filaments, myosin 
(thick) filaments and intermediate filaments (Gabella 1994). 
Actin and mYoosin 
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account for over 90% of muscle proteins. Associated with actin filaments are the 
dense bodies and dense bands. Dense bodies up to 0.35 pm wide and O. 6-1.2 pm lone 
are scattered through the sarcoplasm, without apparent pattern. Dens Kinds are 
structures associated with the cell membrane at the point where contractikk apparatus 
and cytoskeleton are anchored to the cell surface. They are about 30 nm thick and 0.2 
µm wide, their length exceeds I µm (Gabella 1994). 
During blood vessel development, immature smooth muscle cells are in a 
dynamic state of growth and differentiation characterized by proliferation and 
migration (Glukhova et al. 1991). In the adult vessel, they become quiescent and 
assume a fibroblast-like appearance. and become filled with contractile fibers 
(Gordon et al. 1990). The principal function of VSMCs is vasoconstriction and the 
synthesis of extracellular matrix components of the vascular media (Schlant & 
Alexander 1994, Katoh & Periasamy 1996). Although mature SMCs remain quiescent 
until injury or insult occurs, they undergo physiological hypertrophy in response to 
increased load (Bucher et al. 1982. Katoh & Periasamy 1996). 
1.5. Phenotypes of VSMCs 
VSMCs have two different phenotypes: 'contractile' and 'sýnthctic' 
(Glukhova et al. 1991, Woolf 1998a). 
In the `contractile' phenotype. they are filled with myofilaments and contain a 
relatively poorly developed Golgi apparatus and rough endoplasmic reticulum 
(Thyberg et al. 1990). 'Contractile' VSMC respond to agents that induce either 
vasoconstriction or vasodilation, such as endothelin. catecholamincs angiotensin 
11 
(Ang II). prostaglandin E (PGE). prostacyclin (PGI-, ). neuropvptides. leukotrieries and 
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Nitric oxide (NO) (Ross 1993). In normal arteries, the SMCs are primarily of the 
`contractile' phenotype (Schlant & Alexander 1994) and maintained in a quiescent 
growth state (Schlant & Alexander 1994, Hungerford & Little 1999). 
In the `synthetic' phenotype. SMCs are characterized by an ab oundanc: e of 
rough endoplasmic reticulum and Golgi bodies with few and sometimes no evident 
myofilaments (Thyberg et al. 1990). Synthetic phenotype SMCs lose the capacit\ to 
contract, but gain the capacity to divide (Cotran et al. 1994. Woolf 1998a) and are 
capable of expressing genes for a number of growth-regulatory molecules and 
cytokines. They also respond to growth factors by expressing appropriate receptors 
and determining the ECM content (Libby et a!. 1988, Sjölund et a!. 1988). SMCs in 
lesions change from the `contractile' phenotype to the synthetic' phenotype 
(Campbell & Campbell 1986, Campbell & Campbell 1990, Thyberg et al. 1990, 
Kocher et al. 199 1, Owens 1995. 'I'hyberg 1996, Hirschi & D'Amore 1998). 
In culture, VSMCs acquire the synthetic phenotype (Camp ley--Campheil et al. 
1981, Campbell et al. 1989, Schlant & Alexander 1994), within a few days losing 
their myofilaments, and contractility, and developing an extensive rough endoplasmic 
reticulum and a large Golgi complex (Hultgard. h-Nilsson et a!. 1997), similar to the 
features of SMC in developing lesions (Thyberg et al. 1990). In other ways too, 
VSMC in culture grow to resemble the SMC found in lesions, such as through 
alterations in the form of fibronectin (Glukhova et al. 
1989) and expression of 
platelet-derived growth factor-A (PDGF-A) and 
PIXGF-13 genes (Sjölund et a!. 1988. 
Majesky et al. 1988, Valente et al. 1988, Berk 2001). 
Such changes in phenotype are 
reversible once they have achieved confluency. provided 
no more than five 
cumulative population doublings 
have been undergone. other%% ise they remain 
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indefinitely in the `synthetic' state and are thus termed 'irreversible synthetic' 
(Campbell & Campbell 1987, Campbell et al. 1989. Schwartz & Mecham 199i). 
2. VSMC growth in vascular disease 
Changes in vascular structure induced by VSMC may involve: (1) cell growth. 
both hypertrophy (an increase in the size of the pre-existing cells) and by rplasia 
(proliferation, an increase in the number of cells) (Schwartz et al. 1995. Nikol er a!. 
1996)-, (2) programmed cell death (apoptosis). which provides an important means of 
population control for VSMC (Sharifi & Schiffrin 1998); (3) cell migration from one 
locale to another, such as from media to intima in atherosclerosic lesions (Schwartz et 
al. 1995, Nikol et al. 1996); (4) ECM production and degradation which importantly 
contributes to the total mass with the vascular wall (Schwartz et al. ¢ 995. Nikol et a!. 
1996, Egido 1996). 
2.1. VSMC growth in hypertension 
Hypertension is associated with functional and structural changes in resistance 
vessels (Korner et al. 1989, Folkow 1990. Cotran et al. 1994, Rosendoff 
1998. 
Rizzoni et al. 1998). 
Structural changes in resistance arteries constitute the predominant lesions 
in 
essential hypertension (Mulvany & Aalkjaer 1990, Korner 
& Angus 1992. 1leagerty 
cal al. 1993, Schiffrin 1995). The major structural changes 
include reduced vessel 
lumen diameter and media thickening of resistance arteries (Mulvam 
& Aalkjaer 
1990, Schiff 1992. Mulvany et al. 1996. Laurant el a!. 1997. 
Rizzoni er a!. 1998. 
Sharifi and Schiffrin 1998, Williams 1998. Intengan et al. 
1999a). F his may result 
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from increased vessel wall area by VSMC h% perplasia (Mulvanv er at 1985. Lee 
1987, Nag 1996), hypertrophy (Nag 1996, Tsoporis et at. 1998), reorganization of the 
cells around the lumen of the artery (remodeling), and/or altered l: C'M composition 
(Korsgaard et al. 1993, Schwartz & Mecham 1995, Nag 1996, Sharifi et al. 1998. 
Tsoporis et al. 1998, Intengan et al. 1999b). In some studies VS 1C hvperplasia or 
hypertrophy were not seen in small arteries from hypertensive patients or 
spontaneously hypertensive rats (SHR), and in these cases vascular remodeling was 
attributed to changes in extracellular matrix content and to the rearrangement of 
SMCs (Korsgaard et al. 1993, Sharifi et al. 1998. Tsoporis et al. 1998. Intengan et a!. 
1999b). These conflicting data indicate that cellular processes underlying media 
thickening are complex, and exact mechanisms contributing to arterial remodeling in 
hypertension are not yet well understood (Touyz & Schigin 2000). 
In addition, Owens (1989,1990), Lee (1987,1989) and Safar el al. (1998) 
have reviewed the specific structural changes in large arteries in different animal 
models of hypertension. In brief, VSMC hypertrophy in the aorta and several other 
arteries (such as renal and carotid) is regarded as an adaptive change, occurring only 
after hypertension has developed. However. very little is known about the nature of 
the vascular change in large vessels in human hypertension. Thus, although it app cars 
that thickening of the wall occurs in large arteries in humans with essential 
hypertension. it is still unknown whether this thickening is caused by VSMC 
hypertrophy (Lee 1989. Safer et al. 1998). 
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2.2. VSMC in atherosclerosis 
The characteristic feature of advanced atherosclerotic plaque is an irregular 
thickening of the arterial intima, due mainly to accumulation of lipids. prolitCration of 
SMC, and formation of fibrous tissue (Lindop & Dargie 1992). The early changes are 
due to the proliferation of SMC in the intimal and the accumulation of lipids in 'foam 
cells', so called because the cell absorb lipid and their cytoplasm becom swollen 
with lipid globules. Foam cells are derived from two sources: from SNIC's which 
proliferate and migrate into the intima from the media (Figure 1-22) and from 
macrophages derived from circulating monocytes which adhere to and then penetrate 
the Intima (Lindop & Dargie 1992). 
An intima that forms in response to injury is called 'neointima' (Schwartz er 
al. 1995). In the course of neointima formation the remodeling of vascular wall is 
largely related to the phenotypic flexibility of VSMC (Schmidt-Ott et a/. 2000). In the 
neointima, SMCs proliferate. undergo transformation from a contractile to a synthetic 
phenotpe, and produce abundant ECM, such as collagen and fibronectin (Ross 19K6, 
Ross 1993, Schwartz et al. 1995. Ross 1999, Raines 2000). 
3. Factors controlling proliferation in VSMC 
VSMC growth is stimulated by factors produced by neighbouring 
FC,, or 
released from circulating platelets, neutrophils, and monocyte s 
(macrophages) or 
secreted by fibroblast and VSMCs in an autocrine 
fashion (I)ube' er al. 1997, Fallant 
et al. 1999). Growth factors, produced either 
by certain cells in order to act on 
neighbouring cells (paracrine), or produced 
by cells in order to act on themselves 
(autocrine), are regulators of cell growth and differentiation 
(Nikol et a/. 1996). 
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I. The cell cycle 
Three populations of cells may be considered in examining cell division: thou 
actively dividing (cycling cells), those seemingly not involved in cv cling 16 cells). 
and those destined to die without further division (called 'terminally differentiated 
cells', such as neurons and skeletal muscle) (Figure 1-3). Three mechanisms that 
produce an increase in cell number of any given cell population are (1) a shortening (it 
the cell cycle, i. e., the cells divide more frequently, (2) more cells participate in the 
cell cycle, i. e., a decrease in the Go fraction, and (3) a decrease in the rate of cell death 
(Baserga 1999). Those in a state of cycling inactivity can re-enter the cell cycle if 
appropriately stimulated (Baserga 1999). The eukaryotic cell cycle consists of 
alternating periods of interphase and mitosis (Kessel 1998b) (Figure 1-3). Interphak 
is divided into a G, phase, which represents the interval from the end of mitosis to the 
time of DNA replication; an S phase in which replication of the I)NA hý 
semiconservative method occurs; and a G2 phase is the interval from the end of I)NA 
replication to mitosis (M phase). 
In human tissues, the M, G2 and S phases are relatively constant in length. `1 
phase takes 1-2 hours, G, phase from I to 6 hours, and S phase from 7-12 hours. The 
differences in cell cycle time which characterize different tissues are a function of 
variations in the length of G,, which may last for days or even years (Woolf 1998h). 
In cell culture models, arrest of the cell cycle occurs only in the (',, phase. implying 
that once a cell has passed out of the G, phase. the cell cycle proceeds to completion 
(Woolf 1998b). Growth factors can be grouped into two categories based in the mode 
of stimulation of the cell cycle (Stiles er al. 1979). 
Competence growth factors 
stimulate the cell cycle from the Go phase to the competent 
(º, phase without further 
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Figure 1-3. Cell cycle. Note that, as the cell progresses through 
the cell cycle, there is also an increase in size until, just before 
mitosis. the size of the cell is twice that of an irnrnediateIý 
postmitotic cell. (i, arrest results in cells with tetraploid amounts 
of 'DNA. 1'rom Baser a 1999. 
I10 
CHAPTER 1: INTRODUCTION 
progression to S and M phases, while progression growth factors have no effect on the 
cell cycle of Go cells, but stimulate cell cycle progression from the competent (i, 
phase to the S and M phase. Thus, both competence and progression growh factors 
are required for cells to complete a cell cycle. although some single growth factors 
may act as either competence or progression factors (Jahan et al. 1996). PIXiF is a 
typical competence growth factor (Kobayashi et al. 1994) and IGF- I is a progression 
factor (Schlant & Alexander 1994). 
3.2. Endothelial-derived growth factors of SMC growth 
ECs have the capacity to secrete several factors that are thought to be involved 
in the abnormal SMC growth seen during atherogenesis and hypxrtension (Schlant & 
Alexander 1994). 
3.2.1. Platelet derived growth factor (PDGF) 
PDGF consists of two distinct polypeptide ligands (A and 13) that are products 
of unique genes (Ross et al. 1986). The active growth factor exists either as 
homodimers (AA or BB), or the heterodimer. AB and has a molecular mass of 
between 28 and 35 kDa (Hannink & Donoghue 1989. Raines et al. 1990). It is 
produced by a number of cell types including platelets. VSMCs. ERs and 
macrophages (Ross et al. 1986, Ross et al. 1990). The mitogenic potency of the 
different isoforms of PDGF depends on the cell type. and parallels the ahilityý cif the 
cells to bind the different isoforms (Seifert et a!. 1989). 3T3 cells, which express 
high 
levels of both subunits and thus bind high levels of all three 
isoforms. are equally 
stimulated by all three isoforms. By contrast. human 
dermal fibroblasts express fc%% 
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a-subunits, bind relatively little PDGF-AA, and are very poorly stimulated hti. PIX; l-- 
AA (Nister el al. 1988). ECs contain the mRNA for both A and B peptide 
(Kavanaugh 1988). 
A predominant biological role of PDGF is to act as a mitogcn for cells of 
mesenchymal origin, including VSMC. fibroblasts. and osteoblasts (Ross et al. 1986. 
Raines el al. 1990). In VSMC, the PDGF-BB isoform is most potent in inducing 
hyperplastic growth (Nikol et al. 1996). PDGF-BB is also a chemotactic factor that 
induces vascular smooth muscle cell migration (Schwartz et al. 1995). It also 
increases the synthesis of basic fibroblast growth factor (bF(IF) (Schimokawa et al. 
1996, Bilato et al. 1996). 
3.2.2. Fibroblast growth factor (FG F) 
There are 10 genetically distinct genes known to encode F(ºl' polypeptides. 
producing products varying from 155 to 267 amino acid residues (Mchechan et a!. 
1998). These polypeptides have been named FGF-1 to FGF-10, although other 
acronyms are still used, e. g, FGF-1 and FGF-2, are also called acidic F(JF (al"GF) and 
basic FGF (bFGF). These two, which exhibit the widest expression among divers, 
cells and tissues, were first to be cloned and characterized, and consequently have 
been most widely studied. Neither exhibits an apparent N1 {2-terminal secretory signal 
sequence and each appears in intracellular compartments in addition to the 
pericellular matrix. Except for FGF-9, the other FGF polyp ptides exhibit a 
conventional secretory signal and are thought to exit cells by conventional s cretoýry 
mechanisms (McKeehan et al. 1998). All FGFs exhibit a specific affinity 
for heparin 
and heparan sulfate. FGF receptor (FGFR) signal transduction complex consists (, 
t 
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transmembrane tyrosine kinases (FGFRTK), and heparan sulfate proteodl}cans 
(FGFRHS). The involvement of pericellular heparan sulphate proteoglvcans as an 
integral component of the FGFR system and the local origin of F GF and RRRIF RTK in 
tissues suggest that the FGF signal transduction complex is an integrated part of the 
tissue or ECM, with regard to its external domain. and a part of the intracellular 
environment of cells, with respect to its intracellular domain. A wide variety of 
bioactive components in the external environment impinge on the FGF system and, 
therefore, the system serves as a monitor both of the external environment of tissues 
at the level of the organism and of the local extracellular environment at the tissue and 
cell level. As a consequence, there are few external environment conditions associated 
with health and disease that do not have an impact on the FGF system within tissues 
(McKeehan et al. 1998). 
The EC activated by monocytes expresses bFGF (Berk 2001). Many of the 
cells that respond to FGFs also synthesize them, including fibroblasts, VSMC. 
granulosa and adrenocortical cells (Baird & Böhlen 1990). 
bFGF has been detected in ECs (Shimada et al. 1981), and has been shown to 
be a potent smooth muscle mitogen (Lindner et al. 1991). bFGF does not contain the 
signal peptide that usually provides a mechanism for the transporting proteins out of 
cells, and thus is thought not to be secreted by ECs. It is, however, present and stored 
in the subendothelial matrix. and may be released on cell lv sis or 
death (Lindner et a1. 
1991). FGF bound to the matrix can be released by heparin and proteinases (E3ashlcin 
et al. 1989). suggesting that the matrix may serve as a store 
for rapidly mobilizing this- 
growth factor. bFGF is released from 
damaged VSMC and responsible for the 
proliferation and neointima formation (Schwartz er al. 
1995. Baird & Böhlen 1990). 
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suggesting that FGF released from VSMCs may be particularly important in the 
growth response induced by arterial wall injury (Schlant & Alexander 1994). bF(IF 
stimulates angiotensin-converting enzyme (ACE) expression in cultured \'S 1(' 
(Fishel et al. 1995) and increases in neointimal ACE activity in injured arteries were 
blocked with anti-bFGF antibodies (Fishel et al. 1995). Among the growth factors 
studied (PDGF, Transforming growth factor-beta, Ang 11). only bF(IF % vas able to 
upregulate ACE activity (Fishel et al. 1995). These findings suggest that injurv- 
induced increases in bFGF increase Ang II levels via activation of ACE, which in turn 
can stimulate VSMC growth directly or in concert with other autocrine/paracrine 
growth factors such as ET, PDGF, insulin-like growth factor-I (I)ubcy el al. 1997). 
3.2.3. Endothelin (ET) 
ETs are a family of 21 amino acid peptides that exist in three isoforms (F. T-1, 
ET-2, ET-3), encoded by different genes (Inoue el al. 1989). ET-1 is produced by 
ECs, VSMCs, and macrophages (Wang et al. 1996, Fukuda et al. 1996, Karet & 
Davenport 1996, Jones et al. 1996a). It is a potent vasoconstrictor and mitogen (Wang 
et al. 1996, Fukuda et al. 1996, Karet & Davenport 1996, Egido 1996, Gomez-(; acre 
et al. 1996, Brown et al. 1996, Levin 1996), and increases 
DNA synthesis. 
proliferation and migration in VSMC (Egido 1996, Gomez-Garre er a!. 
1996, Brown 
et al. 1996, Levin 1996). In co-cultures, VSMC proliferation was 
induced by the 
conditioned medium of ECs, but not by the conditioned medium of 
ECs treated with 
the endothelin converting enzyme inhibitor. phosphoramidon 
(Peiro el a!. 1995). 
Monocytes/macrophages, which migrate to sites of injury in the vessel express 
ET-1 
(Fukuda et al. 1996, Jones et al. 1996a). Together. these 
findings suggest that locally 
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produced ET-I induced VSMC proliferation in an autocrine-paracrine fashion and 
lead to architectural changes within vasculature (Peiro et a!. 1995. Wang er al. 1996. 
Dubey et al. 1997). The mitogenic effects of ET-I on VSMCs are abrogated by the 
angiotensin type I (AT, ) receptor antagonist losartan and by the ACE inhibitor 
quinaprilat (Egido 1996, Gomez-Garre et al. 1996). This would suggest that 
regulation of cell proliferation by endogenous vasoactive factors is a complex 
network that involves secondary mitogenic pathways. and therapeutic agents used to 
prevent proliferation induced by any one pathway might not prove effective (I)ubcy, el 
al. 1997). 
ET-1 might influence the renin-angiotensin system (RAS). but its effects on 
renin release remain controversial (Ritthaler et a!. 1996, Kramer et a!. 1996). In 
cultured ECs and SMCs, ET-1 increases the conversion of Ang I to Ang 11 and this 
effect is suppressed by ACE inhibition (Egido 1996, Karet & I)avcnport 1996, Brown 
et al. 1996, Levin 1996). It was suggested that increased generation of FT- I within 
the vessel wall may lead to an increase in Ang II which in turn further upregulates 
ET- I production. The generation of Ang II and ET-1 through this positive cycle might 
importantly modulate tone and proliferation of VSMC's (Dubry et al. 1997). 
3.2.4. Insulin like growth factor-I (IGF-I) 
IGF family consists of two related polypeptides. IFG-I and 
IGF-II (Rcchkr & 
Nissley 1990). IGF-I and IGF-II are single-chain poly ptides containing three 
disulphide bonds that are closely related to each other and to 
human insulin (I lumbel 
1984). The biological actions of IGFs are potentially mediated 
by either of two 
specific receptors. The IGF-I receptor (or type 
I IGF receptor) binds both l(IF-I and 
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IGF-I I. The IGF-I I/Mannose-6-phosphate (Man-6-P) receptor (or tvp . 11 IG t- 
receptor) binds IGF-II and also contains a mannose-6-phosphate recognition site 
(Rechter & Nissley 1990). 
The IGFs are synthesized in many tissues in fetal and adult animals (Rcchlcr 
& Nissley 1990), and can be secreted by endothelial cells (Delafontaine er a!. 1991). 
It acts as a progression factor that facilitates movement of cells through the cell cý Ic 
but, by itself, it is not a particularly strong mitogen (Schlant & Alexander 1994). In 
vitro, IGF-I synergistically increases the mitogenic effects of hF(IF (Reape er a/. 
1996, Berk 2001) and PDGF (Clemmons 1985. Berk 2001) in VSMCs. 1 lowever. it 
has been reported that the IGF-I induces mitogenesis in growth-arrested VSMCs via 
IGF-I receptors (Reape et al. 1996) and VSMCs migration via aVP3 integrin 
induction (Jones et al. 1996b). 
3.2.5. Transforming growth factor-ßs (T(, F-ßs) 
The EC activated by monocytes expresses "I (I -P (Berk 2001). Five different 
forms of TGF-ß have been identified. and most evidence suggests that they share 
similar biological activities, at least in certain established cell lines (Roberts & Sporn 
1990). TGF-ß i was first purified to homogeneity from human platelets (Assoian rt al. 
1983), human placenta (Frolik et al. 1983), and bovine kidney (Roberts er al. 1983) as 
a homodimeric. 25 kDa (Frolik et a!. 1983). In culture. TGF-P induces PIXiF A-chain 
mRNA expression and PDGF-AA protein secretion in VSMCS (13attegay er al. 1990). 
Similarly, when endothelial cells in culture are exposed to TGF-P. they express the 
gene for and secrete PDGF-BB (Ross 1993). Thus it was suggested that 
if 1(; ý="ß 
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were released in vivo by activated underlying macrophages, pDGF_BB secretion b,, - 
the adjacent ECs could in turn stimulate underlying SMCs to migrate or replicate 
(Ross 1993). In rat, TGF-P expression is increased at sites of intimal lesion. and anti- 
TGF-ß antibodies inhibit neointima formation (Wolf et a!. 1994). T(ii~-0 is an 
important mediator of ET-induced growth of VSMCs (Wolf et a!. 1994). 
A dichotomous effect occurs in the presence of excess TGF-ß. When FGF-Ii is 
present in high doses, it can inhibit the proliferative effect of secreted PDGF-AA that 
it has induced, by downregulating the relevant PDGF receptor molecules (Battegay er 
al. 1990). This appears to provide a self-regulatory means of preventing 
overstimulation by the PDGF it intitially induces (Ross 1993). In addition, I'G -P 
seems to inhibit cell proliferation by suppression of transcription of the 
protooncogene c-myc, as well as by regulation of ECM synthesis (Moses et u/. 1987, 
Sporn et al. 1987, Moses et al. 1990). 
In addition to modulating cell growth, TGF-ß can also regulate vascular tone 
by suppressing inducible NO synthase (iNOS) activity and inhibiting the generation 
of NO, a potent vasorelaxant (Perela et al. 1996). 
3.3. Ang II in VSMCs growth 
3.3.1. Direct mitogenic response to Ang II in vitro 
The definition of a mitogen is straightforward: a substance that 
increases the 
rate of cell division (Huckle & Earp 1994). 
Over the past 15-20 years a number of 
observations have suggested that the actions of 
Ang II extend beyond those of a 
transiently-acting vasoconstrictor and aldosterone secretogogue 
(Nuckle & Harp 
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1994). Ang II is a powerful mitogen for many cell types (/in merman & Dunham 
1997, Rosendorff 1998, Berk 2001) and a potent competence and, or progression 
factor, stimulating transition from the Go-G, phase in the cell cycle, leading in certain 
conditions to increased DNA synthesis and mitogenesis in combination with other 
growth factors (Owens et al. 1981, Gibbons et al. 1992. Jahan et al. 1996). More 
particularly it has been implied that Ang II triggers responses in VS\1i`s that lead to 
proliferation, migration, and a phenotypic modulation resulting in production of 
growth factor and extracellular matrix (Gibbons 1998, Pratt 1999, Schmidt-Ott et at 
2000, Klahr & Morrissey 2000). 
VSMCs in tissue culture exhibit a hypertrophic response to exogenous Ang 11 
(Campbell-Boswell & Robertson 1981. Geisterfer et al. 1988. Berk er al. 1989). 
Treatment with Ang 11 can induce mitogenic effects on cultured rat aortic SMC's. as 
shown by the observation that Ang 11 increased DNA synthesis 5- to 8-fold in VSMCs 
after 48 hours, as evidenced by increased labeled thymidinc uptake. and cell number 
(Weber et al. 1994), though other studies suggest that Ang 11 induces hypertrophy, but 
not proliferation, in primary adult rat VSMCs (Geisteifer et ul. 1988, Owens 1989). 
Increased cell size and cell number with Ang II stimulation were reported in human 
VSMCs (Campbell-Boswell & Robertson 1981. Makita et al. 1995). Different serum 
concentrations in the medium may partly explain these discrepancies. as hvpvrplasia 
occurs in the presence of serum and hypertrophy occurs in its absence (Jackson 
& 
Schwartz 1992). Furthermore. these discrepancies may be related to phenotypic 
differences among the various VSMC line used in the experiment (Majesky er al. 
1992). More recently. it has been reported that Ang 11 led to an 
increase in cell sire 
without an increase in cell number in cultured 
human pul non r) artery SMC's and 
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this effect was inhibited by the AT, receptor antagonist losartan but not bý the type 2 
(AT2) antagonist PD-123319 (Morrell et al. 1999). 
Ang II has been shown to cause hypertrophy and proliferation of isolated 
aortic smooth muscle cells of both SHR (Spontaneously f lypertensive Rats) and their 
WKR (Wistar-Kyoto Rats) controls (Scott-Burden et a!. 1991. Sachinidis et al. 
I992a). It has also been demonstrated to be involved in the VSMC growth sn in 
disease such as atherosclerosis and restenosis of vascular beds after angioplasty (I )-rau 
1988a, Dzau et al. 1993, Geisterfer et al. 1988, Daemen et al. 1991. Gibbons 1993. 
Gibbons and Dzau 1994). 
3.3.2. Indirect effects of Ang 11 on growth of VSMCs 
In addition to directly stimulating the proliferation of VSM('s, Ang 11 appears 
to enhance the proliferative response of VSMCs by inducing the expression of other 
genes whose products then amplify the mitogenic response and depending in part on 
the patterns of induction of secondary factors that are known to stimulate (f'MI[, 
IGF-1, bFGF, ET-1) or inhibit (TGF-ß) mitosis (I Juckle & Earp 1994, Fukada et 
a1.1998, Klahr & Morrissey 2000) (see CHAPTER 1-4.6.1.3b. Ang 11-induced 
expression of proto-oncogenes and growth factors). 
Components of the ECM also are candidates for regulation by Ang 110 luckk 
& Earp 1994. Intengan et al. 1999b). Ang II stimulates the synthesis of structural 
components of the ECM (Hsueh et al. 1995, Egido 1996), and 
in addition. Ang 11 
increases the activity of matrix rnetalloproteinases responsible 
for ECM degradation 
(Singhal et al. 1995). New ECM deposition. as well as 
localized E(. '\i degration. is 
observed in neointimal lesion and involved 
in migration and proliferation of 
45 
CHAPTER 1: INTRODUCTION 
(Raines 2000). Type VIII collagen stimulates SMC migration in vitro and increases 
production of matrix metalloproteinases (MMPs) in rat SMC isolated from carotid 
neointima, but fails to alter MMP production in rat SMC isolated from normal media 
(Hou et al. 2000). Heparan sulphate species produced by SMC have been rero gnired 
as potent inhibitors of SMC proliferation (Fritze et al. 1985). In addition to direct 
effects, a number of growth factors bind to heparan sulphate-rich ECM (Taipale K 
Keski-Oja 1997), and thus can serve as a local site of storage. Heparin has also been 
shown to be critical for oligomerization of FGF and subsequent stimulation of 
endothelial cells and SMC (Spivak-Kroizman et a!. 1994). In addition. the 
proteoglycans biglycan, versican and hyaluronic acid (HA) have been implicated in 
migration and proliferation of VSMCs (Wight et al. 1992). 
There is evidence of MMP activity in atherosclerotic lesions (Galls el a!. 
1994, Halpert et al. 1996, Nikkari et al. 1996, Sukhova et al. 1999). Overexprcssion 
of MMP enhances SMC migration and alters remodeling in the injured rat carotid 
artery (Mason et al. 1999). 
4. Renin-angiotensin-aldosterone system (RAAS) 
The RAAS is a complex, mixed enzymatic-hormonal system controlling 
electrolyte balance, blood volume and arterial blood pressure (Griendling et a!. 19,93. 
Weir & Dzau 1999). Historically, this hormonal system has been viewed as a 
systemic one, its various components derived from different organs. and 
delivered to 
their site of action by the circulatory system (Griendling et al. 
1993. Weir & [hau 
1999). More recent evidence raises the possibility that there are 
distinct local RAAS 
with different mechanisms of regulation (Danser 
1996. Weir & Diau 1999. 
46 
CHAPTER 1: INTRODUCTION 
Schmermund et al. 1999. Danser et al. 1999. Duprez et al. 2000. Takai ei ul. 2001. 
Berk 2001). 
The primary components of the RAAS are angiotensinogen, renin, ACE. Ang 
II, Ang II receptors and, ultimately, aldosterone (Figure I-4). 
4.1. Renin 
For more than 70 years after the discovery of a 'pressor suhstance' in kidney 
extracts, and coinage of the term 'renin' by Tigerstedt and Bergman in 1898. this 
substance remained obscure until it was purified in stable form in the 1970s (inagami 
1993). The experimental hypertension induced by renal arterial constriction did not 
immediately link renin to the hypertension although Goldblatt later reviewed such a 
possibility in 1938 (Inagami 1993). In the meantime, attempts at the partial 
purification of renin were being undertaken by Pickering and Prinzmetal (1938). 
Identification of renin as an enzyme. rather than a pressor hormone. and evidence that 
Ang II was the product of its enzymic action by Page and Helmer (1940) and Braun- 
Menendez et al. (1940), laid the foundation for the future development of research on 
the RAAS. 
4.1.1. Protein 
Renin is a glycoproteolytic enzyme that is responsible for the 
first step in the 
formation of Ang II (Lumbers 1999). Renin is a single chain aspartyl protease of' 
molecular weight 37-40 kDa and pI 5.2-5.8 (Dzau et al. 
1988). Its primary structure 
contains double domains: that is. the amino- and carboxyl-termini 
contain areas of 
similar sequence (Heinrikson & Poorman 
1990). forming a two-lobed structure 
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Figure 1-4. The rein-angiotensin-aldosteronc system. Adapted from van / ieten 
2000. 
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surrounding the active site. Renin is highly specific for its substrate, angiotensinogen. 
and is most active at neutral pH (Dzau et al. 1988). The main source of circulating 
renin is the juxtaglomerular cells of the afferent arterioles of the kidney (Gomez et al. 
1990, Lumbers 1999, Weir & Dzau 1999). Translation of renin mRNA yields 
preprorenin, which then undergoes cotranslational removal of a signal peptide and 
glycosylation during transport through the rough endoplasmic reticulum to become 
prorenin (Dzau et al. 1988a). Prorenin can be either constitutively secreted from the 
Golgi apparatus or packaged in immature granules and secreted in a regulated fashion. 
Some conversion of prorenin to renin by removal of a 43-amino acid segment can 
occur in the granules, so both prorenin and renin are secreted. Prorenin is the major 
circulating form of renin. The primary site of conversion of plasma prorenin to renin 
remains unclear. Prorenin activating enzymes with trypsin-like activity have been 
found in the kidney as well as in human ECs (Admiraal et al. 1999, van den Eijnden 
2001) and neutrophils (Griendling et al. 1993). The avid uptake of prorenin by blood 
vessels (Samani & Swales 1991. Rosendorff 1996, Admiraal et al. 1999, van den 
Eijnden 2001) and cardiomyocytes (Saris er al. 2001 a, 2001 b) may result in local 
accumulation and activation of prorenin in this tissue, which suggests that blood 
vessels and cardiomyocytes may be the primary site of formation of renin from 
circulating prorenin (Rosendorff 1996, Saris et al. 200 1 a, 2001 b). 
4.1.2. Genomic analysis 
Renin cDNA and genes from the mouse (Rougeon et al. 1981. Masuda et al. 
1982, Mullins et al. 1982, Panthier et al. 1982, Panthier & Rougeon 1983, Panthier et 
al. 1984. Holm et a!. 1984. Burt et al. 1989. Kim er al. 1989). rabbits (Trivedi et a!. 
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1991), sheep (Aldred et al. 1992), rats (Fukamizu et al. 1988, Burnham et al. 1987) 
and humans (Imai et al. 1983, Miyazaki ei al. 1984, Hardman et al. 1984. Hobart ei 
al. 1984) have been cloned and sequenced and have been located on chromosome 
I q32 in humans (Grifiths et al. 1989). 13 in rats (Pravenec et al. 1991), and I in 
mouse (Wilson et al. 1978, Chirgwin el al. 1984). The renin gene consists of nine 
exons interrupted by eight introns (Figur 1-5). In contrast to other species, the human 
renin gene contains an additional mini-exon (termed exon Va), consisting of only nine 
nucleotides and coding for only three amino acids (Hobart et al. 1984, Aldred ei a!. 
1992) (Figure 1-5). Thus, the human renn gene contains 10 exons and nine introns 
(D7au et al. 1988). The entire gene spans about 12 kilobases (kb) of DNA (Hobart et 
al. 1984). Human kidney resin mRNA is about 1.6 kb long, similarly to mouse 
submandibular gland (SMG) renin (Soubrier et al. 1983). Only one copy of the renin 
gene exists in human (Soubrier et al. 1983, Hardman et al. 1984, Miyazaki et al. 
1984, Fukazimu et al. 1986) and rat (Burnham et al. 1987), but several strains of mice 
contain two renn genes, designated Ren-1 and Ren-2 (Mullins et al. 1982, Panthier et 
al. 1982, Piccini et al. 1982, Panthier et al. 1984). These correspond to the renin 
produced in the SMG and the kidney, respectively (Mullins et al. 1982). The product 
of Ren- I differs from other renins in that it is not glycosylated and it consists of two 
chains linked by a disulfide bond. In rat brain, a novel transcript of rat renin gene. 
characterized by the presence of an alternative first exon (exon 1 b) that is spliced to 
exon 2 of the known transcript. has been identified (Lee-Kirsch et al. 1999). 
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4.1.3. Tissue distribution and regulation 
Human renin gene transcription was found to be high in the kidney. adrenal. 
ovary, testis, lung, and adipose tissue and low in the heart and SMG (Sigmund et al. 
1992). Rat and mouse brain and heart express very low levels of renin. and 
renin/prorenin mRNA appears to be absent from the livers of these species (Dzau er 
al. 1988). Some, but not all authors were able to detect renin/prorenin mRNA. using 
PC R technique in myocytes and fibroblasts obtained from heart of neonatal and adult 
rats ([)anser et al. 1999). Renin/prorenin mRNA is expressed only at very low levels 
(Samani et al. 1988. Samani & Swales 1991. Kubo et al. 1999) or is absent (Ekker et 
al. 1989, Touyz & Schiffrin 2000) in the blood vessels. The (pro)renin mRNA was 
found in human pancreas (Tahmasebi e1 al. 1999), reproductive system (Vinson et a!. 
1997) and human eye (Wagner et al. 1996). 
Expression of renin mRNA in various tissues appears to be differentially 
regulated (Griending ei al. 1993, Orth & Kovacs 1998, Lumbers 1999). Sodium 
depletion or ß-adrenergic receptor activation increases renin expression in the kidney, 
heart, and adrenal but not in the submandibular or genital glands (Orth & Kovacs 
1998, Lumbers 1999). In these latter two tissues, renin mRNA is regulated by 
androgens (Dzau et al. 1986). Ang 11 levels also regulate renal renn expression as 
demonstrated by experiments in which transgenic mice transfected with the human 
renin gene were treated with the ACE inhibitor, captopril. The results showed a 5-10 
fold increase in renal renin expression (Sigmund et al. 1992). Similarly, enalapril 
(another ACE inhibitor) treatment increases the expression of renin mRNA in rat 
kidney. and this elevation of renin mRNA is reversible by administration of Ang II 
(Johns et a!. 1990). 
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4.2. Angiotensinogen 
4.2.1. Protein 
Angiotensinogen is the major substrate for renn and the unique precursor of 
Ang II (Corvol et al. 1997). It shares some homology with a-antitrypsin and as such 
belongs to the superfamily of serine protease inhibitors (serpins) (Doolittle 1983). 
Structurally, it is a globular glycoprotein of molecular weight 55-65 kDa and pI 4.3- 
4.9, depending on the degree of glycosylation (Clauser et al. 1989). The majority of 
circulating angiotensinogen probably derives from the liver, in particular, the 
pericentral zone of the liver lobules (Morris et al. 1979, Touyz & Schiff in 2000). The 
newly synthesized protein is then secreted by the cell into the circulation. The plasma 
serves as the major reservoir of this protein, but its levels are a major determinant of 
RAAB activity (Clauser et al. 1989, Weir & Dzau 1999). The structural features of 
human angiotensinogen do not differ significantly from those of the rat or the mouse 
(Gaillard et a!. 1989. Fukamizu et al. 1990). 
4.2.2. Gcnomic analysis 
Analysis of human genomic DNA indicates that there is a single gene for 
angiotensinogen. The gene is composed of five exons and four introns and 
encompasses approximately 13 kb of genomic sequence (Clauser et al. 1989). 
Glucocorticoid. oestrogen, and thyroid hormones increase angiotensinogen mRNA in 
rat hepatocytes (Chang & Perlman 1987). The 5' flanking region of angiotensinogen 
in the rat and human has consensus sequences for three glucocorticoid responsive 
elements (GRE). a thyroid hormone responsive element (TRE), and an oestrogen 
responsive element (ERE) (Clauser el al. 1989, Fukamizu et al. 1990. Zhao et al. 
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1992). In addition, a virus-like enhancer element sequence (ENH) is present in the 
midrange of this region of the gene, and two promoter sequences. a TATA box and a 
CAT element, have been identified near the transcriptional start site (Clauser et al. 
1989). The angiotensinogen gene contains an acute-phase response element (ADRE) 
that binds to two types of nuclear proteins: tissue-specific nuclear factor kB (NFkB), a 
protein that purportedly is regulated by inflammatory mediators and oxidative stress, 
and a family of CCAAT/enhancer binding protein (c/EBP)-like constitutive binding 
proteins (Ron ei al. 1991). 
4.2.3. Tissue distribution and regulation 
In the rat, the highest amount of angiotensinogen mRNA was found in the 
liver, but brain, spinal cord, aorta (smooth muscle and adventitia), pancreas and 
mesentery also contain it (Camlbell & Habener 1986, Chappell et al. 1991, Chappell 
et at 1992, Kubo et al. 1999). Low but detectable levels were found in the kidney, 
adrenal, atria, lung, large intestine, stomach, and spleen, while angiotensinogen 
mRNA was absent from the pituitary, ventricle, testis and small intestine (Campbell & 
Habener 1986). Angiotensinogen mRNA was found in the human eye (Wagner ei al. 
1996) and reproductive system (Vinson et al. 1997). 
In contrast with the rapid changes in plasma renin activity (which may take 
place within seconds or minutes), changes in plasma angiotensinogen are rather slow 
(over hours or days) (Menard et a!. 1993). Angiotensinogen abundance is regulated at 
the transcriptional level through hormonal regulators (Brasier e1 al. 1999). 
Glucocorticoids (especially dexamethasone), oestrogens, Ang U. and thyroid hormone 
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stimulate synthesis and release of angiotensinogen (Tewksbury 1983). Like renn 
mRNA, angiotensinogen mRNA transcription is differentially regulated in various 
tissues. In the liver, there are two different polyadenylation signals. resulting in two 
possible 3' untranslated sequences and thus mRNA species that differ in length by 
200 nucleotides (Clauser et al. 1989). It is unclear whether other tissues also express 
two species or if there is a difference in physiological function. Sodium also has 
differential effects on renal and hepatic angiotensinogen mRNA. Sodium depletion 
stimulates angiotensinogen mRNA expression in kidney but does not influence 
hepatic angiotensinogen mRNA levels (Dzau et al. 1986). 
In the SHR, brain angiotensinogen mRNA is increased compared with that in 
WKR, but liver mRNA is unchanged (Yongue et al. 1991), and renal mRNA is 
decreased (Schunkert et al. 1991). During the acute phase of inflammation or injury, 
plasma levels of angiotensinogen increase markedly. These changes derive from 
alterations in liver synthesis of the protein (Clauser et al. 1989, Tewksbury 1990). 
4.3. Angiotensin Converting Enzyme (ACE) 
4.3.1. Protein 
ACE is a dipeptidyl carboxypeptidase that converts angiotensin I to the potent 
vasoconstrictor Ang II and inactivates the vasodilator bradykinin. The enzyme is 
expressed primarily by endothelial, epithelial, and neuroepithelial cells, as well as by 
some endocrine cells. where it may be membrane bound with the active site outwardly 
directed (Shapiro el al. 1983). ACE has been extensively characterized and purified 
from several sources, including serum lung, seminal fluid, and plasma (Oparil 1983). 
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The molecular weight ranges from 140-160 kDa for endothelial ACE to 90-100 kDa 
for the testicular form, depending on the carbohydrate content of the molecule (Ehlers 
& Riordan 1990). The isoelectric point of the protein also varies with carbohydrate 
content, from 4.3 to 5.2 (Ehlers & Riordan 1990). ACE is a member of the family of 
zinc metallopeptidases and contains a molar equivalent of zinc that functions in the 
hydrolytic step of the catalytic reaction (Bunning et al. 1983, Ehlers & Riordan 1990). 
The enzyme consists of a single chain that is moderately hydrophobic and is 
predominately membrane bound. 
4.3.2. Genomic analysis 
The pulmonary and testicular isozymes of ACE are encoded by two distinct 
mRNAs that are transcribed from a single gene (Kumar et al. 1991). The pulmonary 
ACE mRNA contains between 4.5 and 5 kb of sequence, encoding a protein of 1,309 
residues with a 33-amino acid sorting signal peptide at the amino-terminus 
(Thekkumara et al. 1992). Testicular ACE message is 2.6 kb in length and is encoded 
within the gene for the larger form of ACE (Thekkumara et al. 1992). A single ACE 
gene with 26 exons (Sibony el al. 1993) has been suggested in several species, such as 
human (Soubrier et al. 1988, Lattion et al. 1989, Sibony et al. 1993) and mouse 
(Bernstein et al. 1988, Howard et al. 1990). 
4.3.3. Tissue distribution and regulation 
ACE is present in nearly all mammalian tissues and body fluids (Skidgel & 
Erdös 1993. Zimmerman & Dunham 1997). ACE is positioned ideally in ECs to 
cleave circulating Ang I to form Ang II. Although pulmonary endothelial cells were 
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found to be the principal site of Ang I conversion to Ang II. peripheral tissues may be 
equally important for such activity (Danilov et al. 1987. Ballermann 1989). The 
highest levels of ACE activity in humans have been found in the kidney. ileum. 
duodenum, and uterus, with lesser levels in the lung, prostate, jejunum, testis, and 
adrenal (Ballermann 1989). Testicular ACE appears to be unique in its small size and 
is found on intracellular membranes of sperm (Defendini et al. 1983, Strittmatter & 
Snyder 1984). 
The pulmonary form of ACE is restricted to epithelial and ECs of tissues ( 
Danser 1996) and to stimulated macrophages (Kumar et al. 1991). ACE can be 
induced by corticosteroids in cultured ECs, alveolar macrophages, monocytes, and 
lung (Ehlers & Riordan 1990). The testicular form of ACE is under follicle- 
stimulating hormone (FSH)/luteinizing hormone (LH) control (Velletri et al. 1985). 
The mRNA of ACE was found in human eye (Wagner et al. 1996). 
4.3.4. Pharmacological manipulation 
ACE inhibitor, for example captopril, have been used both therapeutically and 
to dissect the molecular components and physiological roles of the RAS (Griendling 
et a!. 1993. Sharifi et al. 1998). ACE inhibitors are valuable and effective drugs in the 
treatment of hypertension, heart failure, myocardial infarction and nephropathy 
(Howes & Christie 1998). Beyond inhibiting the RAS, ACE inhibitors diminish the 
inactivation of bradykinin, thus leading to an augmentation of nitric oxide (NO) 
release (Ruschitzka et al. 1999). 
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4.4. Angiotensin II (Ang II) 
4.4.1. Ang II catabolism 
Circulating renal-derived renin cleaves hepatic-derived angiotensinogen to 
yield the decapeptide Ang 1. Ang I is liberated by renin cleavage of a leucine-valine 
bond in the N-terminal region of human angiotensinogen or a leucine-leucine bond in 
the angiotensinogen of other species (Clauser el al. 1989). Two amino acids from the 
carboxyl terminus of this peptide are removed by the endothelial-associated 
metalloenzyme ACE, thus producing the active octapeptide hormone Ang II (Orth & 
Kovacs 1998) (Figure 1-6). Cleavage of the NH2-terminal Asp residue from Ang 11 
produces the heptapeptide, Ang III, whose circulating levels are only 20% of those of 
Ang II. Ang I has no known biological activity. Ang II and Ang III are equipotent in 
stimulating aldosterone secretion, but Ang II is a more potent vasopressor agent 
(Bloom el al. 1982. Kiss et al. 1984). 
I'he majority of conversion from Ang I to Ang II occurs within the lung on the 
pulmonary vascular endothelial surface and up to 80% of Ang I at physiological 
concentrations may be converted to Ang II. Ang II formed in the lung is delivered by 
the arterial system to the peripheral tissues, where it exerts its effects by interacting 
with specific Ang II receptors. Ang II has a short half-fife of 10-20 seconds because 
of the action of angiotensinases, principally in peripheral vascular beds. Metabolism 
of Ang II occurs in the vasculature of the kidney, limb, brain, viscera, and liver. In 
particular, a large proportion of arterial Ang II is extracted in the kidney (Bailie & 
Oparil 1977). In man, however, the concentration of Ang II in the renal venous 
outflow is only 20% lower than in arterial plasma. reflecting formation as well as 
degradation in the renal circulation (Semple et al. 1979). 
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4.4.2. Functional role of Aug 11 
Ang II is the most important effector of the RAAS. It plays a central role in 
the regulation of systemic arterial pressure through its systemic synthesis via the 
RAAS cascade (Lumbers 1999, Weir & Dzau 1999). It acts directly on vascular 
smooth muscle as a potent vasoconstrictor and affects cardiac contractility and heart 
rate through its action on the sympathetic nervous system (Sealey & Large 1990, 
Lumbers 1999). Ang II elicits marked contraction of resistance vessels in the kidney 
(Britton 1981), skin (Forsyth et al. 1971), mesentery (Page & Olmstead 1961), 
coronary arteries (Morgan 1987), and brain (Greenfield & Tindali 1968), the 
responses in the vessels of skeletal muscle (Forsyth et al. 1971), and the lung (Morgan 
1987) are far less marked. Resistance vessels are generally more responsive to Ang II 
than large-vessel smooth muscle. Biphasic vascular responses to Ang II have been 
reported (Webb 1982, Toda 1984, Fleming & Joshua 1984). Ang II induced 
contraction is followed by relaxation in dog renal and mesenteric vessel. When the EC 
was destroyed, the relaxation phase was lost and the constrictor response potentiated 
('C'oda 1984). The presence of EC is also critical for Ang 11-induced contraction of 
rabbit mesenteric and cardiac artery segments (Oshiro et al. 1985). 
Ang II increases prostaglandin synthesis in isolated blood vessels (Blumberg 
ei a1.1977) and cultured VSMC (Alexander & Gimbrone 1976, Hassid & Williams 
1983). Ang 11 actions on VSMC are modulated by negative feedback control of 
vasodilatory prostaglandin and NO (Alhene-Gelas et al. 1982. Morgan-Boyd et al. 
1987, Schmermund et al. 1999, Millatt et al. 1999, Klahr & Morrissey 2000). Ang 11 
and the endogenous vasodilator NO have many antagonistic effects, as well as 
influencing each other's production and function (Millatt et al. 1999). In the short- 
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term, Ang If stimulates NO release. thus modulating the vasoconstrictor actions of the 
peptide. In the long-term, Ang II influences the expression of all three NO svnthase 
(NOS) isoforms, while NO downregulates the AT, receptor, contributing to the 
protective role of NO in the vasculature (Millatt et al. 1999). Ang II also alters renal 
sodium and water absorption through its ability to stimulate the zona glomerulosa 
cells of adrenal cortex to synthesize and secrete aldosterone (Sealey & Laragh 1990. 
Lumbers 1999) (for details see CHAPTER I-5.6.1.1. ). Consequently, Ang II plays a 
critical role in both the acute and chronic regulation of blood pressure through its 
systemic endocrine regulation (Weir & Dzau 1999) (Figure 1-7). 
In addition to the vasoconstrictor response in VSMC, Ang II's growth- 
stimulating properties are well accepted (for details see CHAPTER I-3.3. ). 
Chronic production of Ang 11 also affects vascular structure and function via 
paracrine and autocrine effects of local tissue-based synthesis in various organs, 
particularly in blood vessels, the heart, and the kidney (Dzau 1988a, Dzau et al. 1993, 
Gibbons 1993. Gibbons and Dzau 1994). Although the peripheral or systemic RAAS 
as classically understood may be involved in this process, it is the autocrine or 
paracrine production of Ang II through a variety of different pathways that may be 
most important in promoting cardiovascular restructuring and remodeling (Gibbons 
1993. Gibbons and Dzau 1994). 
Ang 11 has numerous postulated atherosclerotic effects (Weir & Dzau 1999) 
(Figure 1-8). In addition to promoting SMC growth and migration, it can also activate 
macrophages and increase their ability to attach to and invade the vascular wall. 
ultimately creating a foam cell that can evolve into an atherosclerotic plaque (Pratt 
1996). Ang II also increases platelet aggregation. stimulates plasminogen activator 
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Figure 1-7. Effects of angiotensin on the regulation of arterial pressure. NA. 
noradrenaline. Adapted from Contreras et al. 2000. 
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inhibitor 1 and promotes endothelial dysfunction and oxidative stress of the blood 
vessel (Dzau et al. 1991, Griending et al. 1993, Feener et al. 1995, Vaughan et al. 
1995). One of the outcomes from stimulators of oxidative stress is the upregulation of 
expression of adhesion molecules and the initiation of the inflammatory response that 
mediates atherosclerosis. Other postulated effects of Ang 11 on vascular structure that 
could promote atherogenesis include inhibition of apoptosis, promotion of leukocyte 
adhesion and migration, and stimulation of thrombosis. All of these actiN ities can he 
blocked antagonizing the ability of Ang II to bind to its high-affinity AT, receptor 
binding site (Weir & Dzau 1999). 
The relationship among Ang II, blood pressure homeostasis, and 
cardiovascular restructuring and remodeling is a delicate one. An increase in pressure 
can result in mechanical stress and physical injury to the vessel wall, leading to 
localized upregulation of Ang II synthetic pathways (Weir & Dzau 1999). Similarly, 
Ang II, produced either systematically or within the vessel wall, may also upregulate 
similar synthetic pathways, ultimately leading to alterations in the structure and 
function of blood vessels. These latter changes may alter the compliance of blood 
vessels and elevates systemic arterial pressure, thus resulting in a vicious circle 
leading to progressive vascular injury (Weir & Dzau 1999). 
In addition, evidence from a number of animal studies suggests that Ang-(1-7) 
is a vasodilator that may confer cardioprotective effects by opposing the action of 
Ang 11 on growth and reactivity of blood vessels (review by Ferrario el al. 1997). 
Ang-(1-7), the aminoterminal heptapeptide. is derived from Ang I and Ang 11 by 
tissue peptidases (Yamamoto et al. 1992, Santos el al. 1992. Chappell et al. 1995, 
Deddish et al. 1998). Unlike Ang 11. Ang-(l -7) does not cause vasoconstriction. 
64 
CHAPTER 1: INTRODUCTION 
aldosterone release, thirst or induction of noradrenergic neurotransmission. Its 
vasodilatory effect is mediated by the production of endothelial NO and bradykinin 
(Li et al. 1997). The growth-inhibitory actions of Ang-(1-7) are mediated by a high- 
affinity specific binding site in VSMC (Tallant et al. 1999). Subtype-selective 
antagonists for the AT, and AT2 receptors have no effect on the inhibitory actions of 
Ang-(1-7), whereas the selective D-alanine7-angiotensin-(1-7) antagonist and the 
nonselective angiotensin receptor blocker sarcosine'-threonine8-angiotensin 11 have. 
Thus it has been suggested that a balance between the tissue concentration of Ang II 
and Ang-(1-7) is critical in the long-term maintenance of vessel structure (Tallant et 
al. 1999). 
In summary, not only does Ang II, formed locally and systematically, play a 
pivotal role in both the acute and chronic regulation of systemic arterial pressure, but 
it also is an important modulator of cardiovascular structure and function and may be 
specifically involved in disease progression, through a variety of different 
mechanisms, whether direct or indirect (Weir & Dzau 1999). 
4.5. Ang II receptors 
The two different major subtypes of Ang II receptor, AT, and AT,, are 
differentiated by their responsiveness to antagonists and their second messenger 
systems (Bumpus et al. 1991, Wong et al. 1992, Inagami 1999, Dinh et al. 2001). 
4.5.1. Pharmacology of Ang II receptors 
AT, receptors are blocked selectively by bipheny limidazoles such as the 
compound losartan (DUP753) (Sumners et a!. 1991. Dinh et al. 2001). whereas AT., 
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binding sites are blocked by tetrahydroimidazopyridines such as PD 123177 
(Bernstein & Alexander 1992, Dinh et al. 2001). AT, receptors are more responsive to 
Ang II than to Ang III, are positively coupled to phospholipase C. and may he 
negatively coupled to adenylate cyclase (Bumpus et al. 1991). Ang II and Ang III are 
equipotent in binding to the AT2 binding site (Summers et al. 1991). 
4.5.2. ATS subtype cloning 
The AT, receptor is a member of the superfamily of G protein-coupled 
receptors that have seven transmembrane regions (Murphy et al. 1991, Sasaki et a!. 
1991, Dinh et al. 2001). The cDNA for this receptor encodes a 359-amino acid 
protein with a molecular weight of 41 kDa (Murphy et al. 1991. Sasaki et al. 1991). 
The protein contains three potential consensus sites for N-glycosylation on the 
putative extracellular domains (Sasaki et al. 1991). 
In rat and mouse, there are two highly homologous subtypes of AT, receptors. 
called AT, A and AT 9B (Iwai & Inagami 1992a, Sasamura et a!. 1992, Elton et a1. 
1992, Inagami 1999, Dinh et al. 2001). ATIA receptors are expressed predominantly 
in the vascular smooth muscle, liver, lung, and kidney (Murphy et al. 1991. Sasaki et 
al. 1991) and are also found in the hypothalamus and subfornical organ of the brain 
(Kakar et al. 1992a). The AT iB receptor is expressed mainly in the adrenal gland and 
anterior pituitary (Murphy et al. 1991, Sasaki et al. 1991), but also in vessels, testis 
and brain (Iwai et al. 1991, Kakar et al. 1992, Sandberg et al. 1992, Iwai ei a!. 1992. 
Kitami et al. 1992, Kakar et al. 1992b). Thus, currently. the vascular receptor has 
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been denoted as AT,,. and the adrenal receptor as ATIB (Griendling & Alexander 
1993, Allen et al. 2000). 
Restriction mapping, differential hybridization. PCR amplification. and 
sequence analysis indicate that the AT, A and AT 1B are encoded by two separated 
genes, which share a 94% amino acid sequence indentity in the open reading frame 
but only a 35% identity in the 3' and 5' flanking regions (Elton et al. 1992). The AT, A 
receptor mRNA encodes a protein of 359 amino acids (41 kDa) in the rat and mouse 
(Sasamura et al. 1992). 
4.5.3. Genomic analysis of the AT, and AT2 receptor 
cDNA coding for the AT, receptor has been cloned and sequenced from 
human (Bergsma et al. 1992. Takayanagi et al. 1992). cattle (Sasaki et al. 1991), 
mouse (Sasamura et al. 1992) and rats (Iwai et al. 1991, Sandberg et al. 1992, Iwai et 
al. 1992a). The gene for the human, mouse and rat AT, receptor has been cloned, 
sequenced (Yoshida et al. 1992, Curnow et al. 1992, Yamano et al. 1992, Furata et al. 
1992, Elton et al. 1992, Lewis et al. 1992, Mauzy et al. 1992) and mapped in the rat 
to chromosomes 17 (ATIA) and 3 (ATIB) (Lewis et al. 1992) and 3 in human (Curnow 
et al. 1992). 
ATi receptor gene structure was first investigated in the rat (Landford of a!. 
1992. Murasawa et al. 1993, Takeuchi et a1.1993). The ATIA and ATI f genes consist 
of four exons and three introns and three exons and two introns respective N, 
(Takeuchi et al. 1993). The ATIA coding region is not interrupted by an intron but the 
5'-untranslated region of the mRNA is derived from either one or two additional 
exons by alternative splicing (Takeuchi et al. 1992). The first report of the cloning of 
67 
CHAPTER 1: INTRODUCTION 
ATIA included evidence for hybridization of the cDNA probe with two sizes of 
mRNA: 2.3 kb and 3.5 kb (Murphy et al. 1991). The whole receptor protein is 
encoded on exon 3. 
The human AT, receptor has a single gene, with 5 exons and 4 introns, the 
entire coding sequence located on exon 5 (Guo et al. 1994. Curnow et al. 1995). 
Alternative splicing of exons 2,3 and 4 potentially result in the production of eight 
different mRNA species (Guo et al. 1994, Curnow et al. 1995). 
The lack of introns within the receptor protein coding region also is a feature 
of the mouse and human AT, receptor genes (Sasamura et al. 1992, Furata et al. 
1992). 
The AT2 receptor gene, initially cloned from rat fetus and rat 
phaeochromocytoma cells, encodes a 363-amino-acid protein, which has only 32% to 
34% amino acid identity with the ATIA receptor protein (Kambayashi et al. 1993, 
Mukoyama et al. 1993). The AT2 receptor gene is located on chromosome X 
(Kambayashi et al. 1993. Mukoyama et al. 1993, Lazard et al. 1994). The human AT, 
gene is about 5 kb in size and composed of 3 exons (Martin & Elton 1995). The third 
exon contains the entire coding sequence (Martin & Elton 1995). 
4.5.4. Regulation of the ATS and AT2 receptor expression 
Ang II reduces ATIA receptor mRNA expression by 50% after 4-6 hours in 
cultured VSMC (L. assiigue et al. 1992) and mesangial cells (Makita et al. 1992). In 
contrast to these results, infusion of Ang II increased AT, receptor mRNA expression 
in the adrenal gland though not that in aorta or kidney (Iwai & Inagami 1992h). 
Agents that elevate intracellular cAMP cause receptor downregulation at the mRN, \ 
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level (Lassügue et al. 1992, Makita et al. 1992). The presence of three potential sites 
for protein kinase C phosphorylation in the C-terminus of the receptor suggests that 
phosphorylation by this enzyme may also play a role in receptor regulation (Bernstein 
& Alexander 1992). To date, there is no direct evidence to support this possibility 
The tyrosine residues present in the cytoplasmic tail of the receptor represent potential 
phosphorylation sites that may be involved in receptor internalization. Again, this 
possibility awaits experimental verification (Griendling et al. 1993). In addition. 
potent VSMCs mitogen such as epidermal growth factor (EGF), bFGF, P[XIF-E3I3 
cause a marked down-regulation of AT, receptor gene expression (Nickenig & 
Murphy 1994). Northern hybridization analysis revealed a decrease of ATS receptor 
mRNA levels to appromimately 20% in proliferating VSMCs in comparison to the 
growth-arrested cells (Nickenig et al. 1996). 
Relatively little is known about the mechanisms for regulation of AT'2 mRNA 
(Nahmias & Strosberg 1995). However, the observed changes in relative abundance 
of the AT, and ATS receptor subtype under various pathological conditions has been 
reported. It was demonstrated that stretching of neonatal myocytes, which supposedly 
also leads to Ang II secretion by these cells (Sadoshima et al. 1993). is accompanied 
by a simultaneous upregulation of AT, and AT2 receptor mRNA. Right ventricular 
hypertrophy and failure in the canine heart was associated with local increases of the 
mRNA level of the ATS receptor, wherease the AT, receptor level decreased (Lee er 
al. 1996). In the human heart failure the AT, receptor mRNA level was found to 
decline, whereas that of AT2 receptor was unaltered (Haywood et a!. 1997). Others 
reported that using rat models of cardiac hypertrophy and failure showed no changes 
in AT, or AT2 receptor mRNA levels (Iwai et al. 1995. Wolf et al. 1996). 
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4.5.5. Tissue distribution of the ATS and AT2 receptor 
The sites of expression of the AT, and AT, receptor in the adult mammal are 
summarised in Figure 1-9 (Allen et al. 2000). 
Highly specific receptors for Ang 11 are expressed on the plasma membrane of 
cells responsive to Ang II (Glossmann et al. 1974. Gunther et al. 1980. Gunther tit at 
1982). Cytosolic and nuclear Ang II receptors have also been described (Re et a!. 
1981, Re & Prarb 1984, Tang et al. 1992, Booz et al. 1992. Eggena et al. 1993). Ang 
II receptors have been demonstrated in kidney. vascular tissue. several sites within 
CNS (Dinh et al. 2001), choroid plexus, liver, and adrenal glands (Mendelsohn er al. 
1987, Dinh et al. 2001), gonads (Vinson et al. 1995a, c, Vinson et al. 1997), pancreas 
(Leung et al. 1998). In the kidney, Ang II receptors are located on vessels, on 
glomeruli, and in the outer renal medulla, on renal vascular bundles, or perhaps on 
proximal straight tubules (Sechi et al. 1992, Dinh et al. 2001). Vascular Ang 11 
receptors are concentrated on VSMC, ECs probably do not express receptors for Ang 
11 according to some authors (Gunther et al. 1982) but not others who have suggested 
that both ECs and VSMCs can express both, AT, and AT2 receptor subtypes (Stoll el 
al. 1995). More recently, it has been reported that. in the vasculature, AT, receptors 
are present at high levels in SMCs and relatively low levels in the adventitia and are 
undetectable in the ECs (Zhuo et al. 1998, Allen et al. 2000). 
AT2 receptors are expressed predominantly in the adrenal medulla. 
myometrium. and myocardium in the adult and in the fetal mesenchyTne (Chang & 
Lotti 1991, Kambayashi et al. 1993, Mukoyama ei al. 1993. Wharton et al. 1998. 
Dinh et al. 2001) and more abundantly in embryonic and neonatal than in adult tissues 
(Grady et al. 1991. Millan et al. 1991, Viswanathan c't al. 1991. Tsutsumi & Saavedra 
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1991 a). Though the AT2 receptor is normally expressed at high levels in fetal tissues. 
it decreases rapidly after birth (Nahmias & Strosberg 1995). T 'he le\ els of .AF, - 
binding sites apparently are highly species and tissue dependent. Rat heart 
cardiomyocytes and fibroblasts express the AT, subtype mainly, whereas ECs possess 
AT, as well as AT2 (Nio et al. 1995). AT, receptor is the predominant suhty " found 
in human heart (Regitz et al. 1995, Regitz et al. I996). In the vasculature. AT2 
receptors predominate in the adventitia and are detectable in the media (I huo er al. 
1998). AT2-binding sites have been identified in the rat cerebral artery ('I'sutsumi 
Saavedra 1991 b), aorta (Chang & Lotti 199 ¢ ). in the monkey aorta and kidne cortex 
(Chang & Lotti 1 991). It should be noted that rabbit aorta expresses the AT, subtype 
receptor only. whereas both ATS and AT2 receptor subtypes are expressed in rat 
arteries (Timmerman er a!. 1993). 
4.5.6. Other Ang II receptors 
Two other Ang II receptors have been described, AT3 and A"I'4. The ATz 
receptor subtype, initially described in the neuro 2A neuroblastoma cell line (Chaki & 
Inagami 1992), is peptide-specfic recognizing mainly Ang 11. This subtype does not 
bind nonpeptide ligands such as losartan, or PD123319 (selective AT, receptor 
antagonist). AT3 mRNA is most abundant in the adrenal cortex and pituitary 
(Sandberg et al. 1992). The AT., receptor, which is distributed in heart, lung. kidney, 
brain, and liver, binds Ang IV (Swanson ei al. 1992, Wright & Harding 1997. Zhuo er 
al. 1998) but not losartan or PD 123319. Since the pharmacology of AT3 and A 
1, 
receptors has not been fully characterized, these receptors were not 
included in a 
definitive classification of mammalian AT receptors as defined 
by the international 
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Union of Pharmacology Nomenclature Subcommittee for Angiotensin Receptors (de 
Gasparo 1995). 
4.6. Signal transduction mechanism mediating the actions of Ang 11 in 
4.6.1. Signal transduction pathway and function of ATS receptor 
The signaling cascades involving the AT, receptor have extensively studied 
(Berk & Corson 1997, Kim & Iwao 2000, Dinh et al. 2001). Ang II elicits complex 
highly regulated cascades of intracellular signal transduction that lead to short-term 
vascular effects, such as contraction, and to long-term vascular biological effects. 
such as cell growth, migration, ECM deposition. and inflammation (i'ouvi & 
Schiffrin 2000) (Figure 1-10). To date, AT, receptors have been shown to mediate 
most of the physiological actions of Ang II, and this subtype is predominant in the 
control of Ang 11-induced vascular functions (Sadoshima 1998). 
4.6.1.1. Immediate signaling events stimulated by Ang 11 
Ang II-induced phospholipase C (PLC) phosphorylation and Src family 
kinases activation occur within seconds and constitute immediate signaling events 
(Touyz & Schiffrin 2000). The G protein-mediated activation of phospholipase C 
results in hydrolysis of phosphatidyl 4,5-bisphosphate to form inositol 1.4.5- 
trisphosphate (1P3) and diacylglycerol (DAG) (Bernmann et al. 1997). Ang 11- 
stimulated IP3 generation may also be mediated, in part, via tyrosine kinase-dependent 
pathways (Goutsouliak & Rabkin 1997). IP, stimulates intracellular calcium release to 
activate smooth muscle contraction. AT, receptor activation also leads to opening of 
calcium channels and an influx of calcium into the cell. Exact m chanisrrts whereh% 
73 
CHAPTER I: IN FR OI)1 (' I'IO\ 
time 
coy rse 
L 
Vl 
V 
Ang 11 
-tyrosine -c 
kinases 7 POS ' hRoslns *. º, r 
Src w kinases '' 
PLC Src ý i 
lp DAG 
Cat` PKC 
CONTRACTION PL-A2 
PLC) 
MAPK - MAPK-o 
Temporal 
rrvsrn " ntn, s, s 
Colt growth ECM d. posltlon growth factor production 
VASCULAR REMODELING 1k 
01 
0 
Figure 1-10. Diagram demonstrating the multiphasic 
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Ang II stimulates Ca 2+ influx are unclear but may involve voltage-dependent calcium 
channels, which are activated by Ang II (Arnaudeau et ut. 19%. Lu et al. 1946). In 
addition, tyrosine kinase-dependent increases in Ca`' have been demonstrated in 
VSMC (Hughes & Bolton 1995, Touyz & Schiffrin 1996, Di & Raatz-Ncl_son 1998). 
Ang II-induced DAG production. together with Ca`' and phosphatidylserine. activates 
protein kinase C (PKC). PKC induces vascular contraction via activation of the 
Na+/H+ exchanger leading to intracellular alkalinization. an important modulator of 
actin-myosin interaction, and of contraction (Aalkjaer & Peng 1997). The Src family 
of protein tyrosine kinases also interact with the Al', receptor (Paxton et al. 1994. 
Marrero et al. 1995, Parsons & Parsons 1997, Thomas & Brugge 1997, Ishida et al. 
1998), and play an important role in Ang Il-induced phosphorylation of PLC and IP: 
formation and Ang II-stimulated [Ca+21. responses in human VSMC (i ouyz et a!. 
1999a). 
4.6.1.2. Early signaling events mediated by angiotensin If 
The signaling pathways linked to long-term regulation of VSMC function. 
such as growth, migration, deposition of ECM, and production of growth factor, are 
stimulated by Ang II within minutes. They include: 
(1) Activation of tyrosine kinases. Ang 11 stimulates phosphors lation of 
tyrosine residue of many VSMCs proteins, including the AT, receptor itself. 
PLC and 
Src family kinases. The AT, receptor stimulates tyrosine phosphors lation of the Janus 
family kinases (Jak i. Jak2. Jak3, and Tyk2) (Ihie 1995, Dostal et al. 1997). JAK 
proteins are key mediators of mRNA expression and are characterized as 
'early 
growth response genes'. JAK phosphorylates signal transducers and activators of 
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transcription (STAT) proteins that are translocated to the nuck: us. where they activate 
gene transcription (Horvath & Darnell 1997). Electroporation of antibcwdics against 
STATI and STAT3 abolished VSMCs proliferative responses to Ang 11 but not to 
other growth factors, implicating an essential role of STAT proteins in Ang 11-Induced 
cell proliferation (Marrero et al. 1997). 
(2) Activation of mitogen-activated protein (MAP) kinascs. \RAP kina cs 
constitute a superfamily of serine/threonine protein kinases involved in the regulation 
of a number of intracellular pathways. Ang II activates extracellular signal-regulated 
kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38, which are the three major 
members of the MAP kinase family (Leduc & Meloche 1995, Kudoh c't a!. 1997. 
'Fouyz et a!. 1999b), in cultured VSMCs, as well as in intact arteries (Schiet cr et a!. 
1996a; b, Epstein et al. 1997, Touyz et al. 1999b; c). Ang 11 stimulates ERK-dependent 
pathways via AT, receptors (Flesch et al. 1995, Booz & Baker 1996. Kudoh et al. 
1997, Touyz et al. 1999c) and is associated with increased expression of the early 
response genes c-fos, c-myc, and c-jun (Naftilan et al. 1989a, Lyall et al. 1992), DNA 
synthesis, cell growth and differentiation, and cytoskeletal organization (Seewald et 
al. 1998, Touyz & Schifarin 1999). In addition to ERKs, Ang 11 activates JNKistress- 
activated protein kinases (SAPKs), which regulate VSMCs growth by promoting 
apoptosis or inhibiting growth (Kudoh 1997, Wen et al. 1997. Ip& Davis 1998. 
Schmitz et al. 1998). Ang 11 phosphorylates JNK/SAPK via p? 1-activated 
kinase. 
which is dependent on intracellular Ca2+ mobilization and on 
PKC activation (Schmitt 
et a!. 1998). Following phosphorylation, the isoforms JNK-I and 
JNK-2 translocate to 
the nucleus to activate a number of transcription factors. such as c-Jun. 
A -I F-2, and 
Elk-I (Ip and Davis 1998). The exact functional effects of : ins: 
II-induced signaling of 
76 
CHAPTER 1: INTRODUCTION 
ERK- l /ERK-2 and JNK/SAPK in VSMCs are ill-defined. but regulation of cell 
growth may be important as Ang II-activated ERKs and JNK'SAPKs hale opposite 
growth effects, with ERKs facilitative and JNK! SAPK inhibitory (TouS r& Schiffrin 
2000). It has been found that Ang II also stimulates p38 MAP kinasc. 1-he sp'ecifx: 
upstream and downstream regulators of Ang 11-activated p38 in VSNICs are unclear. 
but p38 has been implicated to be a negative regulator of ERK-1 /ERK-2 (Kusuhara er 
al. 1998). 
(3) Activation of phospholipase A2 (PLA2) and arachidonic acid metabolism. 
Ang II stimulates PLA2 activity. which is responsible for the release of arachidonic 
acid from cell membrane phospholipids (Bonventre 1992. Rao er a1.1994). Released 
arachidonic acid is processed by cyclooxygenases, lipoxygenases, or cytochronx 
P450 oxygenases to many different eicosanoids in vascular and renal tissue. 
Cyclooxygenases catalyze the formation of prostaglandin P6112, which is 
subsequently converted to thromboxane (TXA) by thromboxane synthase, or to the 
prostaglandin PGI2 (or prostacyclin) by prostacyclin S nthase, or PGP2, P(; D, or 
PGF2a, by different enzymes (Smith et al. 1991). Activated PLA2 and its mctatxolitcs 
in turn activate Ras/MAP kinase-dependent signaling pathways, amplifying PLA2 
activity and releasing additional arachidonic acid by a positive feedback mechanism 
(Muthalif et al. I998a). Ang II-generated eicosanoids regulate vascular contraction 
and growth, possibly by activating MAP kinase and redox sensitive pathways 
(Nasjletti 1997, Dulin et al. 1998). Thromboxanes are involved in Ang 11-induced 
contraction, whereas vasorelaxant prostaglandins such as PGE2 and PG12 attenuate 
Ang II-mediated vasoconstriction in vascular bed (Wilcox & Lin 1993). 
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(4) Activation of phospholipase D (PLD). PLD. which h%drolwes 
phospholipids (mainly phosphatidylcholine) to generate phosphatidic acid, ka critical 
component in cellular signaling associated with mitogenesis (Dhalla er a!. I9t. 
Gomez-Carnbronero & Kiere 1998). Hydrolysis of phosphatid)ichohnc h% PU. l) kad% 
to the production of phosphatidic acid and subsequent generation of DAG hk 
phosphatidic acid phosphohydrolase (Billah 1993). DAG contributes to prolonged 
activation of PKC. This pathway probably represents the major cascade by which Ang 
II-induced activation of PKC remains sustained in VSMC's (Touv z& Schiffiin 2000). 
Ang II-induced PLD signaling has been implicated in cardiac hvpertrophv and in 
proliferation of VSMCs (Morton et at 1995, Dhalla et al. 1997). Fhek effects are 
mediated via phosphatidic acid and other PLD metabolites (Boarder 1994, Wilkie ei 
al. 1996, Dhalla el al. 1997). Phosphatidic acid and other PLD metabolites influence 
vascular generation of superoxide anions by stimulating NADIWWNAI)Pll oxidasc". 
which activate tyrosine kinases and serine/threonine kinase Raf (Boarder 1994, 
Eskildsen-Helmond et al. 1997, Gomez-Cambronero & Kiere 1998). 
(5) Modulation of cyclic nucleotides. AT, receptor stimulation inhibits 
adenylate cyclase and leads to a reduction in cAMP. Because cAMP is av auodilator. 
its reduction after AT, receptor activation is likely to contribute to Ang Il-induced 
constriction (Siragy 1999). 
4.6.1.3. Long-term effects mediated by Ang II 
Ang II stimulated long-term effects are mediated via stimulation of redox- 
sensitive pathways. induction of proto-oncogene expression. cross-talk with tyrosine 
kinases receptor and stimulation of nuclear signaling cascades. ultirnatcl; resulting 
in 
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cellular growth (Figure 1-10. In addition, intracellular cascades underl`-ing Ions; -term 
Ang II signaling involve early activation of various kinases (described abow). 
4.6.1.3a Generation of reactive oxygen species 
A non-mitochondrial, membrane-associated NADH/N. \I)I'II oxidase appear` 
to be the most important source of superoxide anion in vascular cells (Griendling et 
al. 1994, R. ajagopalan et al. 1996, Pagano et al. 1998, Lieberthal et al. 1998). This 
enzyme transfers electrons from NADH or NADPH to molecular oxygen. producing 
superoxide anion. The superoxide anion is rapidly coverted by superoxide dismutas 
to H202, which is scavenged by catalase or by peroxidases (Fridovich 1997). 
Superoxide anion and 11202 can undergo further reactions with each other or with 
iron-containing molecules to generate the highly reactive hydroxyl radical ("01 1) 
(Fridovich 1997). Ang II activation of NADH! NADPII oxidase i,, delayed and is 
detectable in VSMCs about 60 minutes after Ang II stimulation. and the etiect is 
sustained for up 24 hours, suggesting that NADW/NADPEI oxidase-dependent 
signaling pathways probably play an important role in Ang Il- events such as cell 
growth (Griendlirtg et at. 1994, Touyz & Schifrin 1999). It has 
been found that 
reactive oxygen species (the superoxide anion and H202) stimulate 
hyperplasia and 
hypertrophy of VSMCs, whereas antioxidants inhibit growth (Boscoboinik et al. 
1991, Rao & Berk 1992, Puri et al. 1995, Tsai et al. 1996). In addition. 
it has been 
suggested that superoxide anion and H202 act as 
intercellular and intracellular second 
messengers that may play a important role 
in vascular tone and cell growth 
(Alexander 1995, Irani et al. 1997, Diaz et al. 1997, Griendling 
&l Tshio-1~ukai 1997. 
Finkel 1998. Abe & Berk 1998). 
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Figure 1-11. Long-term signaling events in vascular smooth muýCIc C II\ 
induced by Ang 11 stimulation. Activation of upstream regulators by Ang 1I. 
such as tvrosinc kinases. MAP kinases. PLD. and PLA, lead to activation of 
various signaling pathways that modulate long-term functions of vascular 
smooth muscle cells. These include generation of reacti\'e oxygen species 
via membrane-associated NADI I/NAI)Pl I oxidise. induction of 
protooncogene expression. cross-talk with tyrosine Einau receptt)r',. 
stimulation of nuclear signaling cascades and production of other growth 
factors. The biological response of these signaling events is increased 
protein synthesis resulting in cell growth that contributes to vascular 
remodelling. 0, -. superoxide anion: 11202. hydrogen peroxide: SO[). 
superoxide dismutase. From I'ou`7 & SchiflTin 2000. 
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4.6.1.3b. Angiotensin [I-induced expression of proto-oncogenes and growth 
factors 
Ang II induces the expression of several proto-oncogenes in human and rat 
VSMCs, including c-fos, c jun, c-myc, Erg-1, V[. -30, proto-oncoýgenc. acti%ator 
protein I complex (Kawahara et al. 1988, Naftilan et al. 1989h. Taubman et al. 1999. 
Naftilan et al. 1990, Sachinidis et al. 1992b. Lvall et al. 1992. (frohe et al. 1994. Duff 
et al. 1995, Pollack 1995, Puri et al. 1995, Patel et a!. 1996). The c-tips prorm ter 
contains a cAMP/calcium response element (C'R. E). a serum response element (SRl., ). 
and a sis-inducing factor element (SIE) (13hat et al. 1994). 'I*hcsc promoter elcmcnts 
are regulated by various proteins activated by Ang 11. including PKA. PKC. and 
STATs (Marrero et al. 1995b). 
Ang 11 stimulated the induction of various growth factors in VSMCs. 
including TGF-ßl mRNA and protein (Gibbons et al. 1992). PDGF mRNA (Naftilan 
et al. 1989a), vascular endothelial growth factor mRNA (VEGF, Williams el al. 
1995), and insulin-like growth factor-I mRNA and protein (I elafontaine & Lou 
1993). In particular. its relationship with TGF-ßß I can also form a positive loop, as this 
growth factor is also a renin secretagogue. which can thus lead to greater production 
of Ang II (Noble & Border 1997). Ang 11 also stimulates other growth 
facto r/cyto kines, including interleukin-6 (IL-6), ET, platelet-activating 
factor (PAl 
and heparin-binding EGF (HB-EGF), from VSMCs and glomerular mesangial cells 
(Itoh et al. 1993, Giachelli et a!. 1995, Moriyama et al. 
1995.1 isueh et al. 1995. Ikeda 
et al. 1995, Egido 1996. Kagami et al. 1997). 
In VSMC S. Ang 11 as found to 
increase the density of surface receptor for PDGF (Bobik ct al. 
1990) and induce 
transcription of PDGF A-chain (Hahn et a!. 1991. 
Natlilan et al. 1989a. Nahahara et 
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al. 1992, Berk & Rao 1993). bFGF (Itoh et al. 1993). IGF-I (Ieelafontaine t't al. 
1993), heparin-binding EGF-like growth factor (Temizer et al. 1992. Dluz er a!. 1993) 
and ET-I (Rossi et al. 1999). Ang II modulates EGF receptor mRN: \ kkv-eh in rat 
aorta (Sambhi et al. 1992). It has been suggested that Ang II exerts its growth effects 
in part through stimulation of these growth factors mRN \ and protein production 
(Berk 2001). 
In addition, Ang II increases gene expression and production of adhesion 
molecules such as vascular cell adhesion molecule- I (VCAM-1), 1: -k l«tin, and 
integrins (Kim et al. 1996, Krejcy et al. 1996. Gerate et a!. 1997,1 (such c't al. 1998. 
Tummala et al. 1999), and monocyte chemoattractant protein-1 (MCP-1) (('hen er al. 
1998), suggesting a potential role of the RAS in contributing to the atherosclerotic 
process (Tummala et al. 1999). 
4.6.2. Signal transduction pathways and functions of AT2 receptor 
Current knowledge on AT2 receptor-mediated signaling is scarce (Nahmias & 
Strosberg 1995). Despite its structure identification as a t; -protein-coupled seven- 
transmembrane receptor, analysis of putative downstream signaling pathways in 
human embryonic kidney cell overexpressing the AT, receptor 
did not pro% ide 
evidence for its coupling to typical G-protein mediated signaling mechanisms 
(Mukoyarna et al. 1995). 
The function of AT2 receptor is still poorly understood (Weir 
& Dzau 1999). 1t 
may have totally different and opposite actions. compared with 
the A site. when 
stimulated (Dzau et al. 1993). Arºg II binding to 
AT2 receptor activates a phosphatase 
that will dephosphorylate target proteins (Inagami of a. 
1999)" whereas the AT, 
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receptor mediates the activation of kinases. This general mechanism is belies cd to be 
important in causing the antiproliferation, apoptosis. differentiation, and %aso dilat, on 
that is attributed to activation of AT2 receptor (Yamada et al. 1996. %, an Kesteren er at 
1997) (Figure 1-12). 
In addition, the mechanism by which Ang II stimulates : 1I'ß-mcdiated 
vasodilation was explored in the sodium-depleted conscious rat model. A significant 
increase in cyclic guanosine monophosphate (cGMP) release into the renal 
interstitium in association with activation of the renin angiotensin system was found 
after sodium depletion for 5 days (Siragy & Carey 1996a). Administration of Iosartan 
did not affect cGMP levels, wherease PD-123319 suppressed cG\tl' generation 
(Siragy et al. 1996a). The results suggest that increase in c(; MP is an A"I*, -m diatcd 
event (Matsubara 1998). Under such low sodium conditions. the increase in cG MP 
was secondary to the release of nitric oxide. inasmuch as the effect %%as blocked hý 
administration of the nitric oxide synthase inhibitor, nitro-L-argininc-methyl ester (L- 
NAME) (Siragy & Carey 1997). Although circulating Ic%els were unchanged, tissue 
bradykinin levels were increased after sodium depletion, an effect that %%as blocked by 
PD-123319 but not by losartan (Siragy & Carey 1996x, Siragy & Care 1999). Thus. 
Arg II-incuced AT2 receptor stimulation leads to bradykinin production and 
subsequent release of nitric oxide followed by elevation of cGGNIP (Siragy 19($)) 
(Figure I- 12). 
4.7. Local renin-angiotensin system (RAS) in the vasculature 
The concept of local RASs arose from a number of observations. 
The birst of 
these was the observation of renin-like activity and of : eng I and 
11 immunoreactivitti 
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Figure 1-12. Ang II-induced signaling via the AT, receptor is mediated by 
the activation of tyrosine and serine/threonine protein phosphatases. Thew 
proteins dephosphorylate other cell regulatory proteins and lead to 
vasodilation, antiproliferation.. apoptosis, and differentiation. Activation of 
the AT2 receptor also leads to bradykinin production. which induces nitric 
oxide, and in turn, increases cyclic guanosine monophosphate (cG M 
P) to 
contribute to the vasodilator , response. Adapted from Siragy 1999. 
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persisting in the plasma of patients after nephrectom%- (Waite 1973, Seaie% et al. 
1977). Secondly, Campbell (1985) calculated that generation of fing 11 within the 
circulation alone could not account for the concentration found in plasma. He 
concluded that Ang II in blood derived mainly from spillage of koall,. gen rated 
peptide within the vasculature. Thirdly. A('1 inhibitors . vere et1ccti%c in Io, -. ering 
blood pressure in normal or low-renn states (Man er al. 1979. E3runrkr er al. 1979) 
indicating the involvement of systems outside the circulation. Fourthly-. the major 
components of the system are expressed to a variable degree in many difkrent tissues 
(Danser 1996). 
4.7.1. Definition of a local RAS 
What is meant when using the term "local RAS"? One or more of the 
following three situations may exist: 
1) The RAS components required for Ang 11 synthesis, i. e. renin. 
angiotensinogen and ACE, are synthesized in situ, thus allo%% ing local Ang 
II generation to occur independently of the circulating RAS. 
2) The RAS components required for Ang 11 synthesis are not synthesized in 
situ, but taken up from the circulating blood, thus allowing local Ang 11 
synthesis to occur only when RAS components are available in the blood. 
3) Combination of 1) and 2). 
When applying definition 2 or 3, one no longer considers in situ synthesis of 
renn of importance, so that. at least in theory. one should 
better speak of a system 
generating Ang II locally instead of a local RAS (Danser 
1996). 
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4.7.2. Evidence for a local RAS in vasculature 
4.7.2.1. Renin in vasculature 
The main controversy in the field of vascular RAS has surrounded the nature 
and particularly the source of vascular renin (Swales & Heagerty 1987, Samani & 
Swales 1991, Unger & Gohlke 1992, Okamura et al. 1992, Hilgers & Mann et al. 
1993, Rosendorff 1996, Admiraal et al. 1999, van den Eijnden 2001). 
Application of specific antirenin antibody has demonstrated intense staining 
throughout the thickness of the aorta and other large and small arteries, as well as 
arterioles (Molteni et al. 1984). Renin-like activity and immunoreactivity has been 
demonstrated in large and small arteries as well as veins (Gould et al. 1964, Ganten 
et al. 1970, Rosenthal et al. 1984, Dzau 1987). In the isolated, perfused rat 
hindquarter preparation, both Ang I and Ang II are generated (Hilgers et al. 1991). 
When cultured bovine aortic endothelial cell sonicates were incubated with the renin 
substrate, angiotensinogen, linear generation of Ang I was observed, and renin 
9 
antibodies inhibited a large portion of the enzymatic activity (Lilly et al. 1985). Ang I 
generating activity was detected in homogenates of canine aortic smooth muscle cells. 
This enzymatic activity was in large part inhibited by renin-specific antisera raised to 
pure canine renal renin (Re et al. 1981). 
Evidence against the existence of vascular renin rests on the observation that 
I 
bilateral nephrectomy causes a dramatic decrease in arterial renin activity, suggesting 
that the renin-like activity associated with the vascular wall is derived from uptake of 
circulating renin of renal origin (Thurston et al. 1979, Fordis et a!. 1983). Only low 
levels of renin mRNA have been demonstrated in arterial wall (Samani et al. 1988. 
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1 
Dzau 1988b). and in some studies. renn mRNA could not be detected at all (Ekker et 
al. 1989). 
However. three sets of observations do provide more definitive evidence of 
local renin synthesis in vasculature: 1) the production of prorenin and renin by 
cultured ECs and VSMCs (Re et al. 1981. Lilly et al. 1985,1 wai et al. 1989. Müller & 
Luft 1998, Admiraal et al. 1999, Van den Eijnden et al. 2001); 2) the observation of a 
significant rise in vascular renn activity in an isolated rat mesenteric artery 
preparation following treatment with indomethacin (Saito et al. 1988); this cannot be 
explained by uptake, and unless the drug in some way affects the enzymatic assay of 
renin, it must reflect an effect on and hence imply the existence of local renin 
production, and (3) the demonstration of renn mRNA in vascular tissue (Samani et 
al. 1988, Samani et al. 1989). 
4.7.2.2. Angiotensinogen in vasculature 
Compared with renn, much less interest has been focused on angiotensinogen 
in the vascular wall (Samani & Swales 1991). However, the continued production of 
angiotensins (Ang I and Ang II) by isolated vascular preparation (Higlers et al. 1989) 
clearly indicate such availability, and this is supported by direct demonstration of 
angiotensinogen in arterial tissue. Angiotensinogen mRNA and protein have been 
detected in VSMCs. ECs, and perivascular fat (Naftilan et al. 1991. Naftilan 1994. 
Morgan et al. 1996, Kubo et al. 1999). 
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4.7.2.3. ACE in vasculature 
Mere is least contention regarding the presence of ACE in the vessel wall 
(Samani & Swales 1991). Although a major site is the external surface of the 
endothelial cells lining the lumen (Caldwell et al. 1976). there is also e% idence for 
sub-endothelial localization of ACE (Pipili et al. 1989. Okamura et al. 1990, 'I'ouvz & 
Schiurin 2000). ACE is found in high concentrations in the adventitia, as well as in 
cultured VSMCs and ECs (Dzau 1989. Ekker et al. 1989. Naftilan 1994). 
4.7.2.4. Local Ang II production via tissue RAS in vasculature 
Based on the finding that all components of the RAS have been demonstrated 
in a number of tissues, for instance the vasculature (as decribed above), brain (Lenz & 
Scaly 1990), heart (Lindpaintner et al. 1987, Dostal et al. 1997. Mazzolai et al. 1998. 
Schwermund et al. 1999, Lijnen & Petrov 1999), kidney (Schunkert et al. 1991, Kim 
& lwao 2000), and reproductive system (Vinson et al. 1997), it has been proposed 
that so-called local or tissue RASs exist (Danser 1996). Nevertheless incontrovertible 
evidence for the existence of all components of the system in physiologically relevant 
amounts and relationships remains elusive (Griendling et al. 1993, Danser 1996). 
All components of the RAS, except renin., have been demonstrated to be 
produced in the vasculature (Touyz & Schiffin 2000). Since vascular renin 
production is absent. local generation of Ang 11 in the interstitium is regulated by 
tissue ACE that is probably dependent on circulating renn (Touvz & Schiffrin 2000) 
(Figure 1-13). 
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Figure 1-13. Scheme of the tissue renin-angiotensin system. 
Angiotensinogen. ACE. and angiotensin receptors have been demonstrated 
in endothelial and vascular smooth muscle cells, as well as in perivascular 
tut. Tissue-derived angiotensinogen is converted to Ang I by renal-derived 
renin that is adsorbed from the circulation. Ang I is cleaved to Ang II by 
tissue ACV'. ACI:, angiotensin converting enzyme: AT rec, angiotensin II 
receptors, endoth. endothelial cells. From Touyz & Schifirin 2000. 
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4.7.2.5. Alternate pathways of vascular Ang II production 
In addition to the well described renin-ACE enzymic axis, multiple pathways 
of Ang II production may exist in the blood vessel wall (Dzau 1989. Takai et al. 1999. 
Takai et al. 2001) (Figure I-14). It is not known whether these enzymatic pathways 
represent in vitro phenomena, or authentic in vivo alternate pathways which are 
activated only when the renn-ACE pathway is blocked, or whether they are operative 
at all times in the vessel wall (Dzau 1989. Takai et al. 2001). 
Immunoaffinity column separations of renin-like enzymes have yielded 
fractions containing non-renin neutral or acidic proteases capable of generating 
angiotensin I from angiotensinogen (Dzau 1984). Enzymatic pathways independent of 
ACE have been described, which may contribute to the blood vessel wall (Dzau et a!. 
1993). Ang II can be cleaved directly from angiotensinogen, bypassing the 
angiotensin I step, by cathepsin G and elastase in neutrophils, by tissue plasminogen 
activator and tonin in vascular tissue (Dzau et al. 1993, Phillips et al. 1993). Several 
enzymes other than ACE can also generate Ang 11 from angiotensin I in vitro. These 
are tissue plasminogen activator, tonirr and cathepsin (Klickstein et al. 1982, Tang et 
al. 1989) and chymase, which has been found in the heart (Urata et al. 1990, Urata et 
al. 1996) and, more recently, chymase-dependent Ang II formation in human vascular 
tissue was reported (Hollenberg et al. 1998, Takai et al. 1998, Takai et al. 1999). A 
chymostatin-sensitive angiotensin II generating enzyme (CAGE) has been reported in 
aortic tissues of dog, monkey and human (Okunishi et al. 1984, Okunishi et al. 1987. 
Dzau el al. 1988. Dzau 1993. Gibbons 1993. Gibbons & Dzau 1994). They found that 
ACE inhibition only partially reduced vessel wall Ang II production, but that the 
addition of chymostatin resulted in the complete blockade of conversion of Ang l to 
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Figure 1-14. Multiple pathways of angiotensin production. ACE, angiotensin 
converting enzyme; CAGE, chymostatin-sensitive angiotensin generating 
enzyme, EDPAE, endothelial cells-derived prorenin activating enzyme, t-PA. 
tissue plasminogen activator. Adapted from Dzau 1989. 
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Ang II. In addition, a prorenin activating enzyme (s). which is necessary for the 
processing to the active enzyme of locally synthesized prorenin or that derived from 
plasma, is present in the aorta. This is a serine protease with an apparent molecular 
weight of 35 kDa (Tang & Dzau 1988). In cultured ECs, prorenin activating enzyme 
has been observed (Dzau et al. 1989). There are several candidate enzymes which 
have shown this property in vitro. These include tissue plasminogen activator (t-PA). 
Kallikrenin, plasmin, cathepsin G. elastase and tonin (Tang et al. 1989. Wintroub et 
al. 198 1, Takada et al. 1987. Sealey et al. 1980). Of these enzymes, t-PA, Kallikrenin, 
and tonin are localized to the blood vessel. Plasmin and Kallikrenin are activated on 
contact with the blood vessel. Cathepsin (J & elastase are relased by neutrophils in 
response to chemotactic factors. The physiological significance of any of these 
enzymes in vivo has not been established (Dzau 1989, Takai et al. 2001). 
Although local production of angiotensins has been investigated extensively, 
both in vivo and in vitro studies, from many of these studies it is difficult to conclude 
whether angiotensin is produced locally by locally synthesized components, by blood- 
borne components of the RAS which have been taken up from the circulation, or by a 
combination of these two (Danser 1996). There is a growing body of evidence to 
support the existence of locally generated Ang II which could act as part of an 
autocrine or paracrine system (Mazzolai et al. 1998, Oosterga et al. 2000, Schieffer et 
al. 2000). As yet, the functions of such systems, are not entirely clear, although their 
role(s) are presumably different from those of the circulating RAS (Robertson & 
Nicholls 1993, Kubo et al. 1999, Kim & Iwao 2000). 
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4.8. Aldosterone 
Aldosterone is the most potent mineralocorticoid produced by the mammalian 
adrenal cortex. Extra-adrenal aldosterone synthesis is now known to occur in a variety 
of mammalian tissues (see CHAPTER 1-5-7. ). including human ECs (Hatakevama et 
al. 1994), rat heart (Silvestre et al. 1998) and brain (Gomez-Sanchez et al. 1997). In 
mammals, it is secreted by the zona glomerulosa cells of the adrenal cortex. The 
critical action of aldosterone is to promote sodium reabsorption in exchange for 
potassium, magnesium, and hydrogen ions at various sites, including distal tubules 
and collecting ducts in the kidney. Thus, sodium is retained, while potassium, 
magnesium, and hydrogen ions are lost. When there is a physiologically inappropriate 
excess of aldosterone there is consequent elevation of arterial pressure accompanied 
by sodium retention, hypernatremia, potassium deficiency. hypokalemia, and 
extracellular alkalosis (Brown et al. 1964, Brown et al. 1965). It has been suggested 
that aldosterone directly augments peripheral vascular resistance by altering ion fluxes 
in VSMC (Kornel et al. 1982, Berecek et al. 1982, Gomez-Sanchez 1997, Christ & 
Wehling 1999). 
5. Steroidogenesis in the adrenal cortex 
5.1. Steroid biochemistry 
Cholestane (C27) may be considered to be the stem structure from which all 
steroid hormones are derived (Vinson et al. 1992a). Cholestane has four carbon atom 
rings. three of six carbon atoms (rings A. B. C) and one of five (ring D) linked 
together as illustrated (Figure I-15). The different categories of steroid hormone are 
distinguished by the length of the side chain and the number. location and orientation 
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Figure 1-15. The structure of cholestane, not formed 
naturally in nature but considered the parent hydrocarbon for 
cholesterol and other steroid molecules. Adapted from 
Vinson et al. 1992a. 
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of substituent groups. Substituents projecting from the plane of the ring towards the 
observer is designated 0 and shown by a continuous line. Substituents projecting from 
the plane of the ring away from the observer. the a configuration. is indicated by a 
dashed line. Small changes in the structure can have a profound effect on biological 
activity (Fraser 1992). Cholesterol, the most important compound of this class. ditTers 
from the parent hydrocarbon by having a hydroxyl group at C-3 and a double bond 
between C-5 and C-6 (Figure I- 16). 
Based on the cholestane ring structure. the vertebrate adrenal cortex can 
secrete progestogens (C21), androgens (C19), oestrogens (C18) and corticosteroids 
(C21). The 21-carbon corticosteroids, including the glucocorticoids and the 
mineralocorticoids, are structurally characterized by: 
(1) An oxo group at C-3 and a double bond between C-4 and C-5. 
(2) A 2-carbon side-chain on C- 17. 
(3) An oxo group at C-20. 
(4) Presence/absence of hydroxyl groups both at C-1 I and C- 17. 
5.2. Sources of cholesterol for adrenal steroidogenesis 
There are two sources of cholesterol in the adrenal cortex. It may be 
transported from the plasma into the cell with the circulating plasma lipoprotein, low- 
density lipoprotein (LDL) in the human and bovine (Kovanen et al. 1979a, Carr et al. 
1980, Ohashi et al. 1981). or high-density lipoprotein (HDL) in the rat ((; «vnne ei al. 
1976, Gwynne & Hess 1980). Receptor mediated endocvtosis is responsible for 
uptake into cells (Kovanen et al. 1979b. Brown et al. 1979). It can also be 
biosynthesized de novo from acetate (Goad 1984). The rate limiting step for this 
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process is the conversion of 3-hydroxv-3-methvlglutarvl-Co. (HMG-C'oA) to (3R)- 
mevalonic acid by HMG-CoA reductase, a microsomal enzyme (Goad 1984). 
The two sources of cholesterol probably have varying important in different 
species. The rat, such as, is known to have 'fatty' adrenal. where circulating 
cholesterol may be the most important source (Lloyd 1972) whereas in the hamster (a 
`nonfatty' adrenal), that de novo synthesis of cholesterol within the adrenocortical cell 
is extremely important (Lloyd 1972, Lehoux 1980). 
Cholesterol is stored in the adrenal cells in droplets, mainly as cholesterol 
esters (Sandor et al. 1976). Acyl-coenzyme A: cholesterol acyltransferase (ACA 1) 
and cholesterol ester hydrolase (CEII) are two enzymes principally concerned with 
cholesterol esterification and hydrolysis in lipid droplets (Boyd et a!. 1983, Jamal et 
al. 1985). 
5.3. Cytochrome P-450 (CYP) 
Steroid is synthesized from cholesterol via a series of hydroxylation and 
oxidations. These reactions are catalyzed by a hydroxysteroid dehydrogenase system 
and a series mixed function oxidases or 'hydroxylases'. The hydroxylases are 
cytochrome P-450s (CYPs), catalyzing the oxidation of the steroid molecule with one 
molecule of oxygen (Fraser 1992): 
Steroid-H + NADPH + H'+ 02 ----4 Steroid-OH + NADP + H? O 
5.3.1. General features of CYPs 
The CYPs are a large family of oxidative enzymes. all of which contain a 
single haem group. They are termed P-450 (pigment 450) because all exhibit a 
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characteristic 450-nm absorbance maximum when reduced with carbon monoxide 
(Miller 1988). The active site of P450 contains a single iron protoporphyrin prosthetic 
group. Dioxygen is bound, reduced, and activated at this site. Four CYP enzymes are 
involved in adrenal steroid biosynthesis (Figure 1-17). 
The electrons transferred by the mitochondrial enzNmes. CY P' I1 Al and 
CYP I1BI, are provided through an electron transport systun comprised of 
adrenodoxin, a non-haeme iron binding protein that exists in soluble form in the 
mitochondrial matrix, and adrenodoxin reductase. a mitochondrial membrane-bound 
flavoprotein. Adrenodoxin reductase accepts electrons from NADPII and transters 
them to adrenodoxin, which serves as a shuttle to deliver reducing equivalents to 
various CYPs. The enzymes then transfer electrons, by way of oxygen, to the steroid 
(Orth & Kovacs 1998) (Figure I-18). 
The electrons transferred by the microsomal enzymes. CYP 17 and C YP21 A2 
are provided through a single flavoprotein, NADPH-P450 reductase. NADPE I-P450 
reductase supplies electrons to CYP 17 and CYP21 A2. NADPH-P450 reductase 
transfers two electrons sequentially from NADPH to CYP 17. Cytochrome b5 may also 
donate the second electron (Figure I-19). 
The NADPH required to support the various hydroxylations is derived from 
the glucose 6-phosphate dehydrogenase reaction in the cytosol (Haynes & Berthet 
1957). Mitochondria are supplied with reducing equivalents through the 'malate 
shuttle'. which transfers malate from the cytosol to mitochondria. Malate is converted 
to pyruvate, generating NADPH, through a reversible reaction which favours malate 
synthesis in the cytosol and pyruvate and NADPH formation in the mitochondria. 
Thus reducing equivalents are shuttled into the mitochondria (Simpson & Frenkel 
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Trivial Name 
Cholesterol side-chain cleavage enzyme; 
desmolase 
3 3-Hydroxysteroid dehydrogenase 
17a-Hydroxy lase/ 17,20-lyase 
21 -hydroxylase 
II ß-hydroxylase 
Aldosterone synthase; 
Corticosterone 18- 
Methylcorticosterone oxidase/lyase 
Past Current 
P450, 
3I3-HSD 
CYP II AI 
3 3-HSD If 
P450,  CYP17 
P450,21 CYP2I A2 
P450,11 CYPIIBI 
P450,11&s C'YP1 1 B2 
(iene 
(')'PI 1. -11 
1l, S'D3B2 
CIPI7 
C}7 ' 1. "1' 
CYPI1B1 
('}PIIB' 
Figure 1-17. Nomenclature for steroidogenic enzymes and their Genes. 
Recommendations for naming a P450 gene include the italicized root symbol 
'C'}P' and an Arabic numberal representing the individual gene. The same 
numbers and letters in nonitallicized and all capital letters are recommended 
for the corresponding gene product (mRNA, cDNA, enzyme). Adapted from 
Orth & Kovacs 1998. 
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HOCH2 -J1d 
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CYP ,0 
CH; steroid 
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Adrenodoxin CYP 1IAIk 
or pz 
CYPl1Bl 
Figure 1-18. Electron shuttle system for the mitochondrial enzymes, 
CYP l1A1 and CYP 11 B 1. Adrenodoxin reductase receives electrons from 
NADPH and reduces adrenodoxin. which transfers reducing equivalents to 
the CYP enzyme. The enzyme then transfers electrons, by way of oxygen, to 
the steroid. Fp, flavoprotein, Fp.. reduced form of flavoprotein. Adapted from 
Orth & Kovacs 1998. 
1(N) 
NADPH 
NADP 
Fp 
" Fp= 
P450 reductase 
or 
Cv toc: hrome hs 
Fes+ 
HOCH2 - steroid 
r. vD_ CHs-steroid 
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CYP? I 12 02 
H2O 
Figure 1-19. I'lectron shuttle system for the microsornal cnivmes. (')T17 
and CYl'2 I A2. P450 reductase, a ilavoprotein, accepts electrons from 
NAI)Pl I and transfers them to the NADPI 1-P450 enzyme. The enz' nie 
then transfers electrons, hv vv ay of oXv vCfl. to the steroid. A second 
reducing equivalents ma\ be supplied to CYP17 by NA[)I'll-114-50 
reductase or cvtochrome b5 Adapted from Orth & Kovacs 1998. 
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1969). In addition. isocitrate dihydrogenase is NADP' linked in the rat adrenal 
(Vinson et al. 1992a) 
5.3.2. CYPIIAI 
CYP l1A1 (P-450,,,, ) is the cholesterol side-chain cleavage enzyme found in 
adrenal mitochondrial, catalyzing the rate limiting step in the biosynthesis of steroid 
hormones, the formation of pregnenolone from cholesterol. The mitochondrial 
CYPI IAI catalyses hydroxylation first at C-22 and then C-20. followed by side-chain 
cleavage to give the 21-carbon pregnenolone and the 6-carbon isocaproic acid 
(Roberts et al. 1969, Dixon et al. 1970, Hume & Boyd 1978, Larroque et al. 1981. 
Lieberman et al. 1984) (Figure 1-I6, Figure 1 -20). 
5.3.3. CYP17 (P450,17) 
CYP 17 is a microsomal enzyme that catalyzes both the hydroxylation of the 
C 17 of progesterone or pregnenolone (17a-hydroxylase activity) and the cleavage of 
the residual two-carbon side chain at C (17,20-lysase activity) (Bradshaw et a/. 
1987, Chung et al. 1987) (Figure 1-16). In the adrenal cortex of humans, cow, sheep, 
and pigs pregnenolone is converted by CYP17 to 17a-hydroxypregnenolonc. 
Adrenals of rats, rabbits, hamsters, and guinea pigs do not contain C YP 17 and the 
pregnenolone is converted directly to progesterone by the 3ß-IISI) II (3ß- 
hydroxysteroid dehydrogenase/isomerase). The latter enzyme converts 17a- 
. hydroxypregnenolone to 17a-hydroxyprogesterone in humans (Quinn 1988) 
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Figure 1-20. Pathways of steroid biosynthesis in an adrenocortical cell shoý%ins the 
intracellular locations of the five steruidogenic enzymes: P450,; ß (Cholesterol side-chain 
cleavage enzyme: desmolase), P45017(, (I7a-Ilvdroxvlase/ 17.20-lyase), P450,1 (21- 
hvdroxvlase). P45011p (I 1(3-h's'droxvlase). P450", (Aldosterone svnthase) and 3 j311SD (3[-- 
I l\ droxvsteroid dehvdrogenase). The substrate for steroid biosynthesis is cholesterol deri%ed 
from low-density lipoprotein ([. DL). The circled asterisk indicates the rate-limiting step of 
steroidogenesis. that is. the transport of cholesterol across the mitochondrial membranes bý 
the steruido enic acute regulatory (StAR) protein. Stimulation effixt of AC I'll on the earl\ 
path\\a\ of steruidogenesis is mainly mediated by cAMP. Actions of Ang II are mainly 
mediated h\ phosphatidyl inositol hN drul\ sis with release of' inositol trisphosphate ON)) and 
1.2-diacvlgl\cerol (DAG). IN stimulates release of calcium into cytoplasm from intracellular 
stores. Potassium ions are thought to depolarize the cell membrane. resulting in the acti%ation 
of plasma membrane voltage-gated calcium channels: that is. both Ani; 11 and K trigger the 
calcium messenger s\ stems and raise c\ tosolic free calcium concentration to stimulate 
aldosterone secretion. The interrupted arroN\s refer to the transfer of steroids between 
organelles. 13. corticosterone. DH[: A. dehvdroepiandrosterone: DOC. deo\ýcorticosterone. S. 
I -deov\ eortisol. 18-011-[)OC. 1 S-hý droxv- I I-deo\scortirosterone: 
18-011-13.18- 
hý droxveorticosterone. Note that in the row, pig. or sheep, no specific P450,1,,, has been 
reported. The P4501111 reported in these species catalyzed all the reactions from [XX' to 
aldosterone. Adapted from Boon cr cal. 1997. 
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5.3.4. CYP2lA2 
CYP2l A2 is a microsomal enzyme. Both progesterone and 17a- 
hydroxyprogesterone undergoes 21 -hydroxylation by C'YP2 I A2. -which leads to the 
production of deoxycorticosterone (DOC) and I1-deoxycortisol, respcctiv-cl,, - 
(Kominami et al. 1980). 
5.3.5. CYP1IB1 (P450,1ß) and CYPllB2 (P450,, ) 
CYP 1lBI and CYP ll B2 are the enzymes involved in late steps of 
mineralocorticoid and glucocorticoid syntheses. The syntheses in the adrenal cortex 
are zone-specific; glucocorticoids are mainly produced in the zonae fasciculata- 
reticularis, while mineralocorticoids are formed in the zona glomerulosa. Such zone 
specificities are attributable to the localization of CYP 1iB1 and CYP 11132. which are 
responsible for the formation of corticosterone and aldosterone, respectively (Ulick 
1976, Lauber et al. 1987, Kirita et al. 1988. Hashimoto et a!. 1989, Ogishima et a!. 
1989, Nonaka et al. 1989, Matsukawa et al. 1990, C'urnow ei al. 1991, Kawamoto et 
at. 1992). 
5.3.5.1. CYP1IB genes 
Four forms of the rat CYPI IB gene, which were tentatively named C'VP1113 1. 
-B2, -B3 and B4 have been identified (Mukai et al. 1993). 
The numbers and the 
locations of the exons of CYP 11 B1, -B2. and 133 corresponded to each other. 
consisting of 9 exons divided by 8 introns and spanning about 6.5 kb DNA (Niukai cr 
al. 1993. Nomura et al. 1993). The CYP II B4 lacked a sequence corresponding to the 
region encompassing exon 3 and a part of exon 4 present in the other three genes. 
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hhus CYP 11 B4 is likely to be a pseudogene (Mukai et o!. 1993). Among them. 
CYP IIBI and CYP II B2 encode steroid 11 ß-hydroxylase (which has retained the 
name P450i i ß, although the recommended nomenclature is ('YP IIB I) (Nelson ei a!. 
1 996) and aldosterone synthase (CYP I 1132). respectively. while C'VP 11133 is a gene 
highly homologous to CYPlIBI without a known expression product. In the 
nucleotide sequences, CYP IIB1, -B3, and -B4 showed 95-96 and 93-1000/O identities 
in the coding and 0.5 kb 5'-flanking regions. respectively. The overall nucleotide 
sequences of CYP IIB1, -B3 and -B4 have higher homologies than those between an 
one of these three and CYP I1 B2. Thus. CYP IIB1, -B3 and -B4 form a subgroup in 
rat CYP llB genes. 
In contrast, CYP 11BI and CYP 1 1132 have a homology of their nucleotide 
sequence much higher in their coding (88%) than in their 5' upstream (539%%) 
sequences (Matsukawa et al. 1990, Nonaka et al. 1989. Irrmai et al. 1990. Mukai et a!. 
1991, Okamoto et al. 1992, Nomura et al. 1993). This difference in the regulatory part 
of the two genes amply explains considerable differences in their expression between 
the zones of adrenal cortex and in response to various physiological stimuli (Müller 
1998). As a whole, CYP II B2 rather than CYP 1IB1, -B3 or -134 vas found to be more 
homologous to CYPI IB genes of other animals (Mukai et al. 1993. Nomura et al. 
1993). 
In the human, there are only two CYP IIB genes. ('YP 11131 and (' V" P1 1132 
(Zhang & Miller 1996). The CYP 11 B2 gene is located approximately 50 kb upstream 
of CYP 11 B1 and on chromosome 8q22 (Mornet ei al. 1989,1, ifton et al. 1992). 
CYPI 1 B2 shares more than 90% sequence homology with CYP11131 at the protein 
level (Mornet et at. 1989) and appears to have a molecular weight of 49 
k[)a (Curnoa 
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et al. 1991, Ogishima et al. 1991). C YP 11 BI at the protein level is the enzme a 479 
amino-acid protein of molecular weight 51 kDa that is almost identical to the 
CYPI I B2 (aldosterone synthase) (Orth & Kovacs 1998). 
5.3.5.2. The nature of CYP11BI and CYP11B2 
In some species, such as human, rat and mouse. CYPI 1131 is found mainly or 
exclusively in the zona fasciculata (Lauber et al. 1987. Ogishima et al. 1989. 
Matsukawa et al. 1990, Curnow et al. 1991. Domalik et al. 1991. Kawamoto er al. 
1992). It is not aldosterone producing (Boon et al. 1997) and can hydroxv late IXX' 
only at C-I l or at C- 18 (Figure I-21. Figure 1-22). Thus DOC is converted either into 
corticosterone, which is the major glucocorticoid in rodents, or 18- 
hydroxydeoxycorticosterone (18-OH-DOC). In contrast. CYP 11B? is found only in 
the zona glomerulosa. All three terminal steps in the conversion of intermediate DOC 
to aldosterone (1 1 ß-hydroxylation, 18-hydroxylation, and 18-methyl oxidation) are 
catalyzed by CYPI I B2 (Figure I-21, Figure 1-22) (Lauber et a!. 1987, Ogishima et a!. 
1989, Matsukawa ei al. 1990, Curnow et al. 1991. Domalik et al. 1991, Kawamoto ei 
al. 1992). In other species, such as cattle, pigs and sheeps, there is only one type of 
11 ß-hydroxylase although there are two isozymes encoded by two different gene in 
the bovine adrenal cortex (Figure I-23), which is equally expressed in all zones on the 
adrenal cortex (Yanagibashi et al. 1986. Ohnishi e1 al. 1988. Ogishima et a!. 1988. 
Morohashi et al. 1990, Boon et al. 1995). In the glomerulosa. the enzyme converts 
corticosterone to aldosterone. However. «ithin the zona fasciculata and Iona 
reticularis, its inherent aldosterone-producing activity is completely blocked by an 
I Ol 
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unknown mechanism, and only its 11 ß-hydroxv-lase and 18-hydroxvlase acti- itics 
remain intact. 
5.3.5.3. Physiological control of CYP1IB1 and CYP11B2 genes expression in rat 
adrenal cortex 
In the mouse adrenal cortex, CYP 1lB1 is expressed only in the tuna 
fasciculata and reticularis and CYP 11 B2 is expressed only in the zona gloms rulosa 
(Domalik et al. 1991, Yabu et at 1991. Ho & Vinson 1993, Mitani et al. 1995,1997. 
1999, Müller 1998). 
CYP llBI expression in the zona fasciculata depends on plasma AC Il 
concentrations (Mitani et a/. 1996). Treatment with dexamethasone markedly 
decreases CYP 11B1 mRNA levels. Normal levels can then be restored by treatment 
with ACTH (Malee & Mellon 1991. Oertle & Müller 1993). Dexamethasone 
treatment had only a minor inhibitory effect on CYP II B2 expression in the zona 
glomerulosa of normally fed or sodium-restricted rats. Sodium restriction and 
potassium loading markedly increased levels of CYP II B2 mRNA (Malec & Mellon 
1991, Imai et al. 1992, Tremblay et al. 1992, Oertle & Müller 1993). 
The stimulatory effects of sodium restriction and of potassium loading of rats 
on CYP I1 B2 expression were totally or partially blocked by treatment with ACI - 
inhibitor, captopril, indicating that induction of CYP 11 B2 is dependent on the 
systemic or local production of Ang 11 (Shibata et al. 1991. Tremblay el al. 1992). 
Alterations in the sodium and potassium status of rat did not gcncrally affect 
CYPIIBI biosynthesis and CYPIIBI mRNA expression in the zona tikiculata 
(Ogishima et al. 1992. Ho & Vinson 1993). 
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5.4.3ß-hydroxysteroid-dehydrogenase/isomerase (30-HSD) 
30-HSD is found in the microsomal fraction. The reactions catalyzed b this 
enzyme include conversion of pregnenolone to progesterone and I7u- 
hydroxypregnenolone to 17(x-hydroxyprogesterone in human. It has t-v%-o major 
catalytic activities, converting 3ß-hydroxy-5-ene steroid into the 3-keto-4-ene 
configuration; 3ß-hydroxysteroid dehydrogenation and 5-ene-4-ene isomerization 
(Hanukoglu 1992). There are at least 2 or 3 homologous genes for 3ß-HS[) activity in 
each species, the rat has three types. Type I and 11 expressed in the rat adrenal share 
93.8% homology; Type III is expressed only in rat liver (Labrie et al. 1992)). 
5.5. Biosynthesis of steroid hormones in the adrenal cortex 
The main steroid hormones produced and secreted in the adrenal cortex are the 
mineralocorticoid, aldosterone, and the glucocorticoids, corticosterone in the rat and 
cortisol in human and in other species, and, at least in some species, including man. 
the androgens, androstenedione and dehydroepiandrosterone. 
5.5.1. Aldosterone biosynthesis 
Cholesterol is transfered from the outer to the inner mitochondrial membrane. 
and this constitutes the rate-limiting step in steroidogenesis (Jefcoate et u/. 1987). A 
number of factors have been postulated to play a role in this transport (Strotz 1990). 
including a 13.5 kDa steroid carrier protein-2 (SCP-2) (Noland er a/. 1950. 
Chanderbhan ei al. 1983). a 3.2 kDa steroidogenesis activator peptide` (Pedersen & 
Brownie 1983. Pedersen & Brownie 1987). an 8.2 kDa protein (Vanagibashi er o1. 
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1988), and the peripheral benzodiazepine receptor (Papadopoulos er a!. 1991 a. 
Papadopoulos et al. 1991 b). However, the most critical factor may lxx the 
steroidogenic acute regulatory (StAR) protein review by Stocco and ('lark (1997 ). 
Clark et al. (1995) have shown that Ang 11 and K- induce the expression of the StAR 
protein. 
The initial step of the `classic' aldosterone biosynthesis pathway (reviewed by 
Miller 1988) is the conversion of cholesterol to pregnenolone by ("I11IAI in the 
mitochondria. In endoplasmic reticulum, pregnenolone is converted to progesterone 
by 3ß-HSD. Progesterone generated from pregnenolone by 3P-HSD is hydroxv lated 
by CYP21 in the microsomes to produce DOC. This product is transported back to the 
mitochondria for conversion to corticosterone (B), which is finally converted toi 
aldosterone, probably via 18-hydroxycorticosterone (18-011-B) (Figure 1-20, Figure I- 
22). An alternate pathway has been proposed for the late aldosterone biosynthesis 
reaction steps: that is, DOC is 18-hydroxylated to 18-O1-i-DOC before being 11 P- 
hydroxylated to 18-OH-B (Figure I-20, Figure 1-22) (Vinson et a!. 1991, Boon et u!. 
1996). 
5.5.2. Glucocorticoid biosynthesis 
Pregnenolone is also the substrate for glucocorticoid biosynthesis. In 
endoplasmic reticulum. pregnenolone is converted to 
I7a-hydroxtipregnenolone by 
CYP 17 in human. 17a-hydroxypregnenolone is acted upon by 3p-1 1SI) to 
form 17u- 
hydroxyprogesterone. or pregnenolone from pregnenolone (Figure 
1-16. Figure 1-20). 
The progesterone or 17a-hydroxyprogesterone then undergoes 
hydroxylation at C-21 
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by CYP21 A2, which leads to the production of deoxvcorticosterone (DO(' ) and 11- 
deoxycortisol (S), respectively. DOC and S then leave the endoplasmic reticulum and 
enter the mitochondria for the final step in glucocorticoid production. which is 
catalysed by CYP I1BI. Thus DOC is converted into corticosterone. which is the 
major glucocorticoid in rodents, while S is converted into cortisol. the primary 
glucocorticoid in humans (Orth & Kovacs 1998) (Figure 1-16. Figure 1-20). 
In addition, dehydroepiandrostenedione is formed from 17u- 
hydroxypregnenolone, and androstenedione from I7a-hydroxýprogesterone by the 
action of CYP 17 (Figure 1-20). Both dehydroepiandrostenedione and androstenedione 
can serve as precursors for other hormones, such as androgen (Vinson er al. 1992a). 
5.6. Regulation of aldosterone secretion 
Aldosterone secretion is governed by multiple factors that exert complex 
regulatory interaction (Müller 1998). These various factors regulate aldosterone 
secretion by modulating one or both of two biosynthesis steps. The early step is the 
conversion of cholesterol to pregnenolone, and the late step is the conversion of 
corticosterone to aldosterone. 
5.6.1. Factors that stimulate aldosterone secretion 
5.6.1.1. Ang II 
There is a high degree of correlation between plasma Ang II and the secretion 
rate or blood level of aldosterone on various species studied (Boon et al. 1997). such 
as the dog (Nicholls et al. 1978), Rat (Davis & Spielman 1974). and human (Brown et 
al. 1972). 
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Glomerulosa cells respond to Ang 11 stimulation via the AT, receptor. 
involving G proteins and phospholipase C (Ganguly & Davis 1994, Boon et al. 1997. 
Lumbers 1999, Dinh et al. 2001) (Figure 1-20). The binding of : eng 11 to the (1- 
protein-coupled receptor results in increased cytoplasmic [Ca2' ] (Johns)n er al. 1988, 
Agarwal & Mirshahi 1999, Lumber 1999. Dinh et al. 2001). These events lead to 
stimulation of the conversion of cholesterol to pregnenolone and corticosterone to 
aldosterone (Lumber 1999). In rat zona fasciculata/reticularis cells. inositol 
trisphosphate levels are increased by Ang 11 (Whitley er al. 1987). 
5.6.1.2. Potassium 
Elevated extracellular potassium is a direct stimulus of aldosterone secretion 
(reviewed by Miller 1988) (Boon et a!. 1997. Miller 1998, Lumbers 1999). Potassium 
ions depolarize the cell membrane, which activates plasma-membrane voltage-gated 
calcium channels, permitting influx of extracellular calcium (Quinn & Williams 1988, 
Kojima et al. 1985). The increased cytosolic calcium stimulates the same two steps in 
aldosterone biosynthesis as Ang II does (Mckenna et at. 1978, Aguilera & Catt 1979). 
There is a reciprocal relation between serum potassium and aldosterone 
concentrations (Vinson et a!. 1992a. Müller 1998). Potassium directly increases 
aldosterone secretion by adrenal cortex, and aldosterone lowers serum potassium by 
stimulating its excretion by kidney. Small changes in serum potassium concentration 
within the physiological range affect aldosterone secretion. An increase in serum 
potassium of as little as 0.1 mmoVL increases aldosterone by 3 5° o. and a dcecrea-w of' 
0.3 mmoVL reduces aldosterone by 46% (Himathongkam et at 1975). High dietan 
potassium intake increases plasma aldosterone and enhances the aldosterone response 
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to a subsequent potassium or Ang 11 infusion, whereas reduced potassium intake 
results in decreased responsiveness (Dluhy et al. 1972.1-lollenberg et a!. 1975. Quinn 
& Williams 1988). 
5.6.1.3. Sodium 
An altered sodium balance influences aldosterone secretion mainly by indirect 
effects through changes in renin secretion and to a minor extent by direct ct1ects on 
zona glomerulosa responsiveness to Ang II (Lumbers 1999). High sodium intake 
increases vascular volume, which suppresses renin secretion and Ang 11 generation. 
whereas sodium deprivation leads to increased renin secretion (Orth & Kovacs 1998). 
A low-sodium diet increases and a high-sodium diet decreases the sensitivity and 
magnitude of the aldosterone response to Ang II in vivo and vitro (Hollentkrg et al. 
1974, Williams & Braley 1977, Vinson et a!. 1992a, Lumbers 1999). 
Although the major effects of altered sodium balance on zona gloriwrulosa 
function is indirect, there is evidence for a direct action of sodium on aldosterone 
secretion (Orth & Kovacs 1998). The effects of changing the sodium chloride 
concentration in the medium supplying a perfused dog adrenal gland were found to he 
very similar to those of changing osmolarity (Schneider et al. 1985). Decreasing 
plasma sodium concentration from 142 mmol/L to 122 mmoVl.. whilst maintaining 
plasma osmolarity caused an increase in aldosterone (Balla ei al. 1981). I'his effect 
was not due to enhanced activity of the RAS or ACTH secretion. However, E n%edi ý: 
Spät (1981) found that zona glomerulosa cells exposed to vying concentrations cif 
sodium ions in vitro, did not exhibit differences in aldosterone secretion. 
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5.6.1.4. Adrenocorticotropin (ACTH) 
ACTH is a 39-amino-acid peptide. released from the corticotroph cells of the 
anterior pituitary. Its bioactivity disappears from the circulating blood with a half-life 
of 4-8 min (Besser et al. 1971. Orth 1979. Donald 1980). The effects of . \('Tll on 
steroidogenesis can be divided into acute effects. which occur within minutes. and 
chronic effects, which require hours or days (Orth & Kovacs 1998). 
ACTH increases the secretion of all steroids including aldosterone (Lumbers 
1999). ACTH is not regarded as a major physiological stimulus of aldostreone. 
because the aldostreone response to ACTH is not sustained (Lumbers 1999). With 
continuous infusion of ACTH aldostreone levels return to normal within 1-3 days 
while cortisol levels remain elevated (Lumbers 1999). ACTH stimulates secretion of 
glucocorticoids, androgenic steroids, and, to a lesser extent. aldosterone from the 
adrenal cortex. In vitro studies have shown that ACTH causes an increase in the rate 
of aldosterone secretion in adrenal capsular tissue (Kaplan & Barter 1962). Studies 
with the isolated perfused in situ rat adrenal preparation have shown that acute ACTH 
administration increases aldosterone secretion (Hinson et al. 1985). In vivo, ACTII 
secretion increase circulating aldosterone levels, an effect that is blocked by 
hypophysectomy (Williams & Dluhy 1983). However, aldosterone secretion usually 
remains normal after hypophysectomy because the RAS and potassium are the major 
regulators. ACTH increases the rate of synthesis of CYP enzym cs. including 
II lAl (DuBois et al. 1981). CYP 17 (Zuber et al. 1985). C'YP21. \2 (Funkenstcin 
ei al. 1983) and CYP 11 B1 (Kramer ei al. 1983. Müller 1998). However, the effect of 
ACTH on CYP II B2 gene expression is controversial. Holland and Carr (1993) 
reported that CYP II B2 mRNA increased after 3 hours, but decreased after 24 hours, 
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in ACTH-treated rat. Curnow et al. (1991) reported no stimulatory effects of AC I'll 
on the expression of CYP 11 B2 mRNA in cultured human adrenal glonkrulosa cells. 
Müller and Oertel (1993) reported that ACTH decreased the expression of (' VP 1 113' 
mRNA in rat adrenal glands. 
ACTH increases aldosterone secretion by binding to a cell-surface receptor on 
adrenal cells, the melanocortin-2 receptor (Mountjoy et al. 1992, Cone & \tountjoy 
1993) and up-regulates expression of the receptor. thereby enhancing the 
steroidogenic response to ACTH stimulation (Mountjov er al. 1994. Penhoat ei at 
1995). ACTH binding activates adenylate cyclase activation and increases CAMP 
concentration, which in turn activates cAMP-dependent protein kinase (protein kinasc 
A) and phosphorylation of a number of'protein (Gill 1976. Kapas et al. 1998). The 
response depends on extracellular calcium influx (Perrin et al. 1995) and can he 
partially blocked by calmodulin inhibitors (Aguilera & Catt 1986). 
5.6.1.5. Vasopressin 
Vasopressin is known as a hormone from the neurohypophysis with 
vasoconstrictor and antidiuretic activity. Vasopressin has a modest, transient 
stimulatory effect on aldosterone secretion from zona glomerulosa cells in vitro (Orth 
& Kovacs 1998). In the isolated perfused rat adrenal preparation it enhanced 
aldosterone secretion but was far less effective in collagenase dispersed adrenocortical 
cells (Hinson et al. 1987). Vasopressin acts through binding to V2-typc vas opre sin 
receptors and activation of phospholipase C to generate IPi and I): A(º (diacylglyccroll 
(Quinn & Williams 1988, Woodcock et al. 1986). 
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5.6.1.6. Other stimulatory factors 
Catecholamines (Pratt el al. 1985, SzataN et al. 1998). neuropeptide V' ('S`PY ) 
(Mazzocchi & Nussdorfer 1987). vasoactive intestinal polypeptide (Ilinson et vl. 
1996), and serotonin (Quinn & Williams 1988) have been reported to affect 
aldosterone secretion, but their physiological importance is not clear (Orth & Kovacs 
1998). NPY stimulated aldosterone secretion in a dose-dependent manner. and this 
effect was abolished by atenolol, a ß-adrenergic antagonist (Renshaw er al. 2000). 
5.6.2. Factors that inhibit aldosterone secretion 
5.6.2.1. Atrial natriuretic peptide (ANP) 
ANP is secreted from atrial myocytes with potent diuretic, natriuretic and 
vascular smooth relaxant properties (Lumbers 1999). In vitro, synthetic ANP directly 
inhibits aldosterone secretion from rat and bovine glomerulosa cells. ANP inhibits 
Ang II, potassium, and, in part. ACTH-stimulated aldosterone secretion both in vitro 
and vivo in rats (Orth & Kovacs 1998). The effects are partly by interfering with 
extracellular calcium influx (Chartier & Schiffrin 1987. Rebuffat et al. 1988). 
5.6.2.2. Dopamine 
Dopamine inhibits aldosterone secretion in human by a mechanism that is 
independent of effects on ACTH, potassium, and Ang 11 (Orth & Kovacs 1998). The 
adrenal must be under maximal tonic dopaminergic inhibition because dopamine 
infusion does not lower basal, Ang II-stimulated. or ACTH-stimulated aldosterone 
levels, but dopaminergic blockade with metoclopramide increases aldosterone 
secretion (Carey 1982). Dopamine may act directly on zone glomerulosa cells through 
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specific dopamine receptors (Missale et al. 1986). Dopamine has been shown to 
inhibit the adrenal response to exogenous Ang 11 in sodium deplete animals (Lumbers 
1999). As well dopamine inhibits the response of isolated bovine adrenal cells to Ang 
11 (Espiner & Nichols 1993). Unfortunately the effects of dopamine on aldostreone 
are unclear because studies measuring the effects of dopamine agonists and 
antagonists on plasma aldosterone levels have produced confusing results (Lumbers 
1999). 
5.6.2.3. Somatostatin 
Somatostatin inhibits Ang II-stimulated aldosterone production, acting through 
specific receptors on the adrenal zona glomerulosa cells (Maurer & Reubi 1986, 
Quinn & Williams 1988, Aguilera 1993). 
5.7. Extra-renal mineralocorticoids (aldosterone) 
Physiologically significant mineralocorticoids were believed to be synthesized 
in the adrenal cortex. However, increasing evidence suggests that mineralocorticoids 
modulate blood pressure and cardiovascular homeostasis via the effects of circulating 
components generated within the adrenal but also through local synthesis (Takeda per 
al. 1995. Gomez-Sanchez et al. 1997. Silvestre et al. 1998, Slight et a!. 1999, Dupre/ 
cat al. 2000). 
5.7.1. Aldosterone in the blood vessel 
Hatakeyama et al. (1994) demonstrated for the first time that vascular cells are 
steroidogenic with their own responding system. Using reverse transcriptasc 
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polymerase chain reaction (RT-PCR) CYPI I B2 mRNA was detected in both ECs and 
SMCs cultivated from human pulmonary artery (HPAEC, 1IPAS\1(' ).: bout 50 nc of 
poly(A)t RNA from HPAEC or HPASMC was necessary to yield the same signal 
intensity as I ng of that adrenal gland, the amounts of CYPI 1132 mRNA in both 
HPAEC and HPASMC thus being estimated to be about 1 `50 of that in adrenal cortex 
(Hatakeyama et al. 1994). The expression of CYP 11 B 1. CYP 11 B2, and C'VP 11AI 
was detected in the rat mesenteric artery using a RT-PCR (I'akeda er a!. 1994). 
although Gomez-Sanchez et al. (1997) could not demonstrate C'YPI1132 mRN: \ 
expression in the rat mesenteric artery. The evidence that the production of 
corticosterone in the rat mesenteric artery was increased in the adrenalectomi,. ed rats 
showed that CYP 1IB1 exists in the vasculature (Takeda et al. 1994). 
CYP I1 B2 gene expression in HPASMC was stimulated by Ang 11. The levels 
of CYP II B2 and CYP IIBI mRNA were determined by competitive PCR in cultured 
human umbilical veins endothelial cells (IIUVECs) (Takeda et al. 1996). Both Ang II 
and potassium increased the concentration of CYP1 I B2 mRNA, but not that of' 
CYP 11 BI mRNA in HUVECs (Takeda et al. 1996). 
The activity of aldosterone synthase was estimated by conversion of 
['4C]DOC to ['4C]aldosterone (Takeda et al. 1996). Both Ang 11 and potassium 
increased the conversion of ['4C)DOC to ['4C]aldosterone. but A(' F}I did not 
significantly increase the conversion. Aldosterone was detected in the incubation 
medium of HPASMCs (Hatakeyama et al. 1994) and HUVECs (Takeda er al. 1996) 
using radioimmunoassay (RIA) after purification with the high performance liquid 
chromatography (HPLC) system. Ang II, potassium and ACI-II increased the 
production levels of aldosterone in a dose-dependent fashion in LB. VEC's (Takeda er 
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al. 1996). In addition. the aldosterone receptor (type I mineralocorticoid receptor), 
which is required for locally produced aldosterone to exert its action, was also found 
to be expressed in VSMC and, to a lesser extent, in EC (HHatakevama et al. 1994). 
Furthermore, Takeda et al. 0 997) reported that vascular aidosterork and 
CYPI l B2 mRNA levels in the mesenteric arteries of 2-week-old stroke-prone 
spontaneously hypertensive rats (SHRSP) were significantly increased compared with 
those of age-matched WKR. However. vascular aldosterorte in 4- and t)-week-old 
SI1RSP did not differ from that in age-matched WKR (Takeda et al. 1997). "These 
results suggest that vascular aldosterone contributes to the pathophvsiologv of 
hypertension in SHRSP at on the early stage (Takeda ei al. 1997, Uuprez et al. 2000). 
5.7.2. Aldosterone in heart 
Silvestre ei al. (1998) provided the first evidence for the existence of a cardiac 
steroidogenic system in rat heart. Perfusion of Ang II or adrenocorticotropin for 3 
hours increased aldosterone and corticosterone production and decreased 
deoxycorticosterone. by detecting them in both the homogenate and perfusate of 
isolated rat heart using RIA. The results suggested that aldosterone and corticosteronc 
are formed within the isolated heart from a locally present substrate. Using the 
quantitative RT-PCR, CYPI 1 B2 and CYPI I BI mRNA were detected in rat heart. 
The levels of CYPI I B2 and CYPI IBI mRNA were increased in the heart of Ang II- 
treated rats. though the cardiac effects of aldosteronc and corticosterone rennin to be 
elucidated (Silvestre e1 al. 1998). Further more. Silvestre ed a!. (1999) reported that 
myocardial infarction (MI) is associated with tissue-specific activation of myocardial 
aldosterone synthesis. Ml raised CY PI1B. " mRNA by- 2.0-fold and the aldostcrone 
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levels by3.7-fold. Conversely, MI decreased CYPI IBI mRNA by 2.4-ti ld and the 
levels of corticosterone by 1.9 fold. MI also induced a 1.9-fold increase in cardiac 
Ang 11 level. Such cardiac regulations were completely prevented by treatment of the 
infarcted heart with losartan (seven days after MI. rats were randomized to untreated 
infarcted groups or losartan treated groups for 25 days). These findings suggested that 
this increase is mediated primarily by cardiac Ang 11 via AT, receptors (Silvestre et 
al. 1999). 
5.7.3. Aldosterone in brain 
Enzymes involved in aldosterone biosynthesis in the adrenal cortex. have been 
demonstrated in the brain, including CYP 1 ]Al (LeGoascogne et al. 1987). 3 p-t IS 1) 
(Koenig et al. 1995). CYP21 A2 (Iwahashi et al. 1993), (_'YP 11 B1 (Mellon & 
Deschepper 1993) and CYPIIB2 (Gomez-Sanchez et al. 1997). The mRNA 
expression of CYP enzymes, such as CYP IIA1 (Mellon & Deschepper 1993). 
CYP IIBI (Mellon & Deschepper 1993) & CYP 11 B2 (Gomez-Sanchez et a!. 1997). 
is very low, requiring RT-PCR, combined with Southern blotting, for their 
demonstration in the brain, however the enzyme, CYP IIA1, can be demonstrated 
using immmunocytochemistry or Western blots (Iwahashi et al. 1990. Compagnone et 
al. 1995), suggesting the protein is very stable in the brain (Gomez-Sanchez et al. 
1997). 
Incubation of brain sections with [1.2 lfl-deoxycorticosterone 
demonstrated 
the presence of labeled aldosterone, corticosterone. and 
18-O11-UKX'. These studies 
indicated that the rat brain has the enzymatic machinery 
for the synthesis of adrenal 
corticosteroids and is capable of synthesis aldosteronc (Gomez-Sanchez er 
at 1997). 
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Aldosterone paracrine actions might explain why mineralocorticoid 
antagonists effectively lower blood pressure in some low-renin. lo«</normal 
aldosterone forms of essential hypertension models an animals in which circulating 
mineralocorticoids are not elevated (Glorioso et al. 1995). 
5.7.4. Vascular aldosterone -A link to angiotensin 11-induced hypertrophy of 
VSMC. 
The effect of aldosterone on Ang 11 receptors and Ang Ii-stimulated respconks 
in the vasculature deserves special attention (Ullian et al. 1993. Duprez et a!. 2000). 
It has been suggested that aldosterone-mediated increases in Ang 11 receptor 
number are associated with enhanced Ang II-stimulated protein synthesis in rat aortic 
SMC (Ullian et al. 1993). Incubation of quiescent cells (serum deprivation of 
subconfluent VSMC for 48 hours) for 24 hours with Ang II alone resulted in 
concentration-dependent increases in leucine incorporation (protein synthesis), 
whereas incubation for 24 hours with aldosterone alone resulted in concentration- 
dependent decreases in leucine incorporation. Incubation of serum-replete cells with 
10 8M aldosterone for 24 hours followed serum deprivation and incubation with 1(1 
M Ang II and 10'9 M aldosterone for additional 48 hours (experimental conditions in 
which Ang II receptor number was increased but the direct negative effects of 
aldosterone on leucine incorporation were minimized) resulted in increases in Ang II- 
stimulated protein synthesis. and this augmentation was inhibited by the aldosterone 
receptor antagonist spironolactone (10-6 M). 
Hatakeyama et a!. (1994) reported that the Ang-I I-induced increase in 
[3H]leucine incorporation in HPASMCs was significantly enhanced bl aldosteronc 
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but inhibited by ZK91587, a type I mineralocorticoid receptor antagonist suggesting 
that up-regulated aldosterone may potentiate the h`pertrophic response of tilt(' to 
Ang II, probably in an autocrine/intracrine manner (I Iatakeyama et al. 1994). 1-he 
present studies involving in vascular aldosterone provide the starting point for a novel 
understanding of the molecular basis of vascular remodeling and hypertension 
(Hatakeyama et al. 1994). The interaction between locally, generated ring 11 and 
aldosterone within the cardiovascular tissue may well become an important issue for 
future research on cardiovascular disease (Takeda & Miyamori 1995). 
6. Aims 
haken altogether, the data discussed above inevitably lead to the conclusion: 
(1) The abnormal growth of VSMC is an important feature of atherosclerosis and 
hypertension; (2) ECs play an important role in the regulation of VSMC growth; (3) 
Vascular aldosterone may participate in maintaining or enhancing the vascular RAS. 
constructing the vascular RAAS. 
Furthermore the accumulated evidence support the following hypotheses: (1) 
The vascular wall is not only a target, but also a site of the actions and generation of 
RAAS; (2) Ang II affects vascular structure and function via paracrine and autocrine 
effects of local tissue-based synthesis; (3) The up-regulated aldosterone may 
potentiate the hypertrophic and/or hyperplasic response to Ang II. 
The principle objective of this work was to explore these hypotheses. 
(1) To determine whether both of SMC and EC are sites of expression RAS 
components of a local RAS. 
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(2) To evaluate interaction het«een these cell types in the RAS-Jcpendcnt 
regulation of SM(' proliferation. 
(3) 'to determine the potential of % ti\1(' to synthesize alclosterone. and its 
regulation by the RAS. 
(4) 'J o> determine role of aldosterone in S\1(' proliferation. 
In addition, the protein of 18-01 I-DOC carrier. found in rat adrenal\ (Vinson 
Ct a!. I995b), was also sought in VSMC. 
I-.; 
('11: \PTER 11: Al A7'FRI \I. %\I) NI F IIOi)S 
CHAP TR II: \1AI Fall US 
. 
01) Nil: I IIOI)N 
1.. \laterials 
1.1. Animals 
Rats 
Rats used in these studies were adult male (220O-300 -, ) \Vistar rats. obtained 
from commercial suppliers and maintained in the animal unit. t )uc cnM WA and 
Westfield College. 
('alvcs 
'I issue used in these studies were supplied by I)r \V I'dwwards, Ph\'ioIoLic, ll 
laboratory. tlnivcrsitv of Cambridge. 
1.2. Chemicals 
(; cneral laboratory chemicals and reagents of electrophoresis or molecular 
biology grade as appropriate ýNcrc obtained tr'onl Si`gnui Chemical Company I. td 
(Poole, Dorset, UK). Chemical and solvents from 111)11-\Icrek Ltd. (Poole, 
I h) \wrc t\nalar grade. Tissue culture medium, supplements and sterile pLNtis%%are 
\Ncre obtained from f('N I3iomcdic: als Ltd. (High `\'\Comhc, Bucks. (! h) and (iikco 
(Paisl \, 1. K). 
1.3. Radiochcmicals 
1 '-5(I-`O Cý> mnx> ý I). ýýlcýcý, ýtýrý nc. 1, 
Ci nui of and [nicthýl-ý11] l'hvrnidinc-**A. 0 ('i'riirliol ' rc obtained 
from \mer`harn 
1'harniaci. i f3io'tcch (Bucks. VK). 
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1.4. Immunochemicals 
1.4.1. Primary antibody 
Mouse anti-human a-actin antibody was obtained from DAKO Ltd. 
1ý 
(Cambridge, UK). Rabbit anti-human von Willebrand factor antibody was obtained 
from Sigma Chemical Company Ltd.. 
Mouse anti-human renin antibody (2D 12) was generously given by Prof. P. 
Corvol (Institut National de la Sante et de la Recherche Medicale. U36,75005 Paris. 
France). 
Sheep anti-18-OH-DOC (Vinson et al. 1995b) and rabbit anti-aldosterone 
0 
0 
antibodies were made in this laboratory (Kapas et al. 1991). Rabbit anti- 
corticosterone antibody was obtained from Sigma Chemical Company Ltd.. 
1.4.2. Secondary antibody conjugates 
Rabbit anti-mouse IgG FITC conjugate was obtained from DAKO Ltd.. Goat 
anti-rabbit IgG FITC conjugate was obtained from Sigma Chemical Company Ltd.. 
Horse radish peroxidase-linked rabbit anti-sheep IgG and sheep anti-mouse IgG were 
obtained from Amersham Pharmacia Biotech (Bucks, UK). 
1.5. Kits 
Avidin-biotin-peroxidase complex (ABC) kits were obtained from Sigma 
Chemical Company Ltd.. DIG Oligonucleotide Tailing Kit from Boehringer 
Mannheim (Lewes, East Sussex, UK) and RNAce Total Pure kit was obtained from 
Bioline (London. UK). Angiotensin radioimmunoassay kits were obtained from 
1 27 
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'ý ichols Institute Diagnostics (Saffron- Waldon. UK). Wizard PCR Prep-, DN. A 
Purification Sý stem were obtained from Promega (Southampton. UK). 
1.6. Other reagents 
Oligonucleotide primers and probes used in these studies were custom made 
by Amersham Pharmacia Biotech (Bucks, t X). 
Losartan was generously given by Merck Sharp & I)ohnme I. imited 
(Iloddesdon, UK). 
2. Methods 
2.1. ('ell Culture 
?. 1.1. Principle 
A priniar\ cell culture may be obtained either by allowing cells to migrate out 
of fragments of tissue adhering to a suitable substrate or by disaggregating the tissue 
mechanically or enzymatically to produce a suspension of cells, some of which will 
ultimately attach to the substrate. When all the available substrate is occupied or xv hen 
the cell concentration exceeds the capacity of the medium, growth ceases or is greatly 
reduced. At this point either the frequency of medium changing must increase or the 
culture must be divided. The usual practice in subculturing an adherent cell line 
ins ok es removal of the medium and dissociation of the cells with trvpsin. I'he 
passage number refers to the number of times that the culture has been subcultured in 
this \\a\ (Fresimev 1994a). 
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2.1.2. Culture of bovine aortic endothelial cells (BAECs) 
I AL('s were har\ ested enzymatically from bovine aorta following established 
methods (Jaffe et al. 1973, E3oov se ct al. 1975) with minor modifications. The aorta 
was removed from the heart and placed in phosphate buffered saline (PBS. Sigma) 
containing 300 units/ml penicillin G potassium (Gibco) and 300 dig, ml streptomycin 
sulphate ((iibco) for 5 min. The aorta was again washed three times in PBS. The aorta 
was drained of excess fluid and one end of the vessel was filled with 0.25% trvpsin in 
P13'. The free end of the aorta was sealed with a haemostat, placed in a sterile beaker 
containing PI3* and incubated at 37"C for 18-20 min. The cell enzyme mixture Nvas 
removed from the lumen of the aorta and transferred to a centrifuge tube containing 
RPMI-1640 tissue culture medium (Sigma) supplemented with 10% new-born bovine 
serum (NBS, Sigma) and 5% fetal bovine serum (FBS, Sigma). The cells were 
\\ashcd \%ith tissue culture medium, and centrifuged. The supernatant was removed 
and RPMI-1640 tissuc culture medium supplemented with 10% NBS. 5% FBS. 4 
µmol'L L-Blutamine (Gibco) and reduced concentrations of antibiotics (100 units/ml 
penicillin (i potassium and 100 ig/ml streptomycin sulphate) were added to the cell 
ppellet. Aliquots (4 nil) of BAEC suspension ere seeded on to 25 cm2 tissue culture 
flasks. The cultures were incubated at 37 "C' in a humidified atmosphere of 5% CO2 in 
air and the medium \\as changed once after every two days. After confluence. 
achieved m thin two weeks, the cells were rinsed with PBS, and subsequently 
mpsinir; cd with O. O8°o tr\psin in PBS for 1 nein at 37 U. The resulting cell 
suspension was pipettcd into a 75 cm- tissue culture flask: containing 10 ml of the 
medium and incubated as aho\ c. Cells at the 2nd passage were used for the 
c\pcr' l1Cnt`. 
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2.1.3. Culture of aortic smooth muscle cells (. ASMCs) 
-\SMCs ere isolated from rat thoracic and abdominal artery (R. A*\IC) and 
fx)V-ine aorta (F3.1ý'ý1t, ) H. the media explant method and cultured oN cr several 
passages according to Ross (1971) with minor modifications. Segments of both 
abdominal and thoracic aortas were obtained from rats by caretül dissection tTonl 
killed rats. Segments of aorta «erc obtained from calves under anaesthesia. The 
segments of aorta were placed in a depression slide containing tissue culture medium. 
after which the adventitia and the outer portion of each scgnmcnt was carefully 
removed under a dissecting microscope. The remaining inner portion of the tissue and 
the intima ýýere removed to a separate dissecting dish and washed several times with 
fresh culture medium. At this point each segment was cut into approximately I nlm 
squares and placed can 25 cm` tissue culture flask. The flasks were loosely capped and 
placed in a humidified ('O-, incubator. After two hours. 4 ml of RPMI-1640 culture 
medium supplemented with 100 units/ml of penicillin, 100 µg/ml streptomycin, 4 
pmol'l. L-glutamine and 20"o IBS vý as carefully added to the flasks without 
dislodging the tissue. Samples ýýere fed with fresh medium after one week. The cells 
from the explants were relati\el\ confluent within a period of approximate1N 2 ýýeeks. 
I'hc\ ýN erc then rinsed \\ ith PBS, and subsequently trvpsinized «ith a solution of 
0.12-5, o tnp,, in and 0. l) o FD lA in PBS for 1-1 min at 37°C. I he rcýtilting 
suspension of cells was pipetted into 75 cm2 tissue culture flasks containing 10 ml 
culture medium and incubated as above. Fxperiments «crc pertirmed with cells from 
S, 
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2.1.4. Viability assays for cultured cells 
The assay is used to measure the proportion of viable cells following a 
potentially traumatic procedure such as subculture disaggregation. Viable cells are 
impermeable to trypan blue and a number of other dyes (Kaltenbach et al. 1958). 
In this work, high cell viability (>99%) was maintained during the course of 
each experimental procedure, using the 0.4% trypan blue (w/v) (Sigma) exclusion 
test, as described (Freshney 1994b). Briefly, 50 µl of cell suspension was mixed with 
50 µl of 0.4% trypan blue solution, and stained and unstained cells were counted 
using hamocytometer. Viability was calculated as follows: 
Cell viability (%) = total viable cells (unstained) -- total cells (stained and 
unstained) x 100. 
2.2. Cell proliferation index 
Due to the complexity of the protocol the overall study for VSMC 
proliferation is detailed in Figure II-1. 
2.2.1. Principle 
The usual protocol for determining the capacity of a factor to promote SMC 
growth in vitro involves rendering cells quiescent by incubating them in a medium 
that is deficient in growth supporting substances. The factor to be tested is then added, 
and growth is measured either by determining the increase in cell number or by 
measuring the incorporation of a labelled nucleotide such as [3H]thymidine or 2'- 
bromodeoxyuridine. These metabolic precursors can be used to identify cells that are 
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synthesizing DNA, with the rate of proliferation being expressed as the proportion of 
the cells in the culture that are positively labelled (Jackson 1995). 
2.2.2. Conditioned Medium (CM) 
CM was denoted the medium that had been in contact with either cultured 
RASMC or BAEC. Unconditioned medium (UM) was the medium that had not been 
in contact with any cultured cells. BAEC conditioned medium (BAECCM) and 
RASMC conditioned medium (RASMCCM) were collected as described (Castellot et 
al. 1981). 10 ml of the cell suspension (105 cells/ml) was distributed on 75 cm` tissue 
culture flask in RPMI-1640 medium containing 20% FBS. After 24 hours, the cells 
were washed with PBS and the culture medium was replaced with 10 ml medium with 
2% serum replacement (Sigma). After an additional 48 hours, the medium was 
removed and immediately filtered through a 0.22µm filter (BDH), and stored at -20 
°C prior to use. Before adding it to cells, CM was mixed 2: 1 with medium RPMI- 
1640 containing 2% serum replacement. 
2.2.3. Cell count 
A suspension of RASMC (0.5 x 105 cells/ml) were prepared on the first day of 
the experiment using RPMI-1640 supplemented with 20% FBS. One nil of this cell 
suspension was distributed to each well of a 24-well multiwell dish. The medium was 
replaced 24 h after the subculture with appropriate experimental media (Figure II- I) 
with three wells per group. Experiments were terminated after an additional 48 hours 
incubation. The cells were resuspended by washing them with PBS and treatment 
with 0.3 ml PBS containing 0.125% trypsin and 0.02% EDTA. Digestion was stopped 
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by addition of 0.7 ml 20% FBS RPMI-1640 to each well. Cells were counted in a 
haemocytometer using light microscopy. 
2.2.4. Tritiated thymidine uptake 
RASMC or BASMC suspensions (0.3 x 10' cells/rnl) were prepared as above. 
The quiescent (serum-derived) or serum-replete cells were incubated v ith the 
appropriate experimental media (Figure II-l) for 48 hours with 6 or 4 wells per group. 
3H-methylthymidine (0.1 mCi/ml) 10 µl was added to each well (1 ml medium/well). 
24 hours after the addition of radioactive thymidine, media were aspirated and the 
cultured cells were rinsed 3 times with cold PBS as previously (Oikawa et al. 1987). 
Cells were then dissolved in 0.5 ml of 0.1 N NaOH and a 0.3 ml aliquot was mixed 
with 3.5 ml of scintillation fluid (Packard Instrument B. V. Chemical Operations, 
Groningen, the Netherlands) and, after standing overnight at room temperature, 
tritium content was assayed in a liquid scintillation counter. 
2.3. Protein antigen detection 
Details of experimental design for protein antigen detection are given in 
Figure 11-2. 
2.3.1. Immunocytochemistry 
Immunocytochemistry can be considered as the demonstration of antigens in 
tissue sections or smears by the use of specific antigen-antibody interactions which 
culminate in the attachment of a marker to the antigen. For light microscopy. the 
marker may be a fluorescent dye, an enzyme. or colloidal gold. The aim is to achieve 
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reproducible and consistent demonstration of specific antigens with the minimum of 
background staining whilst ideally, preserving the integrity of tissue architecture 
(Jackson & Blythe 1993). 
2.3.1.1. Avidin-biotin methods 
2.3.1. la. Principle 
Streptavidin, a protein (60 kDa), has four high affinity binding sites for biotin. 
Biotin can be attached to a single molecule of protein (peroxidase) (Jackson & Blythe 
1993). The biotinylated protein (peroxidase) can thus bind to more than one molecule 
of Streptavidin. Streptavidin and biotinylated peroxidase are simply mixed at 
appropriate concentration and allowed to stand for 30 min at room temperature for the 
complex to form (Jackson & Blythe 1993). This preformed complex is attached to the 
biotinylated antibody-antigen complex. This allows the pre-formed complex to bind 
and provides a very high signal at the antigen binding site (Figure 11-3). The staining 
for light microscopy depends upon enzyme-substrate reactions- diaminobenzidine 
(DAB) reaction, which produces a brown end product insoluble in alcohol, xylene. 
and other inorganic solvents (Jackson & Blythe 1993). 
2.3.1.1b. Protocol 
BAECs grown on glass microscope slides, were fixed in 100% cold acetone 
for 15 min and incubated in 0.3% hydrogen peroxide-methanol for 15 min to block 
endogenous peroxidase activity, and in 20%/PBS bovine serum albumin (BSA, 
Sigma) for 20 min to block non-specific staining. Cells were then incubated at 37 "C 
for 90 min with mouse anti-renin (human) monoclonal antibody "D12. diluted in PBS 
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I 
Biotinylated B 
Anti-Rabbit Igs 
antigen 
JAK R on NDIM 
Peroxidase streptavidin- 
biotin complex 
Rabbit Primary 
Anfiserum 
Figure 11-3: Avidin-biotin complex immunolabelling method (see 
chapter 11-2.3.1.1a. for description of immunolabelling sequence). P, 
peroxidase: B. biotin. A. avidin. Adapted from Jackson & RI the 
1993. 
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1: 1000. Slides were then treated for 30 min at room temperature with biotin fated 
secondary antibody rabbit anti-mouse IgG (diluted in PBS 1: 400) and then avidin- 
biotin-peroxidase complex (ABC kit, Sigma) were applied to the samples for 4-5 min 
at room temperature. All intermediate washes were in PBS. Peroxidase activity was 
visualised by a DAB reaction using DAB tablet sets (Sigma) and observing under the 
microscope after 10 min. Each tablet set was dissolved in I ml water to yield a 
buffered solution containing DAB and urea hydrogen. The slides were washed in 
water for 10 min, dehydrated 2 times for 5 min in 70% ethanol, 2 times for 5 min in 
95% ethanol, 2 times for 5 min in 100% ethanol. Finally, the slides were cleared with 
xylene twice and mounted in DePeX mounting medium (BDH). In control sections, 
PBS was used instead of the primary antibody. This procedure consistently resulted in 
no staining. 
2.3.1.2. Indirect immunofluorescence 
2.3.1.2a. Principle 
In immunofluorescence methods the primary (specific) antibody is used in its 
native form to bind the antigen in the specimen. This is followed by treatment with 
second antibody, raised against the immunoglobulin of the first antibody. and 
conjugated to a fluorochrome such as fluorescein or rhodamine (Freshney 1994c). 
2.3.1.2b. Protocol 
Briefly, BAECs grown on glass microscope slides were fixed for 20 min in 
3.7% formaldehyde in PBS, as described (Wagner et al. 1982). and RASMC for 5 min 
in cold (4 0) methanol (Majack et al. 1985). After fixation. BAECs were 
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permeabilized in 0.5% Triton X-100 in PBS for 15 min at room temperature. exposed 
to rabbit anti-human von Willebrand factor antibody (details given in Chapter 1-1.2. ) 
(1: 200 in PBS) for 30 min at room temperature and goat anti-rabbit IgG FITC (1: 160 
in PBS) for 30 min at room temperature. In this method, the primary antibodies used 
were mouse anti-human a-actin (1: 10 in PBS) or sheep anti 18-OH-DOC antiserum 
(1: 10 in PBS). To reduce non-specific signals with the latter, RASMCs were exposed 
to 10% rabbit normal serum for 10 min at room temperature. After incubation . %-ith 
primary antibodies for 30 min at room temperature, the RASMCs were exposed to 
FITC-labeled rabbit anti-mouse IgG (1: 20 in PBS) or FITC-labeled rabbit anti-sheep 
IgG (1: 100 in PBS) as appropriate for 30 min at room temperature, respectively. All 
intermediate washes were in PBS. Glass microscope slides were then mounted with 
cover glass in PBS/glycerol (1: 3) containing a fluorescence-quenching inhibitor 25 
mg/ml DABCO ( 1,4-diazabicyclo- [2.2.2 ]octane), and photographed using a Nikon 
Photo microscope. 
2.3.2. Western blotting 
2.3.2.1. Principle 
The samples to be assayed are solubilized with detergents and reducing agents. 
separated by polyacrylamide gel electrophoresis, and transferred to a solid support 
(usually a nitrocellulose filter), which may then be stained. The filter is subsequently 
exposed to unlabeled antibodies specific for the target protein. Finally, the bound 
antibody is detected by one of several secondary immunological reagents such as 
'251- 
labeled protein A or anti-irnmunoglobulin, or anti-imflmunoglobulin or protein A 
coupled to horseradish peroxidase or alkaline phosphatase (Sambrook et a!. 1989a). 
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2.3.2.2. Preparation of samples 
Cells were harvested by trypsinisation, washed with PBS and centrifuged 
(1200 rpm for 10 min). The supernatant was removed and 500 µI I% Triton X-100 
solubilization buffer containing 50 mM Tris-HCI (pH 7.4), 1 pg/ml each of protease 
inhibitors aprotinin and soybean trypsin inhibitor and 30 tg ml 
phenylmethylsulphanyl fluoride (Sigma) was added to the cell pellet, mixed at 4 "C 
for 40 min, and centrifuged (12,000 rpm for 10 min) again. The protein in the 
solubilized fraction was estimated by the Lowry method (Lowry et a!. 1951). 
2.3.2.3. Gel electrophoresis and immunoblotting 
2.3.2.3a. Discontinuous sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Discontinuous SDS-PAGE consist of a resolving or separating (lower) gel 
(7.5% polyacrylamide) and a stacking (upper) gel (4% polyacrylamide) (Details are 
given in Appendix 1). Aliquots of the solubilized fraction, equivalent to 400 pg of 
protein, were loaded into each well and subjected to SDS-PAGE using the methods of 
Laemmli (1970) with prestained SDS-PAGE molecular weight standards (Sigma) in 
an adjacent well. The gel was run overnight at 30 volt at 4 "C or for 3 hours at 200 
volt at room temperature. Proteins were electrotransferred to Hybond-EC'L 
nitrocellulose membrane (Amersham) overnight at 30 volt at 4 °C using the following 
transfer buffer: 18.2 g Trizrna base and 71.3 g glycine, in I litre methanol and 2 litre 
water. Non-specific binding sites on the gel were then blocked with I O% milk powder 
(Marvel, Sainburys, UK) for 3 hours at room temperature. Membranes %%ere washed 4 
times for 10 min with washing buffer (1.4 g Na2HPO4 8.8 g NaCl and I ml Twcen-20 
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in I litre water, PBS-T) and incubated with primary anti-renin antibody (2D 12 ) 
diluted 1: 1000 in PBS-T for I hour at room temperature. Membranes were then 
washed twice for 10 min in PBS-T, incubated for one hour with horseradish 
peroxidase-linked sheep anti-mouse IgG (Amersham) diluted 1: 5000 in PISS-T at 
room temperature. Positive bands were visualized using ECL western blotting 
detection reagent (Amersham). In controls. PBS was used instead of the primar\ 
antibody. 
2.3.2.3b. Continuous non-denaturing PAGE 
Continuous non-denaturing PAGE consists of one component (7.5° ° 
polyacrylamide) (Details in Appendix 1). Aliquots of the solubilized fraction. 
equivalent to 100 pg of protein, were loaded into each well and subjected to non- 
denaturing polyacrylamide gel electrophoresis using the methods described in Mini- 
Protein 3 Cell Instruction Manual (BIO-RAD) with Rainbow coloured protein 
molecular weight markers (Amersham) in an adjacent well. The gel was run for one 
hour at 100 volt at room temperature. Proteins were electrotransferred to Ilyhond- 
ECL nitrocellulose membrane (Amersham) overnight at 5 volt at room temperature 
using the following transfer buffer: 3.03 g Trizma base, 14.41 g glycine. 200 nil 
methanol, made up to 1 litre with water. Membranes were washed using gashing 
buffer (PBS-T). Non-specific binding sites on the gel were then blocked with Io 
milk powder in PBS-T for 2 hours at room temperature. Membranes were briefly 
rinsed twice using two changes of PBS-T, then once for 15 min and twice for 5 min 
with fresh changes of PBS-T at room temperature. Membranes were then incubated 
with primary sheep anti 18-OH-DOC antibody (stock 1.46 mg/ml) (Vinson e< at 
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1995b) diluted 1: 300 in PBS-T for l hour at room temperature. Membranes were then 
washed as above, and incubated for I hour with horse-radish peroxidase-linked rabbit 
anti-sheep IgG (Amersham) diluted 1: 3000 in PBS-T at room temperature. Positive 
bands were visualized using ECL western blotting detection reagent (Amersham ). As 
a control for specificity, primary antibody (10"5 M) was also used after first incubating 
with 10"3 M 18-OH-DOC [Sigma or Fluka Chemika-BioChemika (Gilling, England)] 
in PBS-T overnight at 4 °C before immunoblotting (Noorden 1993). 
2.4. mRNA detection 
2.4.1. In situ hybridization 
2.4.1.1. Principle 
Nucleic acid hybridisation techniques rely upon the fact that complementary 
sequences of single-stranded nucleic acid spontaneously re-anneal, under approprate 
conditions, to form a double-stranded hybrid (duplex) (Davies 1993). In situ 
hybridization is the localization of specific mRNA or DNA species in tissue, cells or 
chromosomes using nucleic acid probes. The probe, which is the fragment of nucleic 
acids that is labelled for detection during the in situ hybridisation, can be various 
forms of nucleic acids double or single stranded DNA, single stranded RNA. or 
synthetic oligodeoxyribonucleotides (oligonucleotides) (Maniatis et a!. 1982. Berger 
& Kimmel 1988). Synthetic oligonucleotides probes used in this experiment are non- 
radioactively labelled by incorporation of digoxigenin-labeled nucleotide. After 
hybridisation to target nucleic acid, the oligonucleotide probes are detected by 
enzyme-linked immunoassay using an antibody-conjugate (anti-digoxigenin alkaline 
phosphatase conjugate. anti-DIG-AP). A subsequent enzyme-catalysed colour 
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reaction with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium salt 
(NBT) produces an insoluble blue precipitate. 
2.4.1.2. Preparation of probe 
Human renin oligonucleotide probe was designed by this laboratory 
(Tahmasebi et al. 1999). Human renin oligonucleotide antisense probe (46 bases) was 
used. The human renin oligonucleotide sense probe (46 bases) was used as negative 
control. The sequences of sense and antisense probe were 5'- 
AATGCCCTCAATCCGAGAAAGCCTGAAGGAACGAGGTGTGGACATG-3' 
and 5'-CATGTCCACACCTCGTTCCTTCAGGCTTTCTCGGATTGAGGGCAT F- 
3', respectively. The sense and antisense probe correspond to nucleotides 142-187 and 
187-142 of exon 2 of human renn gene. The 3'-end of probes were labelled with 
digoxigenin (DIG) labelled dUTP using a DIG Oligonucleotide Tailing Kit 
(Boehringer Mannheim). For the generation of the DIG-labeled probes, dATP and 
DIG-labeled dUTP (DIG-dUTP) was applied and added in a template independent 
reaction. The probes were stored at a final concentration of 50 ng/pl at -20 
°C prior 
to use. 
2.4.1.3 Preparation of cells 
BAECs grown on glass microscope slides were washed with PBS at 37 "C. 
fixed with 4% (w/v) formaldehyde for 20 min, washed with PBS at room temperature. 
dehydrated in 70%, 90%, and 100% ethanol, and stored until required at -70 
°C. 
Before hybridization, cells were rehydrated by incubating successively in 100%, 90%. 
and 70% ethanol. and treated for 30 min at 37 °C with TE buffer (100 mM Tris-HC 1. 
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50 mM EDTA, pH 8.0) containing Proteinase K 20 µg/ml. and finally prehvbridized 
for 20 min at 37 °C with prehybridization buffer containing 50% formamide. 4X 
saline sodium citrate (SSC) (1 X SSC: 0.15 M NaCI, 0.015 \1 sodium citrate: pH 7.0). 
10 mM tris-HC1 (pH 7.5), 1X Denhardt's solution (Sigma), 500 µg/ml salmon testis 
DNA (Sigma), 10% dextran sulphate (Sigma). 
2.4.1.4. Hybridization 
The slides were incubated with hybridization solution containing I ig'ml 
DIG-tail labelled oligonucleotide probe in prehybridization buffer in a moist chamber 
at 42 °C for overnight. They were then washed twice for 15 min in 2X SSC at room 
temperature, 2 times for 15 min in 1X SSC and 2 times 30 min in 0.1 X SSC. 
2.4.1.5. Immunodetection of in situ hybridization signal 
Slides were washed with DIG-buffer I (100 mM Tris-HCI, pH 7.5,150 mM 
NaCl), blocked with Buffer I containing 0.1 % Triton X- 100 and 2% normal sheep 
serum for 30 min, and further incubated for 2 hours with buffer I containing 500 x 
diluted anti-DIG polyclonal antibody conjugated alkaline phosphatase (Bochringer 
Mannheim), 0.1% Triton X-100,1% normal sheep serum at room temperature. The 
slides were washed twice for 15 min in buffer I and incubated once for 10 min in 
buffer 11 (100 mM Tris-HCI, pH 9.5.100 mM NaCl, 50 mM Mg('I2) with colour- 
substrate solution containing nitroblue tetrazolium (450 µg/ml), 5-brow)-4-chlore-3- 
indolyiphosphase (175 µg/ml) and levamizole (1 mmoIL) in buffer It. The colour 
reaction was developed in a moist chamber for 48 hours in the dark. The reaction was 
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stopped by adding buffer 1110 0 mM tris-HCL pH 8.1; 1 mM EDT. ) for 30 min and 
sections were mounted with an aqueous mounting solution, Aquarnount (BDI-I ). 
2.4.2. RT-PCR 
2.4.2.1. Principle 
Polymerase Chain Reaction (PCR) is based on three simple steps required for 
any DNA synthesis reaction: 1) denaturation of the template into single strands; 2) 
annealing of primers to each original strands for synthesis of new strands: and 3) 
extension of the new DNA strands from the primers (White 1993) (Figure 11-4). 
Reverse transcription (RT) reaction provides the complementary DNA (ci3NA) by 
extension from a primer complementary to the RNA sequence. Reverse transcription 
may be primed by using a specific antisense primer for the gene of interest, 
oligodexoynucleotide (oligo(dT)), or random hexanucleotide primers. Random 
hexanucleotide primers will prime all species of RNA present and allow the 
amplification any desired target sequence from the RT mixture (Innis et al. 1990). 
RT-PCR is reverse transcription of RNA followed by PCR. 
2.4.2.2. Isolation of total cellular RNA 
Total cellular RNA was extracted from cultured cells using the RNAce Total 
Pure kit (Bioline) according to the manufacturers' protocol, and quantified 
spectrophotometrically by measuring absorbance at 260 and 280 nm. Id of sample 
total RNA was added to 100 Nl of DEPC-water. Absorbance was measured at 260 nm 
and 280 nm and concentration estimated as: Absorbance x 40 (one unit of absorbance 
is equivalent to 40 µg RNA) x 100 (dilution factor) = pgý m1. The total RNA purity 
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Cell disruption 
RNA Extraction 
mRNA 
5"     A: A: \ ' 
Reverse Transcription 
_    
AAA 3' 
3.5' (GI)NA) 
Denature and PCR primers 
AAA 3' 
3.4 . ý 
1 PCR 
Amplified segment 
3, 
ii 
5. 
Figure 11-4. Schematic representation of the RT-PC'R method. 
AAA: poly A tail of the mRNA molecule. Brown rectangle: 
antisense primer: black rectangle: senk primer. Adapted from 
White 1993. 
146 
CHAPTER II: MATERIAL 
. AND METHODS 
A26WA2g, ratio was between 1.6-1.9. and the samples were stored at -70° C until 
required. 
2.4.2.3. Annealing temperature and primer preparation 
Annealing temperature (Td), the temperature at which one-half of the primers 
are annealed to their target sequence, is roughly calculated by following equation 
(Wallace & Miyada 1987): 
Td=4(G+C)+2(A+T) 
where A, T, G, and C are the number of those bases in the oligonuclcotidcs. 
Some of the oligo nucleotide PCR primers used in this work were designed 
using a computer programme (Primer Designer, tJK) from GeneBank sequence data. 
These included primers for bovine GAPDH and for rat CYP 11B1 /CYP 11132. The 
primers for human renin were designed by this laboratory (Dr A. J. Ogedeghe). The 
others were obtained from previously published sequences, including those for Al,., 
and rat GAPDH. The sequences and their source are summarized in Figure 11-5. The 
primers for CYP 11 B1 and CYP 11 B2 were chosen in homologous parts of the exon I 
and exon 2 regions of CYP IIB1 and CYP II B2 (Figure 11 -6), based on the sequence 
data from Gene bank. The sequences of the sense and antisense primers for the 5'- 
flanking region and exon 2 of CYP IIBI correspond to bases -486 to -469 and 284 to 
267, respectively (Figure 11-7). The sequences of the sense and antisense primers for 
the 5'-flanking region of CYP 11 BI correspond to bases -480 to -463 and - 18 3 to - 
'100, respectively (Figure 11-7). All primers were custom made bý Amcrsham 
Pharmacia Biotech (Bucks, UK). 
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Target Primer Sequence (5'-3') Source Product 
mRNA Size (bp) 
ATM S CAA TCT CGC CTT GGC TGA CTT Wheeler- 1036 
(rat) A TCT TCT CTC AGA GTT TTA GTC Schilling et 
al. 1999. 
GAPDH S CCC TCA AGA TTG TCA GCA ATG C Horikoshi & 410 
(Rat) A GTC CTC AGT GTR GCC CAG GAT Sakal: ibaaa 
2000. 
Renin S GTG TCT GTG GGG TCA TCC M 101 c1 *2062 141 
(human) -2079 (exon 8) 
A ATC AAA CAG CCT CTT CTT GGC 2202-2182 
(exon 8) 
GAPDH S GTC ATC ATC TCT GCA CCT TCT G U85042(cds)* 519 
(Bovine) 319-340 
A GTG AGT ATC GCT GTT GAA GTC G 837-816 
CYPI IBl/C S GGA TGG CAA TGG CTC TCA GG Exon 1 314 
YP11 B2 B 1('D 14086)*: 
(rat) 499-518; 
B2(D l 4092 ): 
497-516 
A CTG GTG CAG CTT CTC AGC GT Exon 2 
BI: 1182-1163 
B2: 1180-1161 
5'- S GGA CTC AGG TTC TCA TAG 5'-flanking: 770 bp 
flanking/exo -486 to -469 
n2(CYPI 1B A AGA CAC AAT CTG TGC TCC Exon 2: 
1) (rat) +284 to +267 
5'-king S AGG TTC TCA TAG TTG ACC -480 to -463 298 bp 
(CYP11B1)( A GGT GCA GAC TCT ACT TTA -183 to -200 
rat) 
Figure 11-5. Oligo nucleotide primers used for RT-PCR * : accession number. 
S 
sense. A= antisense. 
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r, YP11B1 WVWLY 
CYP11B4 -- AGCAGATGTGTGGCTGGCAAGACCCTGGC 46 
CYP11B2 - ". -AGCAGATGTGTGGCTGGCAAGACCCTGGC 54 
CYP11B3 -- . AGCAGATGTGTGG---GCAAGACCCTGGC 43 
........................... ............. 
CYP11B1 AGTGCCTGCACAGGACGAGGGCACTGGGCACTACGGCAAAAGTGGCCCCCAAGACACTGA 12C 
CYP11B4 AGTGCCTGCACAGGACGAGGGCACTGGGCACTACGGCAAAAGTGGCCCCCAAGACACTGA 106 
CYP11B2 AGTGCCTGCACAGGACGAGGGCACTGGGCACTACGGCAACACTGGCCCCTAAGACACTGA 114 
CYP11B3 AGTGCCTGCACAGGACGAGGGCACTGGGCAGTACGGCAACACAGGCCCCCAAGACACTGA 103 
* .... ****... **....... 1 ........ ........ . ...... ......... 0 
CYP11B1 AGCCCTTTGAAGCCATACCACAATACTCCAGGAACAAGTGGCTGAAGATGATACAGATCC 180 
CYP11B4 AGCCCTTTGAAGCCATACCACAATACTCCAGGAACAAGTGGCTGAAGATGATACAGATCC 166 
CYP11B2 AGCCCTTTGAAGCCATACCACAATACTCCAGGAACAAGTGGCTGAAGATGATACAGATCC 174 
CYP11B3 AGCCCTTTGAAGCCATACCACAATACTCCAGGAACAAGTGGCTGAAGATGATACAGATCC 163 
*+s*ftttf*f+s+is+*+s*+i**"*"""+"+*". +".. ... *e,... ".. """. "a" 
CYP11B1 TGAGAGAGCAGGGCCAAGAGAACCTACACCTGGAGATGCACCAGGCCTTCCAAGAGCTGG 240 
CYP11B4 TGAGGGAGCAGGGCCAAGAGAACCTACACCTGGAGATGCACCAGGCCTTCCAAGAGCTGG 226 
CYP11B2 TGAGGGAGCAGGGCCAAGAGAACCTACACCTGGAGATGCACCAGGCCTTCCAGGAGCTGG 234 
CYP11B3 TGAGGGAGCAGGGCCAAGAGAACCTACACCTGGAGATGCACCAGGCCTTCCAGGAACTAG 223 
ffi$ii}ff1*i"*i*f"s"*a"*7f"""*7"*. "". """"""""". "f""""" 
I2 
CYP11B1 GGCCCATTTTCAGGCACAGTGCAGGGGGAGCACAGATTGTGTCTGTGATGCTGCCTGAGG 300 
CYP11B4 GGCCCATTTTCAGGCACAGTGCAGGGGGAGCACAGATTGTGTCTGTGATGCTGCCTGAGG 286 
CYP11B2 GGCCCATTTTCAGGCACAGTGCAGGGGGAGCACAGATTGTGTCTGTGATGCTGCCTGAGG 294 
CYPI1B3 GGCCCATTTTCAGGCACAGTGCAGGGGGAGCACAGATTGTGTCTGTGATGCTGCCTGAGG 283 
ll 11.1 ................ "64f00.1***f******4t*"6.46404"006400"4 
CYP111 ; GAGAGTATCCTCCCGCATCGGATGCCCCTGGAGCCGT 360 
CYP111{i ; GAGAGTATCCTCCCGCATCGGATGCCCCTGGAGCCGT 346 
CYP11I GAGAGTATCCTCCCGCGTCGGATGCACCTGGAGCCGT 354 
CYP1iI , GAGAGTATCCTCCCGCGTCGGATGACGCTGGAGTCGT 343 
CYP11B1 GGGTGGCCCACAGAGAACTCCGTGGCCTGAGACGTGGTGTGTTCTTGCT 409 
CYP11B4 GGGTGGCCCACAGGGAACTCCGTGGCCTGAGACGTGGTGTGTTCTTGCT 395 
CYP11B2 GGGTGGCCCACAGGGAACTCCGTGGCCTGAGACGTGGTGTGTTCTTGCT 403 
CYP11B3 GGGTGGCCCACAGAGAACTCCGTGGCCTGAGACGTGGTGTGTTCTTGCT 392 
Figure 11-6. Nucleotide sequences of exon I and exon 2 of the rat CYP 11131. - 
132, -133, and 134 genes. The sequences were aligned using 
the C LE TSTAI. \V 
(1.81) Programme. Identical nucleotides in the alignment are indicated h) ". 
The 
nucleotide number, 1, is assigned to the predominant transcription 
initiation site. 
Primer sequences are highlighted by black. with arrowheads 
in exon I and 2. 
The direction of arrowheads is from 5'-end to 3'-end of nucleotides. 
1: xon I and 
exon 2 are separated by vertical bars. marking with I and 
2. 
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-4 92 AGATC ý1. ' 
-432 TGGAGTý -.:.. 
-372 AACCGTAI. 1-. "I 
-312 ACTAGGATGA ATCATTCAAG GTTCCACAAA 
-27 . GAAAGAAG GCTCTGACCA 
"'_ CCCACCCA CCAGCAGGCA 
'r'l', A AGAACCATCA GCTCAGTATA 
-72 TGCAGTGACA TTTTTI-. GTCA GCGATTTATA 
-12 AAACACAGGA Ar' '. ' = AGG ATGGCAATGG . ib 
49 CAAGACCCTG -: CTG CACAGGACGA 
109 CCAAGACACT TTT GAAGCCATAC 
169 TGATACAGAT CCTGAGAGAG CAGGGCCAAG 
1112 
229 TCCAAGAGCT GGGGCCCATT TTCAGGCACA 
289 TGCTGCCTGA GGACGCTGAG AAGCTGCACC 
349 CCCTGGAGCC GTGGGTGGCC CACAGAGAAC 
409 T 
=AAATGAGA 
AOTCCCTAA 
GGGAAAATAT 
CCATTGGACT 
TTGCAGAGGT 
CATTTCTAGG 
TCCTCAAGAC 
CTCTCAGGGT 
GGGCACTGGG 
CACAATACTC 
AGAACCTACA 
GTGCA :: _E 
AGGTGGAGA6 
7 (-rr7r, (-, T 
AATTCTAAAA 
ATCTGGCTAG 
GTGCATCTGA 
ATTTTTGAGT 
AGGAAAAGGG 
GCAAGTCCAG 
AAGATAAAAG 
GACAGCAGAT 
CACTACGGCA 
CAGGAACAAG 
CCTGGAGATG 
b :: %:. >J Ivv, 
GCCAACACTT 
(, i1ý111.1ý1. M 1 l. l. 
GCCACGGACT 
GTGTGGCTGG 
AAAGTGGCCC 
TGGCTGAAGA 
CACCAGGCCT 
C 
Figure 11-7. Nucleotide sequences of the -tanking regions, exoil I and 
exon 2 of ('YP 1 1131 gene. The nucleotide number. 1, is assigned to the 
predominant transcription initiation site (highlight 
black). Fxon 1 and exon 2 
are separated by vertical bars, marked w\ ith 
I and 2. The sequences of the 
sons and antisense primers 
for the -flanking region and exon 
2 of 
C'YP 11UI were indicated by open square. correspond to bases -486 to -469 
and + 2284 to +267, respectively. 
The position of the primers liar the ; '- 
flanking region of ß'YP IIBI is indicated by highlight grey, correspond to 
bases -480 to --463 (grey) and -18 
3 to -200, respectively. 
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2.4.2.4. RT-PCR 
RNA was reverse-transcribed to yield cDNA as follows. A 20µl reaction 
mixture was used containing the following components; 5µg I)NAse-treated total 
RNA, 4 µl 5x First Strand Buffer (250 mM Tris-HCI, p}1 8.3 at room temperature. 
with 375 mM KC1,15 MM MgC12), 2 µ1 O. 01 M DTT. and 1 µ1 of 10 mM solutions of' 
each of dATP, dGTP, dCTP and dTTP at neutral pH (Gibco). I µl random hexamc rs 
(3 µg/µ1, Gibco), 1 µl RNase inhibitor (10 U/pt Gibco). 1 µl reverse transcriptase 
(Moloney Murine Leukemia Virus Reverse Transcriptase, M-MLV RT) (200 1 1/pl. 
Gibco). Water was then added to make the volume up to 20 µl. and the contents 
mixed. After incubation at 23 °C for 20 min and 42 "C for 60 min. the samples were 
heated at 95 ° for 5 min to terminate the reactions. and stored at --2O " until use. As a 
negative control for the experiment, reverse transcription was performed by omitting 
the M-MLV RT (to control for amplification of genomic DNA) or RNA (to control 
for cDNA contamination of reagents). 
Single-stranded cDNA (1 µl) in the 20 pl reaction mixture was amplified with 
25 pmol each of sense and antisense primers and 0.5 pl Taq DNA polymerase (5 
U/µi) added to 50 µl PCR buffer - 20 mM Tris-HCI (pH 8.4). 50 mM KC'1.1.5 mM 
MgCI2.0.2 mM each of dATP, dGTP, dCTP and dTTP. Reactions were performed 
using a cycling conditions as summarized in Figure 11-8. Other control reactions 
containing all reagents, except for cDNA or Taq DNA Polymerac. were pertbrmcd 
for each experiment to control for DNA contamination. 
R I'-PCR products %%erc 
electrophoresed in 10 µl aliquots on 1.4% agarose gel. 
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Denatur Annealing Extension Nºº. of Final 
Target mRNA -ation ("t /min) ("Clmin) CN-eles LXtcn"iW1 
(°C/min) 
Renin (human) 95/ 1 SS 1 
AT IA (rat) Q4 45 sec 54/ 1 72' 1 
(ºAP[)11 (Rat) IN '1 001 I -I -5 
7' 5 
ºAPDH (Bovine) 94/ 1 00 I 72 1 
C'YP11BI/CYPI I B2 (rat) 95/ 1 00-1 72/ 1 5 72/5 
5'-flanking region/exon 2 94/1 54/1 72/I 1ý 
of CYPI I1I (rat) 
5'-flanking region of 91/1 52/1 
CYi'11111 (rat) 
Figure 11-8. PCR cycling conditions. 
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2.4.2.5. Analysis of PCR products 
2.4.2.5a. Agarose gel electrophoresis 
RT-PCR products were analyzed against molecular weight standards E3ioline 
IV (Bioline, London, UK), or 100 bp ladder (Helena BioSciences. Sunderland. Inne 
and Wear, UK), on 1.4% agarose gel stained with ethidium bromide and 
electrophoresed in TBE (Tris-borate) buffer (Appendix 2). Gels were examined under 
ultraviolet light and photographed by Transilluminator and Camera System (t I ltra- 
Violet Products Inc., San Gabriel, CA. USA) and printed by Video ('opt- Processor 
(Mitsubishi Electric Corporation, Japan). 
2.4.2.5b. Restriction enzyme digestion 
In order to test the specificity of amplified sequences. the PCR products of 
ATIA were digested with EcoR I (Gibco) in the reaction as reported previously 
(Wheeler-Schilling et al. 1999): 10 tI PCR products, I µ1 EcoR 1 (10 U), 2 µI 10 x 
React 3 (buffer, supplied with EcoR I), and 7 pi water, and incubated at 37"C' for one 
hour. The specific restriction products were visualized after separation on a 1.49'0 
agarose gel stained with ethidium bromide. 
2.4.2.5c. Purification of RT-PCR products and sequencing 
The PCR products were purified using gel extraction (Sambrook et al. 1989b). 
To obtain sufficient double stranded DNA (200 ng) for a sequencing reaction. 
PCR was performed by amplifying several aliquots of cDNA from one mRN: \ 
template and separating the PCR reaction products by electrophoresis in a TAE (Tris- 
acetate) low melting temperature agarose gel containing ethidium bromide using 
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standard protocols (Sambrook et al. 1989b) (Appendix . 2). RT-PCR products were 
purified using Wizard PCR Preps ¢DNA Purification System kits according to the 
manufacturer's protocol. The desired DNA band was excised using a sterile scalpel. 
The 300 µl (300mg, 3-5 lanes) agarose slice was transferred to a 1.5 ml 
microcentrifuge tube and incubated at 700 C until the agarose had melted completely 
(3-5 min). The DNA was eluted from PCR Preps DNA Purification Resin in , ater. 
and thus free of any salt or macromolecular contaminants. The quality of the purified 
products was checked by running 5 µ1 on a 1.40o agarose gel containing ethidium 
bromide in a TBE buffer. The samples of RT-PCR products for C'YP 1 11321CYP 1 1131 
and the 5'-flanking region of CYP 11131 were sequenced by the Microchemical 
Facility, University of Cambridge (BBSRC, E3abraham Hall. l3abraham. Cambridge). 
The similarities of the sequences of products with published sequences wvcre 
compared using NCBI's (National Center for Biotechnology Information, NUBI) 
sequence similarity search tool (BLAST). 
2.4.3. Competitive RT-PCR 
2.4.3.1. Principle 
Competitive PCR has emerged as a valuable method for determining the 
relative levels of mRNAs. The greatest advantage of competitive PCR is that useful 
data can be obtained during either the exponential phase or plateau phase of PCR 
amplication (Nedelman et a!. 1992). In other methods, such as co-amplification of the 
target gene with an endogenous housekeeping gene. the PCR products must 
he 
obtained before the plateau phase of the reaction occurs. 
This is necessar for both the 
housekeeping gene and the target gene. which often exhibit dif 
Brent amplification. 
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In competitive PCR, a DNA fragment containing the same primer sequences 
as the target fragment is allowed to compete in the same tube with the target for 
primer binding and amplification. PCR reaction tubes containing the target samples 
are spiked with a dilution series of the competitor fragment. The competitor fragment 
is called the mimic. When the molar ratio of PCR products generated from target and 
competitor is equal to one, the mount of target is equal to that of the competitor. and 
since this is known, the amount of target can thus be determined (Siebert & Larrick 
1993). In order to differentiate between the PCR products generated from the target 
and the competitor, the competitor can be engineered to be slightly larger or smaller 
than the target (Gilliland et al. 1990). 
2.4.3.2. Generation of competitive PCR mimic 
The generation of competitive PCR mimics (the competitive templates), was 
" achieved by two successive PCR amplifications of heterologous DNA pBluescript II 
(+) Vector, shown in Figure 11-9. For the primary PCR, two composite primers are 
used. One composite primer contained the upstream 5'- flanking region nucleotides of 
CYP 11 B 1(-480 to -463) linked to 17 nucleotides that anneal to one strand of 
pBluescript 11 KS (+) Vector DNA fragment corresponding to 491-507 of the 
4 published sequence (Figure 11-7, Figure 11-10). The other composite primer contained 
the downstream 5'- flanking region nucleotides of CYP 11 B1 (-183 to -200) linked to 
18 nucleotides that anneal to the opposite strand of pBluescript II KS (+) Vector 
DNA fragment corresponding to 890-873 of the published sequence. The two 
composite primers and a small quantity of pBluescript II KS (+) Vector DNA 
fragment were added to a PCR reaction as follows: 5 µl 10 x PCR buffer (100 mM 
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composite primers 
heterologou s 
DNA fragment 
primary PCR with 
composite primers 
1 
I secondary PCR with 
gene-specific primers 
wizard PCR Preps DNA 
Purification System 
07 
PCR MIMIC 
(with gene-specific end sequences) 
Calculate molar quantity 
Figure 11-9. Flowchart dcscribing the generation of 
competitive PCR mimic. . -Adapted 
from Siebert & Kellogg 
1995. 
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421 
481 
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ATTTTTTAAC 
GATAGGGTTG 
CAACGTCAAA 
CTAATCAAGT 
CCCCCGATTT 
AGCGAAAGGA 
CACACCCGCC 
CAATAGGCCG 
AGTGTTGTTC 
GGGCGAAAAA 
TTTTTGGGGT 
AGAGCTTGAC 
GCGGGCGCTA 
CAACTGTTG(, 
GGGATGTGCT 
TAAAACGACG 
GCCCCCCCTC 
ATCCACTAGT '. 
GAGGGTTAAT '. 
ATCCGCTCAC 
CCTAATGAGT 
GAAACCTGTC 
GTATTGGGCG ( 
GGCGAGCGGT i 
ACGCAGGAAA 
CGTTGCTGGC 
CAAGTCAGAG ( 
GCTCCCTCGT ( 
TCCCTTCGGG 
AGGTCGTTCG ( 
CCTTATCCGG 
CAGCAGCCAC 
TGAAGTGGTG ( 
TGAAGCCAGT 
CTGGTAGCGG 
AAGAAGATCC 
AAGGGATTTT ( 
AATGAAGTTT 
GCTTAATCAG 
GACTCCCCGT 
CAATGATACC 
CCGGAAGGGC 
ATTGTTGCCG ( 
CCATTGCTAC 
GTTCCCAACG 
CCTTCGGTCC 
TGGCAGCACT 
GTGAGTACTC 
CGGCGTCAAT i 
GAAAACGTTC 
TGTAACCCAC ' 
GGTGAGCAAA i 
GTTGAATACT 
TCATGAGCGG i 
CATTTCCCCG 
JCAAGC; CGAT 
CCAGTGAGC 
3AGGTCGACG 
CTAGAGCGG 
GCGCGCTTG 
4ATTCCACAC 
3AGCTAACTC 
3TGCCAGCTG 
: 7TCTTCCGCT 
4TCAGCTCAC 
3AACATGTGA 
3TTTTTCCAT 
TGGCGAAAC 
3CGCTCTCCT 
4AGCGTGGCG 
ZTCCAAGCTG 
TAACTATCGT 
TGGTAACAGG 
3CCTAACTAC 
ACCTTCGGA 
TGGTTTTTTT 
TTGATCTTT 
3GTCATGAGA 
TAAATCAATC 
TGAGGCACCT 
ý', GTGTAGATA 
SCGAGACCCA 
: -'GAGCGCAGA 
3GAAGCTAGA 
4GGCATCGTG 
4TCAAGGCGA 
TCCGATCGTT 
3CATAATTCT 
4ACCAAGTCA 
4CGGGATAAT 
TTCGGGGCGA 
TCGTGCACCC 
4ACAGGAAGG 
ZATACTCTTC 
4TACATATTT 
AAATCGGCAA 
CAGTTTGGAA 
CCGTCTATCA 
CGAGGTGCCG 
GGGGAAAGCC 
GGGCGCTGGC 
CGCCGCTACA 
-GGC 
TAAGTTGGGT 
GCGCGTAATA 
GTATCGATAA 
CCGCCACCGC 
GCGTAATCAT 
AACATACGAG 
ACATTAATTG 
CATTAATGAA 
TCCTCGCTCA 
TCAAAGGCGG 
GCAAAAGGCC 
AGGCTCCGCC 
CCGACAGGAC 
GTTCCGACCC 
CTTTCTCATA 
GGCTGTGTGC 
CTTGAGTCCA 
ATTAGCAGAG 
GGCTACACTA 
AAAAGAGTTG 
GTTTGCAAGC 
TCTACGGGGT 
TTATCAAAAA 
TAAAGTATAT 
ATCTCAGCGA 
ACTACGATAC 
CGCTCACCGG 
AGTGGTCCTG 
GTAAGTAGTT 
GTGTCACGCT 
GTTACATGAT 
GTCAGAAGTA 
CTTACTGTCA 
TTCTGAGAAT 
ACCGCGCCAC 
AAACTCTCAA 
AACTGATCTT 
CAAAATGCCG 
CTTTTTCAAT 
GAATGTATTT 
AAAAGTGCCA C 
AATCCCTTAT 
CAAGAGTCCA 
GGGCGATGGC 
TAAAGCACTA 
GGCGAACGTG 
AAGTGTAGCG 
GGGCGCGTCC 
CTCTTCGCTA 
AACGCCAGGG 
CGACTCACTA 
GCTTGATATC 
GGTGGAGCT«, 
GGTCATAGCT 
C- 
CGTTC CC C7,, 
TCGGCCAACG 
CTGACTCGCT 
TAATACGGTT 
AGCAAAAGGC 
CCCCTGACGA 
TATAAAGATA 
TGCCGCTTAC 
GCTCACGCTG 
ACGAACCCCC 
ACCCGGTAAG 
CGAGGTATGT 
GAAGGACAGT 
GTAGCTCTTG 
AGCAGATTAC 
CTGACGCTCA 
GGATCTTCAC 
ATGAGTAAAC 
TCTGTCTATT 
GGGAGGGCTT 
CTCCAGATTT 
CAACTTTATC 
CGCCAGTTAA 
CGTCGTTTGG 
CCCCCATGTT 
AGTTGGCCGC 
TGCCATCCGT 
AGTGTATGCG 
ATAGCAGAAC 
GGATCTTACC 
CAGCATCTTT 
CAAAAAAGGG 
ATTATTGAAG 
AGAAAAATAA 
AAATCAAAAG 
CTATTAAAGA 
CCACTACGTG 
AATCGGAACC 
GCGAGAAAGG 
GTCACGCTGC 
CATTCGCCAT 
TTACGCCAGC 
TTTTCCCAGT 
TAGGGCGAAT 
GAATTCCTGC 
''N =, 'TTTTGT 
7T : '` TGTG 
CGCGGGGAGA 
GCGCTCGGTC 
ATCCACAGAA 
CAGGAACCGT 
GCATCACAAA 
CCAGGCGTTT 
CGGATACCTG 
TAGGTATCTC 
CGTTCAGCCC 
ACACGACTTA 
AGGCGGTGCT 
ATTTGGTATC 
ATCCGGCAAA 
GCGCAGAAAA 
GTGGAACGAA 
CTAGATCCTT 
TTGGTCTGAC 
TCGTTCATCC 
ACCATCTGGC 
ATCAGCAATA 
CGCCTCCATC 
TAGTTTGCGC 
TATGGCTTCA 
GTGCAAAAAA 
AGTGTTATCA 
AAGATGCTTT 
GCGACCGAGT 
TTTAAAAGTG 
GCTGTTGAGA 
TACTTTCACC 
AATAAGGGCG 
CATTTATCAG 
ACAAATAGGG 
AATAGACCGA 
ACGTGGACTC 
AACCATCACC 
CTAAAGGGAG 
AAGGGAAGAA 
GCGTAACCAC 
TCAGGCTGCG 
TGGCGAAAGG 
CACGACGTTG 
TGGGTACCGG 
AGCCCGGGGG 
TCCCTTTAGT 
TGAAATTGTT 
,,; CCTGGGGTG 
: TCCAGTCGG 
GGCGGTTTGC 
GTTCGGCTGC 
TCAGGGGATA 
AAAAAGGCCG 
AATCGACGCT 
CCCCCTGGAA 
TCCGCCTTTC 
AGTTCGGTGT 
GACCGCTGCG 
TCGCCACTGG 
ACAGAGTTCT 
TGCGCTCTGC 
CAAACCACCG 
AAAGGATCTC 
AACTCACGTT 
TTAAATTAAA 
AGTTACCAAT 
ATAGTTGCCT 
CCCAGTGCTG 
AACCAGCCAG 
CAGTCTATTA 
AACGTTGTTG 
TTCAGCTCCG 
GCGGTTAGCT 
CTCATGGTTA 
TCTGTGACTG 
TGCTCTTGCC 
CTCATCATTG 
TCCAGTTCGA 
AGCGTTTCTG 
ACACGGAAAT 
GGTTATTGTC 
GTTCCGCGCA 
Figure 11-10. pE3luescript 11 SK(+) Vector DNA Sequence. The sense and antisense 
composite primers of 5-flanking region of CYP 11B1 were highlighted bý grew , 
correspond to nLICIeotides 491-507 and 873-890, respectvvelk, cif pl3luescript II KS (+) 
Vector DNA sequence. 
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tris-HCJ pH 8.3,500 mM KC1,15 mM MgCl,. 0.2% gelatin). 1 µl 50 X dNTP mixture 
(10 mM of each dNTP), 2 µl pBluescript KS II (+) (1 ng/µl). 1 pl each composite 
primer (20 pmol each), 0.4 µ1 Taq DNA Polymerase (5 U/µl). Distilled water was 
then added to make the volume up to 50 µl. 16 PCR cycles were performed as 
follows: denaturing at 94°C for 45 sec; annealing at 60°C for 45 sec: polymerising at 
72"C for 90 sec; with a final polymerisation step for 7 min. An aliquot (5 µl) of the 
reaction mixture was separated on a 1.4% agarose gel, to check that a strong band was 
obtained, otherwise another 4 PCR cycles were performed. In this work, a single band 
with the expected size of 439 bp was obtained after 16 cycles (Figure II-11). During 
amplification of the pBluescript 11 KS (+) Vector DNA fragment, the primer 
sequences of the 5'-flanking region of CYP 11 BI were incorporated into the PCR 
products. The secondary PCR was performed using the specific primers of 5'-flanking 
region of CYP IIB1. A2 µd aliquot of the primary PCR mixture was added to a PCR 
reaction tube containing 83.4 µl distilled water, 10 µl 10 X PCR buffer, 2 µd 50 X 
dNTP, 2 µl (20 pmol) each of the specific primers of 5'-flanking region of CYP 11 B 1, 
0.6 µl (5 U/µl) Taq DNA Polynerase. PCR, 35 cycles, was performed using the same 
amplification profiles as for primary PCR, and 5 µl of the reaction mixture was 
separated on a 1.4% agarose gel. A strong band of the expected size was obtained 
( Figure II-12). 
2.4.3.3. Purification and determination of the mimic 
The mimic was purified using Wizard PCR Preps DNA Purification System as 
described in section 2.4.2.5c.. 
158 
CHAPTER II: MATERIAL AND METHODS 
Figure 11-11. Primary PCR tor the mimic 
generation. After 16 cycles primary PCR using 
composite primers of 5-flanking region of 
CYP 1lBI gene. a single band with the expected 
size of 439 hp N\ as obtained. 
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439 hp -º 
506 hp 
396 hp 
Figure 11-12. The stcondarv PCR för the mimic 
generation. After 35 cycles of PCR using the 
specific primers of 5'-flanking region of 
CYPI 1131 gene, a strong single band with the 
expected size of 439 bp was obtained. 
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The quantity of PCR mimic was determined by measuring the absorbance at 
260 nm. The yield was calculated as follows: ng/ml = A260 (dilution factor) x (0.05) 
x 1000, and the mass quantity was converted to a molar quantity using the 
approximation that I ng of a 300 bp DNA fragment is equal to 5.4 x 103 amol [1 
attomole (amol) = 1O 18 moles]. This conversion factor is derived by using an average 
molecular weight of 310 g/mol for each nucleotide. A portion of the mimics was 
diluted to 100 amoVµl in water, and the concentrated stock was stored at -20 °C. 
2.4.3.4. PCR mimic work dilution series preparation 
Single stranded complementary DNA (cDNA) was synthesised as in chapter 
II-2.4.2.4. 
To set up a preliminary PCR mimic dilution series, tenfold serial dilution of 
the mimic was coamplified with I µl of the single-stranded cDNA, starting with the 
mimic stock solution (100 amoVµl) and using the same PCR conditions as for 
competitive PCR (see following section-2.4.3.5. ) (Figure 11-13). The molar amount of 
target added to the reaction is equal to the molar amount of mimic when the ratio of 
their products becomes equal. The results obtained from the Figure II-13 enable the 
setting up a two-fold mimic dilution, which is used to measure relatively small 
changes in mRNA levels (less than 20-fold). Though starting with an amount of 
mimic to give a ratio of mimic to target PCR products of about 1: 1 (10 amoVµl) 
(Figure 11-13) there is no obvious difference between 16-4 amol/}. I and 0.5-0.125 
amoVµl (Figure 11-14). A 2-5 fold mimic dilution between 100-0.1 amoVµl was thus 
selected as the final programme for the PCR mimic dilution series. 
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500 hp 
400 hp 
300 hp 
200 hp 
431) hp (mimic) 
298 hp (5'-flanking) 
Figure 11-13. A preliminary I'CR mimic dilution series 
preparation. Ten fold serial dilution of the mimic was 
coamplified with 1 µl of the single-stranded cUNA, 
starting with the mimic stock solution (100 amol/Ml). 
Lane M: DNA marker, Lanes 1-6: mimic concentration 
from 100 amoVpl to 10-3 amoLµl. 5'-Clanking indicated 
that PCR was amplified using the primers derived from 
5'- flanking region nucleotides of CYP IIBI gene. 
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Sao bp 
40() bp 
300 bp 
200 hp ý`ýý hp 1` -flailkinM ) 
Figure 11-14. A preliminary PUR mimic dilution series 
preparation using a two fold mimic dilution. Lane M: I)NA 
marker; Lanes 1-3: 16-4 amol/pl; lanes 4-6: 0.5-0.125 arnol/pl. 
't'here is no obvious difference between 16-4 amoViI (lane 1-3) 
and 0.5-0.125 amoUpl (lane 4-6). 5'-flanking indicated that PUR 
was amplified using the primers derived from 5'- flanking region 
nucleotides of CY1111131 gene. 
163 
, 
%, I1 31 
CHAPTER II: MATERIAL AND METHODS 
2.4.3.5. Competitive PCR 
Competitive PCR was performed using 0.5 µl Taq DNA polymerase (5 U/µl). 
1 µ1 of different concentrations of the mimic, 0.5 µ1 (50 pmoVµl) each of sense and 
antisense primers specific for 5'-flanking region of CYP IIB1. and I pl of the single- 
stranded cDNA in 50 . t1 PCR buffer. The reactions were performed using the same 
programme as described in Chapter II- 2.4.2.4. (Figure 11-8). Aliquots (10 µl) of 
amplification products were used for electrophoresis on a 1.4 % agarose gel 
containing with ethidium bromide, and photographed by Transilluminator and Camera 
System (Ultra-Violet Products Inc., San Gabriel, CA. USA) and printed by Video 
Copy Processor (Mitsubishi Electric Corporation, Japan) 
The signal intensity was quantified by computerized densitometry using 
Molecular Analyst System (Bio-Rad Ltd., UK). The data were plotted as a function of 
the log of target optical density (OD)/mimic OD against the log of attomole 
concentrations of mimics added to the PCR reactions (Siebert & Kellogg 1995). 
2.5. Radioimmunoassay (RIA) 
2.5.1. Principle 
The concentration of an unknown antigen is determined by measuring its 
ability to compete with a fixed amount of radio labelled antigen for a limiting quantity 
of antibody (Hudson & Hay 1980). As the concentration of the antigen in the reaction 
increases, the amount of radiolabeled antigen able to bind to the antibody decreases. 
By measuring the amount of bound radioactivity as a function of the concentration of 
the unlabeled antigen in standard reaction mixtures, it is possible to construct a 
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'standard curve' from which the concentration of the antigen in unknown samples can 
be determined (Patrono & Peskar 1987. Dwenger 1984). 
2.5.2. Ang II assay 
Ang II assay was performed using an angiotensin radio immunoassay kit 
obtained from Nichols Institute Diagnostics (Saffron-Waldon, UK). according to the 
manufacturer's protocol. 
The sensitivity of the assay was measured as the smallest single value which 
can be distinguished from zero at the 99% confidence limit. This kit has a calculated 
sensitivity of 3.8 pg/ml. The specificity of this kit was determined by measuring the 
cross-reactivity of several compounds at the 50% B/Bo where B= percentage labelled 
antigen specifically bound to antibody in sample (or standard) tube and BO is that in 
the absence of unlabelled antigen. The results are described on Appendix 3. 
2.5.2.1. Sample extraction 
BAECCM and RASMCCM were concentrated by Freeze Dryer Micro 
Modulyo (Edwards, UK). The tenfold concentrated medium was used in the assay. 
Chilled ethanol (5 ml) was added to each sample. Tubes were mixed by 
inversion for 30 minutes at 40 C. Recovery tubes (R) were set up by pipetting I ml of 
a random sample and adding 0.1 ml 125I-angiotensin II, and extracting at the same 
time as the samples. Total recovery (TR) tubes were set up by adding 0.1 ml '251- 
angiotensin II and 0.3 ml Assay Buffer (supplied with the kit). Extraction tubes were 
centrifuged for 15 min at 4° C at 2500 rpm. and supernatant decanted from each 
extraction tube into the prepared set of tubes. Supernatants were evaporated to 
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dryness in a 370 C water bath under dry nitrogen gas. Dried sample and R extracts 
were reconstituted by adding I ml Assay Buffer to each tube. mixed, and isotope 
content assayed in a gamma counter. 
2.5.2.2. Standard curves 
Before each assay, fresh working standard curves were prepared hý diluting 
the angiotensin II standard (supplied with the kit) with Assay Buffer (Figure 11-15). 
Typical standard curve generated using angiotensin II standard for angiotensin 11 
assay was shown in Figure II-16. 
2.5.2.3. RIA Procedure 
Aliquots (0.4 ml) of each working standard level and each samples were 
pipetted into polystyrene tubes in duplicate and cold anti-angiotensin 11 antibody (0.1 
ml) (supplied with the kit) was added. Total non-specific binding (NSB) tubes were 
set up by pipetting 0.5 ml cold Assay Buffer in duplicate and tubes were incubated 
for 6 hours at 40 C. 0.1 ml of cold '251-Angiotensin II was added to all assay tubes 
and mixed thoroughly, and incubated for 18 hours at 40 C. To separate antibody- 
bound Ang 11 from free Ang II by using anti-rabbit coated cellulose in suspension as 
the solid phase, Anti-Rabbit Precipitant (0.1 ml, supplied with the kit) was added to 
each assay tube except total counts (TC). Tubes were mixed and incubated for 30 min 
at room temperature. Distilled water (1 ml) was added to each assay tube except U'. 
The decanted assay tubes were centrifuged at 40 C for 15 min at ? 500 rpm and isotope 
content assayed in a gamma counter. 
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Standard Name Volume of Assay Volume of Spiking Standard 
Buffer 
Stock - 400 pg/ml Ang H* 
A Standard 200 pg/ml 1.0 ml 1.0 ml stock 
B Standard 100 pg/ml 1.0 ml 1.0 ml A 
C Standard 50 pg/ml 1.0 ml 1.0 ml B 
D Standard 20 pg/ml 1.2 ml 0.8 ml C 
E Standard 10 pg/ml 1.0 ml 1.0 ml D 
F Standard 5 pg/ml 1.0 ml 1.0 ml E 
G Standard 0 pg/ml Assay Buffer 
Figure 11-15. The preparation of the individual standard levels for Ang II. 
* The actual stock Ang II concentration may vary between batches. 
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120 
100 
80 
60 
° 40 
20 
0 
Rý =n 44'2 
0 0.5 1 1.5 2 2.5 
Log Ang II concentration 
Figuretl-16. Representative standard curve generated using 
Ang II standard för Ang II assay. N=2 for each point. R 
0.9933. B() = the average corrected counts of the zero standard 
tubes. B= the average corrected counts for each standard tube. 
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2.5.2.4. Sample Calculations 
These were: 
(1) Standard curves were generated at the time of each assay. 
(2) Percent recoveries were generated by the following equation: 
Recovery = 
CPM Recovery Tube 
x 
1.0 ml x 100 
CPM in total Recovery Tubes 0.4 ml 
A typical percent recovery calculations for Ang II assay were given in 
Appendix 3. The percent recovery for Ang II assay was 87% ± 4% (n = 4). 
(3) Standard curves were plotted as %B/B against Ang II concentration. 
Samples were read against the standard curve, corrected for recovery and 
expressed as pg/mU 106 cells. 
2.5.3. Aldosterone RIA 
The aldosterone RIA method used in this work was established in this 
laboratory (Kapas et al. 1991). Aldosterone was assayed using an antibody raised in 
sheep to aldosterone-Keyhole Limpet Haemocyanin (KLH). Full details of the assay 
validation procedure are provided in Appendix 4 (in house data). 
2.5.3.1. Preparation of samples 
One millilitre aliquots of a RASMC suspension (105 cells/ml) in RPMI-1640 
supplemented with 20% FBS were distributed to a 24 well multiwell plate on the first 
day of the experiment. The medium was replaced 24 hour after subculture with 
serum-free medium (SFM) containing 10-'0.10"9.10-8.10-' and 10-' M Ang II with or 
169 
CHAPTER II: MATERIAL AND METHODS 
without losartan (10"5 M) with 4 wells per group and experiments were terminated 
after 48 hours. Medium was collected and stored at -20 
°C prior to use. 
2.5.3.2. Reagent preparation 
The aldosterone antibody, prepared in-house was freeze-dried at a 1: 10 
dilution. A working concentration of 1: 25,000 was prepared by reconstituting the 
freeze dried antibody and diluting it using 0.15 mM phosphate buffer solution 
containing 0.1 % bovine serum albumin (BSA buffer). 
[1,2,6,7_3 H]AIdosterone stock solution in ethanol was stored at -20"C. The 
working dilution for indirect radioimmunoassays (where samples are extracted into 
ethyl acetate prior to assay) was prepared in ethyl acetate. For direct assays on 
aqueous samples, the working dilution was prepared in BSA buffer. 
Dextran-coated charcoal (DCC) for radioimmunoassay was prepared in 0.1 5 
mM phosphate buffer solution containing 0.05% (w/v) dextran, 0.5% (w/v) charcoal 
and 5% (v/v) glycerol, stirred at 4°C. This was used for both direct and indirect RIA. 
2.5.3.3. Indirect radioimmunoassay protocol 
The samples were extracted with ethyl acetate using methods previously described 
(Henville et al. 1989). Briefly, I ml sample was mixed with 1.5 ml ethyl acetate and 
centrifuged at 2,500 rpm at 4°C for 15 min. Supernatants were decanted into 15 ml 
glass test-tubes, and the extraction was repeated. The combined extracted solution 
were evaporated at 60°C using dry nitrogen gas and taken up in I ml ethyl acetate. 
Standard aldosterone dilution series were performed as in Figure 11-17. A typical 
standard curve is shown in Figure 11 -18. 
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Concentration of Aldosterone Aldosterone Ethyl Acetate 
(fmo1I100µ1/tube) (2000fmoU l OOµl) 
A: 1000 I ml I ml 
B: 500 1 ml A1 ml 
C: 250 1mlB lml 
D: 100 100 µl A 900 }al 
E: 50 100µ1B 900µl 
F: 0 1 ml 
Figure 11-17. Standard aldosterone dilution series. 
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2.5 
X 
2 
1.5 
1 
0.5 
0 
0 500 1000 1500 
[Aldosterone] fmoI/100µI 
Figure 11-18. A typical standard curve obtained using a 
working dilution of aldosterone antibody; n=2 for each point. 
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Aliquots (300 µl) from each sample or the aldosterone standards (100 µl) were 
assayed in duplicate in 15 ml glass tubes. 100 µl of the diluted 3H-aldosterone (10,000 
CPM) was added to all tubes. Solvent was evaporated at 60°C under dray nitrogen gas. 
Finally 200 µl of the diluted antibody was added and the tubes mixed thoroughly and 
incubated overnight at 4°C. After addition of 200 . tI DCC (Dextran-coated charcoal). 
the tubes were incubated at 4°C for 10 minutes, centrifuged at 2,500 rpm at 4°C for 20 
minutes, and 200 µ1 of the supernatant were removed to a scintillation vial with I nil 
of a scintillation fluid (Optiphase HiSafe 3. Pharmacia. Milton Keynes, UK). Fach 
sample was counted by liquid scintillation counter (Wallac 1410, Pharmacia, Milton 
Keynes) for 5 min. 
2.5.3.4. Direct radioimmunoassay protocol 
The assay was performed directedly in 1.5 ml eppendorf tubes to evaluate 
aldosterone antibody cross-reactivity with possible competing steroids- l 8-O11-DOC 
and corticosterone. Aldosterone standards were prepared as for the indirect 
radioimmunoassay except BSA buffer replaced ethyl acetate, and the concentration of 
aldosterone required to displace 50% of the bound label was determined. Competing 
steroids (18-OH-DOC and corticorsterone) (20 x 104 -1000 x 104 fomL100 µl) were 
prepared in BSA buffer in duplicate and the diluted 3H-aldosterone (100 µl) and 
antibody (200 µl) was added. These were then treated as for the indirect 
radio immunoassay, with the difference that eppendorf tubes were centrifuged at 
10,000 rpm in a bench-top microfuge, at 4°C for 10 minutes prior to removal of 200 
µ1 of the supernatant, which was then counted as for the indirect radioimmunoassay. 
173 
CHAPTER II: MATERIAL AND METHODS 
Cross-reactivity was determined at the point at which 50% of the labelled aldosterone 
was specifically bound, using the following calculation: 
Cross reactivity (%) - 
Concentration of aldosterone at 50% bound label -\ 100 
Concentration of competing steroids at 50% bound label 
The standard curves obtained using a working dilution (1: 25.000) of 
aldosterone-KLH antisera raised in sheep and increasing concentrations of 
aldosterone, 18-OH-DOC and corticosterone were shown in Figure I1-19, Figure Il- 
20, and Figure II-21, respectively. The aldosterone antibody cross-reactivity with 
competing steroids- l 8-OH-DOC and corticosterone is shown Figure 11-22. 
2.5.4. Corticosterone RIA 
Corticosterone was measured using an antibody purchased from Sigma 
Chemical Company Ltd (Poole, Dorset, UK). The antiserum was developed in rabbits 
using corticosterone 21 -thyroglobulin as the immunogen. 
2.5.4.1. Preparation of samples 
As for aldosterone RIA described in 2.5.3.1.. 
2.5.4.2. Reagent preparation 
The antibody was prepared by resuspending the lyophilised powder in 5 ml of 
0.05 mM Tris-HCI buffer (pH 8.0, with 0.1 mM NaCl, 0.1 % BSA and 0.1 % sodium 
azide). The stock solution was kept frozen, it was diluted in 1: 10 before use. 
[1.2.6.7- 3 HICorticosterone stock solution in ethanol was stored at 20"C. The 
working dilution for radioimmunoassays was prepared in ethyl acetate. 
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Figure 11-19. The standard curve obtained using 
increasing concentrations of aldosterone and a ýwrking 
dilution ( 1: '5.000) of aldosterone-K1,11 antikera raised in 
sheep, designed to discover the concentration of 
aldosterone to displace fifth' percent of the bound label. ti 
_ for each point. 
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Figure 11-20. The standard curve obtained using increasing 
concentrations of 18-hydroxydeoxycorticosterone and a working 
dilution (1: 25,000) of aldosterone-KLH antisera raised in sheep, 
designed to discover the concentration of 18- 
hydroxydeoxycorticosterone to displace fifty percent of the bound 
label. N=2 for each point. 
176 
CHAPTER II: MATERIAL AND METHODS 
100 
ß 
C 
O 
75 
m 
w 0 50 
0 
C 
m 25 
I- m 
CL 
0 
0 200 400 600 800 1000 1200 
[corticosterons) x 10 4 fmoV100ui 
Figure 11-21. The standard curve obtained using increasing 
concentrations of corticosterone and a working dilution (1: 25,000) 
of aldosterone-KLH antisera raised in sheep, designed to discover 
the concentration of corticosterone to displace fitly percent of the 
bound label. N=2 for each point. 
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Compound 
18-Of I-DOC 
% Cross Reactivity 
< 0.02 
Corticosterone <0.01 
Figure 11-22. ('rosti reactivity of the aldosteronc antihodý ýý ith 18- 
OH-IX)C and corticosterone. Note that the precision and 
, 'cnsitiv It) of' this aldosterone assav method used in this vwrk 
was also evaluated prey iousl\ (in house data, see 1Appendix 4). 
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Dextran-coated charcoal (DCC) for radioimmunoassav was prepared in 0.05 
mM Tris-HCI buffer (pH 8.0) containing 0.1 mM NaCl. 0.1 °ro BSA and 0.1 °0 sodium 
azide. 
A stock standard solution of I µg/m1 corticosterone was prepared in absolute 
ethanol. A portion of the stock solution was diluted with ethvI acetate to a 
concentration of 2,000 pgl100µl. This was further diluted with ethyl acetate to obtain 
standard solutions at the following concentrations: 1000,500,250.125,50 and 0 
f nol/100 t1. A typical standard curve is shown in Figure 11-23. 
2.5.4.3. Radioimmunoassay protocol 
As for aldosterone RIA described in 2.5.3.3., except for [ L2,63- 
3H ]Aldosterone replaced with [ 1,2,6,7-3H ]Corticosterone. and an ti-aldosterone 
antibody replaced with anti-corticosterone antibody. 
2.6. Data statistical analysis 
Values were given as means ± S. E. M.. The level of significance for difference 
between means was evaluated by Student's t-test for unpaired data and ANOVA (where 
appropriate) using Microsoft Excell data analysis tool. Significance was assumed at P 
< 0.05. 
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Figure 11-23. A typical standard curve obtained with a 
working dilution of the corticosterone 21-thvroglohulin 
antisera raised in rabbits (n =2 for each point: r=0.9905). 
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CHAPTER III: RES('LTS 
1. Characterization of cultured cells 
1.1. Light micrographs of cultured cells 
L3AEC and RASMC in culture were characterized by light microscopy. BAF'(' 
exhibited a typical cobblestone appearance (Figure III- I). RASMMC grew out slowly 
from the original explant (Figure 111-2 (A)) in multiple overlapping layers, showing 
typical of "peak" and "valley" structure (Figure 111-2 (13)). 
1.2. Immunofluorescence staining of cultured cells 
Immunofluorescent localization of von Willebrand factor and cx-actin was 
obtained in cultured BAEC (Figure 111-3 (A)) and RASMC (Figure 111-4 (A)), 
respectively. Both the BAFC and RASMC negative control slides, from which 
primary antibodies were omitted, remained unstained (Figure 111-3 (B), 4 (E3)). 
2. The expression of renin in cultured BAEC 
2.1. Renin protein detection 
Immunoreactive renin was found to he present in the cytoplasmic 
compartment of cultured bovine endothelial cells, though possibly more concentrated 
in the perinuclear region (Figure 111-5 (A)). Negative control slides, from which 
primary antibody was omitted, remained unstained (Figure III -5 (B)). 
1: vidence that the protein recognised in bovine endothelial cells h. 
immunostaining was indeed renin was obtained by immunoblotting after SDS-PAGE:. 
Using soluhilizcd cell fractions from cultured endothelial cells. two immunoreactive 
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100 
Figure 111-1. Cultured E3AFC exhibited 
the typical "cobblestone" appearance. 
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(A) x 100 
(13) t1 00 
Figure 111-2. (A) RASMC growing out 
from the original explant. (B) RASMC in 
multiple overlapping layers, showing 
typical of `peak' (black arrow) and 
-valley' (white arrow) structure. 
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(A) . 400 
(13) ' 4W) 
Figure 111-3. (A) The cytoplasmic pattern 
of immunotluorescence of von Willebrand 
Factor was exhibited in cultured BAFC. 
(B) The negative control slides, in which 
primary antibody was omitted, remained 
unstained. 
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(A) t 400 
(B) . 400 
Figure 111-4. (A) The cvloplasmic pattern of 
immunofluorescence of a-actin in cultured 
RASMC. (B) The negative control slides, in 
which primary antibody was omitted, 
remained unstained. 
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1" I:; 
. ýt 
"; 
(B) x 200 
Figure 111-5. (A) Immunoreactive renin 
(brown) in the cytoplasmic compartment 
of cultured BAEC, though possibly 
more concentrated in the perinuclear 
region. (B) The negative control slides, in 
which primary- antibody was omitted, 
remained unstained. 
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bands were obtained with molecular mass of approximately 3740 kDa. similar to the 
expected values for renin and prorenin (Figure 111-6). No band was obtained in 
negative control, in which primary antibody was omitted. 
2.2. Renin mRNA detection 
In situ hybridization showed that the specific signals of the renin antisense 
probe were located in the cytoplasm of cultured endothelial cells (Figure 111-7 (A)). 
No signal was detected in negative controls in which sections were hybridized with 
the sense probe (Figure 111-7 (B)). 
RT-PCR, using bovine endothelial cell RNA and primers derived from the 
human renin sequence, gave a single band with the size predicted for renin of 141 bp 
(Figure 111-8 (A)). No bands were detected in negative controls, from which one of the 
following components were omitted: reverse transcriptase, RNA template (in the RT 
reaction), cDNA and Taq DNA polymerase, respectively. As positive control, the 
amplified product corresponding to transcripts of renin was also detected in bovine 
kidney (Figure 111-8(B)). Furthermore control primers for the GAPDI1 "house 
keeping" gene gave the expected band of 519 bp (Figure 111-9). 
3. Ang II formation in cultured BAEC and RASMC and its effects on VSM(' 
proliferation 
3.1. The formation of Ang II in BAEC and RASMC 
Radioimmunoassay demonstrated Ang II generation in both BAI: C'('M (1-0-5 
± 4.67 pg /106 cells/48 hours per 10 ml) and RASMCCM (11.16 ± 1.8 pg /106 cells/48 
hours per 10 ml), and the values obtained were significantly higher than that of the 
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116 kDa- 
84 kDa 
58 k Da 
45 kDa- 
36 kDa 
26 k Da- as 
- 37-40 kDa 
Figure 111-6. Immunoblotting for renin in 
cultured bovine aortic endothelial cells, using anti- 
resin (human) antibody 2D 12. I'Nk, o 
immunoreactive hands with a molecular mass of 
approximately 37-40 kDa are recognised. Lane . 
renin and prorenin; lane -, negative control, from 
which primary antitx)dy was omitted. 
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Figure I11-7. In situ hybridization for the 
detection of' renin mRNA with DI(; - 
labelled antisense and sense probes. There 
is positive staining in the cytoplasm of 
cultured BAFC (A) (black arru\ý) and no 
positive cells are detected using the sense 
probe (B). 
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154 hp 
134 hp 
(A) 
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100 bp º 
(B) 
"- 141 h1) 
--111 bp 
Figure 111-8. (A) Using, RI -PCR of RNA extracted from 
BAIT with primers specific for renin, a single band was 
detected, which had the predicted size of 141 hp for renin. 
M, DNA marker, lane 1. renin. lane 2-5, negative controls 
NN ithout the toIIoNN ing components: reverse transcriptase 
template (in reverse-transcribed reaction) lane 2, RNA 
template (in reverse-transcribed reaction) lane 3. cl)\. \ lane 
4 and I aq DNA polvmerase lane 5. (B) As positive control. 
141 bp amplified product corresponding to transcripts of renin 
was detected in bovine kidney. Lane +: renin: Lane -: negatiNe 
controls %% ithout reverse transcriptase (in reg erse-transcrihe-d 
reaction). 
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600 hp 
500 bp 
400 hp 
ý-- 519 hp 
Figure 111-9. Rl -E'CR for bovine (iAPDH mR\. \.. -A single 
hand was detected with the expected size o1519 bp. Lane M. DNA 
marker. lane 1. bovine GAPDH. lane 2-5 negative controls «ithout 
the 1üilowing components: reNerse transcriptase (in reverse- 
transcribed reaction) lane '. RNA template (in reverse- 
transcribed reaction) lane cDNA lane 4 and Iaq DNA 
polymerase lane 5. 
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blank values obtained from unconditioned medium (RPMI-1640 medium containing 
2% serum replacements, 3.2 ± 1.04 pg per 10 ml) (P < 0.05, Figure III-10 ). 
3.2. The effects of conditioned medium from BAEC and RASMC on the 
proliferation of BASMC and RASMC 
BAECCM increased thymidine incorporation into BASMC (P < 0.01) and this 
was inhibited by losartan 10"S M (P < 0.01) (Figure 111-1 1). 
Tritiated thymidine uptake in RASMC was not significantly enhanced by 
RASMCCM, but it was significantly decreased in the presence of losartan 10-5 M (P < 
0.01) (Figure 111- 12). 
3.3. The effects of ATS receptor antagonist, losartan, on the proliferation of 
RASMC stimulated by Ang II 
Tritiated thymidine incorporation into RASMC was increased with different 
concentration (10'8.10-7 and 10' M) of Ang II (P < 0.01, Figure 111-13), and this was 
inhibited by losartan 10"5 M (P < 0.01). Tritiated thymidine incorporation into 
RASMC treated by Ang II with losartan was significantly reduced compared with that 
of control (at 10-8 M: P<0.0 1, at 10"7 and 10-6 M: P<0.05, Figure II1-13 ). 
Losartan also inhibited tritiated thymidine incorporation into R: 1SMC 
incubated with SFM alone (P < 0.05) (Figure 111- 14). 
Using cell counts as measure of proliferation, the number of RASH(' in 
groups treated with different concentration (10-8,10"' and 10"' M) of Ang 11 was 
significantly increased (P < 0.05. Figure 111- 15) and at 10-6 M nearly twice that of 
controls (at 10"" M: 2.97 ± 0.07 x 105 cell vs control I. 55 ± 0.04 x 105 cell). The 
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Ang 11 Concentration n 1) 
BAECCM 15.05 ± 4.67 pg /106 3 
cells/48 hours per 10 ml 
BAECCM 
RASMCCM 11.16 ± 1.8 pg / 10`' cells/48 3 
hours per 10 ml 
RASMCCM 
UM 3.2± 1.04pgper 10 mlUM 3 
Figure 111-10. Ang II generation was demonstrated in conditioned 
medium prepared from cultures of bovine aortic endothelial cells 
(106 cells) and rat aortic smooth muscle cells (106 cells) incubated 
with RPMI-1640 medium containing 2% serum replacement for 48 
hours. UM (RPMI-1640 medium containing 2°, o serum 
replacement) was used as control. Values are means ±S. C. M.. * 
indicates P<0.05 vs control (LIM) (Student's t-test). BAECC\t: 
bovine aortic endothelial cells conditioned medium. RASMC('M: 
rat aortic smooth muscle cells conditioned medium. UM: 
unconditioned medium. 
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Figure 111-11. Incorporation of 'H-nmethýlth>nmidine into 
bovine aortic smooth muscle cells (BASMC'). BASMC' (0.3 x 
10, /mUwell) were incubated with I3AEC'CM with or without 
losartan (10-5 M) for 48 hours. Data are means ± S. E. M.. N= 
6. ** P<0.01 (Student's t-test). Control: RPMI-1640 
medium containing 2% serum replacement. B AI: CC'M: 
bovine aortic endothelial cell conditioned medium. UPM: 
disintegrations per minute. 
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Figure 111-12. Incorporation of '11-mcthvlthvmidinc into rat 
aortic smooth muscle cells (RASMC). RASM(' (0.3 x 
1(Y /ml/well) were incubated with RASMCCM ki ith or 
without losartan (10-5 M) för 48 hours. Data are means ± 
S. F. M.. N=6. ** P<0.01 (Student's t-test). Control: RPM! - 
1640 medium containing ?00 serum replacement; 
RASN1('('N'l: rat aortic smooth muscle cell conditioned 
medium; I)PM: disintegrations per minute. 
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Figure 111-13. 'l1-methvlthvmidine incorporation into rat aortic 
smooth muscle cells (RASMC). Quiescent RASM(' (0.3 x 
101 1; were incubated with serum-free medium (SI I) 
containing dit1trent concentrations of Ang II with or without 
losartan (10- M) Ihr 48 hours. Value are means ± S. F. M.. N-6 
per group. Tritium incorporation was increased in the Ang 11 
treated groups. Losartan inhibited the 11-thvmidine uptake 
induced by An, 11. ANOVA: P. 0.001: Student's t-test: ** P 
0.01. *P0.05. I)PMM: disintegrations per minute. 
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Figure 111-14.1{-meth\ lthvmidine incorporation 
into rat aortic smooth muscle cells (RASM('). 
RASMC (0.3 x W/ml/well) were incubated with 
strum-free medium (SFM) with or without losartan 
(10" M) iör 48 hours. Value are means ± S. F. M.. N 
=4 per group. Tritium incorporation was decreased 
in the presence of losartan. *P<0.05 (Student's t- 
test). DPM: disintegrations per minute. 
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  Control (20% FBS RPMI-1640 medium) M Ang II Q Ang II + Iosartan m bFGF (5Ong/ml) 
Figure 111-15. Cell count for rat aortic smooth muscle cells 
(RASMC). RASMC (0.5 x 1W/ml. ell) were incubated with 
20% F 13S RPMI-1640 medium containing ditTerent concentration 
of Ang 11 in the absence and presence of losartan (1 ((' M) for 48 
hours. The number of RASMC in groups treated with Ang Il 1ýt 
M was nearly twice that of controls. The increase in cell number 
was inhibited by losartan. hl=GF was used as a positive control. 
Value are means ± S. F. M.. N=3 thoughout. ANO A: P< 
0.001. Student's t-test: ** P -_ 0.01. *P<0.05. 
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increase in cell number was inhibited by losartan 10-5 M (P < 0.01. Figure II1-15 ). 1-he 
number of RASMC treated by Ang II with losartan was significantly reduced 
compared with that of control (P < 0.05. Figure III-15 ). As a positive control. the 
number of RASMC in group treated with bFGF (50 ng/ml) was significantly 
increased (P < 0.05, Figure 111- 15). 
3.4. The expression of ATIA receptor in RASMC 
Using RASMC RNA and primers derived from the AT, A receptor sequence. a 
single band was detected, with the size predicted for AT1 A receptor of 1036 bp (Figure 
111-16). No band was obtained in negative controls that lacked one of the following 
components: Taq DNA polymerase, cDNA, RNA template (in RT reaction) and 
reverse transcriptase (in RT reaction). The ATIA PCR products were digested with 
restriction enzymes and the specific restriction products were detected, with the size 
predicted for AT, A of 356 bp and 679 bp (Figure 111-17). Furthermore using control 
primers for the rat GAPDH house keeping gene the expected band with 410 bp was 
obtained (Figure 111- 18). 
4. Aldosterone formation in cultured RASMC and its effects on RASMC 
proliferation 
4.1. The effects of Ang II on steroid biosynthesis in cultured RASMC 
The effects of increasing concentration of Ang 11 on the secretion of 
aldosterone by cultured RASMC are presented in Figure I1I-19. Ang 11 added alone at 
10-8 and 10'7 M significantly enhanced aldosterone formation (at 1O M: 123.8 ± 
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1036 hp 
Figure 111-16. R'I -PC'R of 'Ali,, m 
RN, 
,; \ in RAYMU. Lane M. 
DNA marker; lane 1, AT,, A lane 2-5. negative controls 
containing all reagents, except für reverse transcriptase lane 2 (in 
reverse-transcribed reaction). RNA (in reverse-transcribed 
reaction) lane 3, cI)NA lane 4 and Taq I)NA polyrnerase lane 5. 
2(X) 
M12345 
CHAPTER III: RESt 1. Ts 
124H) hp 
1031 hp 
9(NI hp 
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ý 10: %46 hp 
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-. 4 1 kA 1i p 
Figure 111-17. RT -PC'R of AT1.. 
mRNA in RASMC. Lane M. DNA 
marker. lane 1. A I', ý receptor. lane 2. 
restriction enzyme digestion. 
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Figure 111-18. R I'-PC'R ti)r rat CGAP! )I I mRNA in 
RASMC. A single band was detected ýNith the expected 
size of 4 1O hp. Lane M. DNA marker; lane 1, rat (; API)I1. 
lane 2-5 negative controls N% ithout the I'011 0%% ink; 
components: reverse transcriptase (in reverse-transcribed 
reaction) lane 2, RNA template (in reverse-transcribed 
reaction) lane 3, cDNA lane 4 and I aq [)NA polk merase 
lane 5. 
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Figure I11-19. Aldosterone formation by rat aortic smooth 
muscle cells (RASMC'). Samples (conditioned medium) were 
obtained from RASMMC (10'/ml/wti'el1) incubated «ith serum-tree 
medium (SF ißt) containing diftrent concentrations of' Aug II 
with or without losartan (10-ý IVl) for 48 hours. Aliquots (0.3 nil) 
cif each sample were assayed, and results are therefore expressed 
as tillc)UO. 3 x 10' cells/48 hours. Ang II significantly enh nccd 
aldosterone formation at 1 0-x and 10- M . 
but the increase was 
inhihited by losartan. Values are means 4 pcr 
group. ANOVA: P<0.01; Student's t-test: ** E' . 0.01. *P :- 
0.05. 
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14.85 fmol/0.3 x 105 cells/48 hours vs control 71.28 ± 8.7. P<0.01: at 10" NI: 172.38 
± 33.44, P<0.05), but the increase was inhibited by losartan 10'4 \1 (P < 0.05). 
Corticosterone was not detectable in CM obtained from RAS\t(' treated a-s 
that used in aldosterone RIA. 
4.2. The effects of Ang II on the proliferation of RASMC in the presence of 
aldosterone receptor antagonists spironolactone 
Tritiated thymidine incorporation was increased in the cells stimulated with 
Ang II alone (at 10"9 M, P<0.05; at 10-8,10"' and 10"' M, P<0.01), but this effect 
was inhibited in the presence of spironolactone 10'5 M (at 10'9.10"8 and 10'7 M: P< 
0.01; at 10-6M: P<0.05, Figure 111-20). Spironolactone also inhibited 'F1-thymidine 
uptake in wells in which the concentration of Ang 11 (10-10 M) was not stimulator` (P 
< 0.0 1, Figure 111-20). 
4.3. The effects of aldosterone on the proliferation of RASMC stimulated by Ang 
The Ang 11-induced increase in tritiated thymidine incorporation into R: ASMC 
was significantly enhanced by aldosterone 10"1° and 10-8 M (P < 0.01. Figure 111-21 ). 
Aldosterone alone did not significantly change the tritiated thymidine incorporation 
when compared with controls (Figure 111-22). 
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Figure 111-20. 'II-m thvlthvmidine incorporation into rat aortic smooth 
muscle cells (RASMC). RASMC (0.3 x 10. /rUwell) stiere incubated with 
scrum-tree medium (SFM) containing different concentrations of Ang 
with or without spironolactone (10-; M) for 48 hours. Tritium 
incorporation was increased in the Ang II treated group at 10M, 10-x. 10 
and 1()-" M. Spironolactone inhibited the 'l 1-thvnlidine uptake enhanced hs 
Ang 11. Spironolactone also inhibited the -I1-thynlldine uptake In the 
presence of a non-stimulatory Ani: 11 concentration ( I(11' M). Values are 
means ± S. F. M.. N=4 per group. ANOVA: P, 0.001: Student's t-test: 
** P -- 0.01, *P<0.05. DPM: disintegrations per minute. 
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Figure 111-21. '11-me'thvlthvmidint incorporation into rat aortic smooth 
muscle cells (RASMC). Quiescent RASMC (0.3 x 10'7! rlwellº were 
incubated with serum-free medium (SFN1) containing different 
concentrations of aldosterone with or without Anz 11 (I (1 M) fier 4S hours. 
1I-methvlthvrnidine incorporation into R \S\1(' was increased in the Ang 11 
treated group. The tritium incorporation induced by Ang 11 was enhanced h. N 
aldosterone at 1()-"' and 10-8. but not at 10-`2 and 1(J M. Value are swans ± 
S. F. M.. N-4 per group. f\NO VA: P <- 0.001: Student's t-test: ** P. O. 01, 
*P'0.05. I)PM: disintegrations per minute. 
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Figure 111-22. 'l l-methvlthvmidine incorporation into rat aortic sni oath 
muscle cells (RASMC). Quiescent RASMC (0.3 x l0 ml uelh %%cre 
incubated with serum-free medium (SI NI) containing diflerent 
Concentrations of aldosterune for 48 hours. Tritium incorporation as 
increased in the Ang II treated group. but not when treated %%ith 
aldosterone alone. Value are means ± S. E. M.. N=4 per group. * I' < 0.05 
(Student's t-test). DPM: disintegrations per minute. 
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4.4. The effects of the 3ß-hydroaysteroid-dehydrogenase inhibitor, trilostane, on 
the proliferation of RASMC stimulated by Ang II 
Tritiated thymidine incorporation into RASMC treated %%ith ; ins; 11 10-' was 
significantly increased compared with that of control (P < 0.01). but this effect was 
inhibited by trilostane l0'6and 10"5 (P < 0.05. Figure 111-23). 
The number of RASMC in groups treated with Ang 11 IO"' NI was signitirantiý 
increased compared with that of control (P < 0.01). but this effect was inhibited by 
trilostane at 10-6 and 10"5 M (P < 0.05, Figure 111-24). 
5. CYPI IB gene expression in cultured RASMC 
5.1. The expression of CYPI IB genes in RASMC 
Using RASMC RNA and primers derived from the homologous parts of the 
exon 1 and exon 2 regions of CYP 11 BI and CYP II B2, RT-PCR resulted in a hand 
with the size predicted of 314 bp and a greater band than that expected (Figure 111-25). 
The greater band was also detected in negative control reaction, in which re%erse 
transcriptase was omitted in reverse-transcribed reaction (Figure 111-2-5). suggesting aus 
genomic DNA amplification for CYP IIBI and CYP 11132 with the size predicted of' 
684 bp based on the size for intron I of CYP 1IBI and CYP 11132 of 3 70 hp (Figure 
lit-25). 
After purified using Wizard PCR Preps DNA Purification System. the desired 
PCR product amplified from CYP I1BI /CYP 11 B2 mRNA gave a single band With the 
size predicted for 314 bp (Figure 111-26). Sequences of the PCR product for ('YP 11111 
and CYP II B2 were 96% and 94% similar to the published sequence of 
CYP 1 1131 
2US 
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Figure 111-23. 't 1-meth\ lthvrnidine incorporation into rat aortic 
smooth muscle cells (RASMC'). Quiescent RASM1C (0.3 x 
105/mUwell) were incubated with serum-tree medium (Si \1) 
containing An& Il (10-' M) with or without different concentrations 
of trilostane tör 48 hours. '1 l-methv lthvmidine incorporation into 
RASMC was increased in the Ang II treated group. The tritium 
incorporation induced by Ang II was inhibited by trilostane at 1 0" 
and I01 but not at 10-". 10-8 and 10-' M. Value are means 
N=4 per group. ANOVA: P -- 0.001; Student's t-test: ** 1' - 0.01. * 
P<0.05. [FPM: disintegrations per minute. 
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3.5 
  Control (20% FBS RPMI-1640 medium) ®Ang 11   Ang 11 + tnilostane 
Figure 111-24. Cell count for rat aortic smooth muscle cells 
(RASM('). RASMC (0.5 x 10-'/ml/well) were incubated with 2O°ßö 
1 liti IZI'MI-1640 medium containing Ang 11(1O 11) with or vv ithout 
ditlercnt concentrations of trilostane !r 48 hours. Number of 
RASMU in groups treated with Ankh II 10- NI was signiticantlý 
increased. compared with controls. The Ang 11 stimulated increase in 
cell number was inhibited by trilostane at 1(Y and 10-5 but not at 10" 
10-8 and I ()-7 M. Value are means ± S. F. M. N=3pr group. 
ANO VA: I' -- 0.001; Student's t-test: ** P<0.01. *PO. 05 
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Roo hp 
700 bp 
600 hp 
400 bp 
300 bp 
200 bp 
-- 314 hp 
Figure 111-25. RT-PCR for CYPI1I31/CYPI113_2 niR\: A 
in RASMC. Lane M, [)NA marker; lane I. 
CYPI 1131/CYPI 1 [32. lane 2-5 negative control, %%ithuut 
the foliloew ing components: reverse transcriptase (in 
reverse-transcribed reaction) lane 2. RNS template (in 
reverse-transcribed reaction) lane 3, cDNA lane 4 and 
'Faq [)NA polymerase lane 5. 
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400 bp 
300 hp 
200 hp 
314 hp 
Figure 111-26. RI -P('R products 
amplified with primers derived from 
homologous parts of the exon I and 
exon 2 region of ('YP1 1131 and 
CYPI1132 were purified using Wizard 
PCR Preps I)NA Purification System. 
A single hand with the size predicted 
tier 3 14 hp was indicated. 
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(Figure 111-27) and CYPI 1B2 (Figure 111-28). respectivel`'. [he scyuence anal sis of 
PCR products from regions in which differences exist between ("VP I Ili I and -132 
sequences, was dominated by the CYP IIBI sequence. and that for ('Y P 11112 was not 
observed (Figure 111-29). 
5.2. RT-PCR for 5'-flanking region of CYPI 1BI 
Using RASMC RNA and primers derived from the S'-flanking region and 
exon 2 of CYP1IB1, the expected band was detected. with the sue predicted of 770 
bp (Figure 111-30). No band was detected in negative controls (Figure 111-30). 
Using RASMC RNA and primers derived from the 5'-flanking region of 
CYPI 1131, a single band was detected, with the size predicted of 298 hp (Figure III- 
31). No band was detected in negative controls (Figure 111-31). Sequences of the P('R 
product for the 5'-flanking region of CYP IIBI was 99° o similar to the puhlishcd 
sequence (Figure 111-32). 
5.3. Competitive RT-PCR for 5'-flanking region of CYPI 1BI 
Increasing the concentration of mimic for 5"-flanking region of t'YP 11 Ii 1 
from 0-100 amoles /µl increasingly inhibited the amplification of cndogcno w 
ý'- 
flanking region of CYP 11 BI cDNA from RASMC incubated with 
4if'ti1t-1 t (º 
containing 20% FBS for 48 hours (Figure 111-33). The concentration of 
('YP IIRI 
mRNA in the RASMC was 0.39 ± 0.008 amoles per 5 µg total 
R\., \ (Figure 11 t- 34 !. 
Increasing concentration of mimic for 5'-flanking region of 
(' )P 11 B1 
increasingly inhibited the amplification of endogenous 
5-flanking region of 
CYP 1IBI cDNA from RASMC incubated with SF\1 
with or without fing 11 10 \1 
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CYP11B1(g) ggatggcaatggctctcagggtgacagcagatgtgtggctggcaagaccctggcagtgcc 
IIIIIIIIIIIIIIIII IIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
CYP11B1/2 ggatggcaatggctctcngggtnacagcagatgtgtggctggcaagaccctggcagtgcc 
CYP11B1(g) tgcacaggacgagggcactgggcactacggcaalaMtggcccc©aagacactgaagccct 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIIIIIIIIIIIIIIIII 
CYP11B1/2 tgcacaggacgagggcactgggcactacggcnaaagtggcccccaagacactgaagccct 
CYP11B1(g) ttgaagccataccacaatactccaggaacaagtggctgaagatgatacagatcctgagmg 
III IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
CYP11B1/2 ttgnagccataccacaatactccaggaacaagtggctgaagatgatacagatcctgagag 
CYP11B1(g) agcagggccaagagaacctacacctggagatgcaccaggccttccaQgagctggggccca 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII III111 IIIIIIIIIIII 
CYP11B1/2 agcagggccaagagaacctacacctggagatgcaccaaaa-ttccaaaagctggggccca 
CYP11B1(g) ttttcaggcacagtgcagggggagcacagattgtgtc 
II 1111111111111111111111111111 111111 
CYP11B1/2 ttttcaggcacagtgcagggggagcacagantgtgtc 
Figure 111-27. Alignment of the sequences of RT-PCR products from RASMC 
mRNA amplified with primers derived from homologous parts of the exon 1 and 
exon 2 regions of CYP I1B1 and CYP 11 B2 and the published sequence for 
CYP 11 B 1. CYP IIBI (g): published sequence. CYP IIB1 /2: sequence of amplified 
product. Identical nucleotides in the alignment are indicated by vertical bar. Bases 
indicated in highlighted black represent the bases obtained from the published 
sequence, where differences between CYP 11 BI and -B2 are located. There was a 
96% sequence identity between both sequences. The similarities were compared 
using NCBI's (National Center for Biotechnology Information, NCBI) sequence 
similarity search tool (BLAST). 
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CYP11B2(g) atggctctcagggtgacagcagatgtgtggctggcaagaccctggcagtgcctgcacagg 
IIIIIIIII IIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
CYP11B1/2 atggctctcngggtnacagcagatgtgtggctggcaagaccctggcagtgcctgcacagg 
CYP11B2(g) acgagggcactgggcactacggcaaQastggcccclaagacactgaagccctttgaagcc 
IIIIIIIIIIIIIIIIIIIIIII I 11111111 IIIIIIIIIIIIIIIIIII IIII 
CYP11B1/2 acgagggcactgggcactacggcnaaagtggcccccaagacactgaagccctttgnagcc 
CYP11B2(g) ataccacaatactccaggaacaagtggctgaagatgatacagatcctgagmgagcagggc 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIII 
CYP11B1/2 ataccacaatactccaggaacaagtggctgaagatgatacagatcctgagagagcagggc 
CYP11B2(g) caagagaacctacacctggagatgcaccaggccttccaQgagctggggcccattttcagg 
IIIIIIIIIIIIIIIIIIIIIIIIIIIII Hill IIIIIIIIIIIIIIIIIIII 
CYP11B1/2 caagagaacctacacctggagatgcaccaaaa-ttccaaaagctggggcccattttcagg 
CYP11B2(g) cacagtgcagggggagcacagattgtgtc 
IIIIII1111111111111111 111111 
CYP11B1/2 cacagtgcagggggagcacagantgtgtc 
Figure 111-28. Alignment of the sequences of RT-PCR products amplified from 
RASMC mRNA with primers derived from homologous parts of the exon I and 
exon 2 regions of CYP I1Bl and CYP 11 B2 and the published CYP 11 B2 
sequence. CYP 11 B2(g): published sequence. CYP 11 B1 /2: sequence of 
amplified product. Identical nucleotides in the alignment are indicated by 
vertical bar. Bases indicated in highlighted black represent the bases obtained 
from the published sequence where differences between CYP 11 BI and -B2 are 
located. There was a 94% sequence identity between both sequences. The 
similarities were compared using NCBI's (National Center for Biotechnology 
Information, NCBI) sequence similarity search tool (BLAST). 
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CII AP TF R 111: RF. s( 1.1 
CYP11B1 AG: -. 
CYP11B4 --- r-AGCAGATGTGT CCM 46 
CYP11B2 --- r ',,: AGCAGATGTGTGGC CGCAAGACCCTGGC 54 
CYP11B3 --- , CAGCAGATGTGTGG---GCAAGACCCTGGC 43 
.............................. ............ . 
AG 
CYP11B1 AGTGCCTGCACAGGACGAGGGCACT'; '-; '; -A'7:, ';; '"-"+'. -ACTGA ; 'iJ 
CYP11B4 AGTGCCTGCACAGGACGAGGGCACTGGGCAC: A, GG -:: 'EGA 106 
CYP 11 B2 AGTGCCTGCACAGGACGAGGGCACTGGGCACTACGGA"' -, ACIGA 114 
CYP11B3 AGTGCCTGCACAGGACGAGGGCACTGGGCAGTACGG"-: ', - -ACTGA 103 
CYP11B1 AGCCCTTTGAAGCCATACCACAATACTCCAGGAACAAGTGGCTGAAGATGATACAGATCC I80 
CYP11B4 AGCCCTTTGAAGCCATACCACAATACTCCAGGAACAAGTGGCTGAAGATGATACAGATCC 166 
CYP11B2 AGCCCTTTGAAGCCATACCACAATACTCCAGGAACAAGTGGCTGAAGATGATACJIGATCC 174 
CYP11B3 AGCCCTTTGAAGCCATACCACAATACTCCAGGAACAAG'1GGCTGAAGATGATACAGATCC 163 
ÄA 
YI'l IF'1 TGAC AG A; ;irA';; ivy -TA A ... - 
(: Yf'11B4 Tr; Fý ; ; r; AC; CAGG000AAC'AGAACCTACACi TGGA, 'A- Cri` rt4; vLC; :; ; rli 4. p 
CYP11B2 '1'(, A( (; AGCAGGGCCAAGAGAACCTACACCTGGAGATGCACCAGGCCTT TGG 234 
CYP11B3 TGAGGGAGCAGGGCCAAGAGAACCTACACCTGGAGATGCACCAGGCCTT, TAG 223 
+++++++a""**". ". "+. "*o.. ". """. "". ". +............. """"""" 
11i2 
CYP11B1 GGCCCATTTTCAGGCACAGTGCAGGGGGAGCACAGATTGTGTCTGPGATGCTGCCTGAGG 300 
CYP11B4 GGCCCATTTTCAGGCACAGTGCAGGGGGAGCACAGATTGTGTCTGTGATGCTGCCTGAGG 286 
CYP11B2 GGCCCATTTTCAGGCACAGTGCAGGGGGAGCACAGATTGTGTCTGTGATGCTGCCTGAGG 294 
(; (: ('('('Tk'1'TTTCAGGCACAGTGCAGGGGGAGCACAGATTGTGTCTGTGATGCTGCCTGAC. :ya 
......... ................................................... 
CYP11)3,1 %+GAGTATCCTCCCGCATCGGATGCCCCTGGAGCCGT 3io 
CYP11B. ' r -ýGAGTATCCTCCCGCGTCGGATGCACCTGGAGCCGT 354 
CYP11Bi '+GAGTATCCTCCCGCGTCGGATGACGCTGGAGTCGT 343 
. ...... waaaar.. " **too** 060000 ". s 
CYP11B1 GGGTGGCCCACAGAGAACTCCGTGGCCTGAGACGTGGTGTGTTCTTGCT 409 
CYP11B4 GGGTGGCCCACAGGGAACTCCGTGGCCTGAGACGTGGTGTGTTCTTGCT 395 
CYP11B2 GGGTGGCCCACAGGGAACTCCGTGGCCTGAGACGTGGTGTGTTCTTGCT 403 
CYP11B3 GGGTGGCCCACAGAGAACTCCGTGGCCTGAGACGTGGTGTGTTCTTGCT 392 
faitiaa r+"f a" faaaaaaaaaaaaaaawaaaaaa a" aaaa a" 
Figure 111-29. Nucleotide sequences ofexon I and exon 2 oft he rat ('x'1'1 Ili I. 
-132, -133, and 134 genes. The sequences were aligned using 
the ('1.1 SI., \I, WX 
(1.81) Programme. Identical nucleotides in the alignment are indicated by .. V lx: 
nucleotide nunmber. 1. is assigned to the predominant transcription 
initiation site. 
Primer sequences are highlighted by black. mth arrowheads 
in exon I and 2. 
The direction ofarrowheads is from 5'-end to 3'-end of nucleotides. 
Fxon 1 and 
exon 2 are separated by vertical bars, narking with I and 
2. Ras s indicated in 
red represent the bases obtained from sequences analysis of 
PCR pr ucts. 
%\ here the diflerenres between ('VP 11X31 anti -112 are 
located (highlighted hs 
hike). 
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188 ijPp 
600 bp 
Figure 111-30. RT-PC R for 5'-Clanking region and exon 2 
of C'YP 1 1131 from RASMC mRNA. The expected band 
was detected. with the size predicted of 770 bp. Lane M. 
DNA marker: lane 1. C YP 1IBI (5'-Clanking region and exon 2), 
lane 2-5 negative controls %% ithout the following components: 
reverse transcriptase (in reverse-transcribed reaction) lane I. 
RNA template (in reverse-transcribed reaction) lane 3, cDNA 
lane 4 and Fay DNA pull merase lane 5. 
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344hp 
298 hp º 
220 hp 
-- 298 bp 
Figure 111-31. RT-PUR of RASNiC mRN \ for 5'- 
t1anking region of CYP 11131. Lane M, DNA marker, 
lane I. C YP IIBI 5'-flanking region, lane 2-5 negative 
controls without the following components: reverse 
transcriptase (in reverse-transcribed reaction) lane 2. 
RNA template (in reverse-transcribed reaction) lane 3, 
cDNA lane 4 and Taq DNA polymerase lane 5. 
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iilllilllilllllilill illllilllll{IilllIIIIIIlilýiIIIIIIIIIII 
5'-end(s) taccctatggcaaatggagttcattgttatttctcaatttgaagagaaatgagaaattct 
5'-end(g) aaaagccaacacttaaccgtaaatcacgacagtgagtaaagacccactccctaaatctgg 
IIIIIIIIIIII! IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIHi II 
5'-end(s) aaaagccaacactnaaccgtaaatcacgacagtgagtaaagacccactccctaaatctgg 
5'-end(g) ctagggaattttaaactaggatgaatcattcaaggttccacaaagggaaaatatgtgcat 
II II III III II III III III III III IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
`)'-end(s) ctagggaattttaaactaggatgaatcattcaaggttccacaaagggaaaatatgtgcat 
5'-end(g) ctgacggctctcaccatgggggaggagaaagaaggctctgaccaccattggactattttt 
1111111 IIIIIIIIIIIIIIIIIIIIIIIIIIIIIII111111IIIIIIIIIIIIIII 
S'-end(s) ctgacggctctcaccatgggggaggagaaagaaggctctgaccaccattggactattttt 
`. 5'-end(g) gagtgttaaagtagagtctgcacc 
H IIIIIIIIIIIIIIIIIIIIII 
5'-end(s) gagtgttaaagtagagtctgcacc 
Figure 111-32. Alignment of the sequence of 5'-flanking region for C'YP 11131 
based can the sequences of RT-PCR products from RASMC mRNA and the 
published sequence. 5'-end(g): published sequence. 5'-end(s): sequence of 
amplified product. Identical nucleotides in the alignment are indicated hý 
vertical bar. There was a 99% sequence identity between both sequences. I'he 
similarities were compared using NC13I's (National Center for Biotechnology 
Information. NCIRI) sequence similarity search tool (I3I. AST). 
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500 hp - 400 hp - 
300 hp - 
20() hp - 
Figure 111-33. Competitive R"1'-PCR för 5'-flanking region of('YP1 1131 
in cultured RASMC with RPMI-1640 medium containing 20% I" ISS ft3r 
48 hours. Increasing the concentration of mimic for the 5'-flanking 
region cif CYI' 1 1131 from 0-100 attomoles /µl increasingly inhibited the 
amplification of endogenous 5'-flanking region of (. 'YP11131 cl)NA in 
the RASMC. 
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Figure 111-34. (A) A representative quantitative anal\ sis o fcompetiti\ eRI- 
PUR experiment in cultured RASMC incubated with RPMI-1640 with 20% 
FI3S tor 48 hours. The log of the ratio of the corrected 01) (optical density) 
of the target and mimic was plotted against the log of the attomoles 
concentrations of mimic added to the PCR reaction. The molar amount of 
target added to the reaction is equal to the molar amount cif mimic when the 
ratio of' their products represented as OD is I (lei ratio I: I= 0). (I3) The 
values NNere calculated on the ratio that molar amount of target added to the 
reaction is equal to the molar amount of mimic when the ratio of their 
products is 1. Data are mean ± S. F. M.. N=3. 
k" II yý3ýU 
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for 48 hour,, (Figure 111-35). The concentration «a, ý much lower in cell: maintained in 
SF-'. A1 (0.045 ± 0.002 amoles per 5 LtII total RNA), but «-as ne%erthcless ýi rlýtiýantlý 
increased by Ang 11 (0.076 ± 0.006) (f=igure 111-36.37). 
6. The expression of a putative protein carrier for 18-OH-1)O(' in cultured 
RASM(' 
6.1. Immunoblotting for a putative carrier protein for 18-011-I)OC in R S\1C 
Using immunoblotting analysis a putative 18-OH-I)OC carrier protein ý%as 
detected in cultured RASMC. A single immunoreact i\ c hand was obtained in 
cultured RASMC, with molecular weight approxirnatelý 55 kl)a similar to that 
obtained from rat adrenal tissue (Figure ¢¢i-38). The ratio of the OD) of 
immunoreactive bands to that of adrenal was significantly reduced by preincuhation 
ofthe antibody with authentic 18-011-DOC (P < 0.05. Figure l1(-3')). 
6.2. Immunofluorescence staining for 18-OH-DO(' in RAS\I(' 
t(sing a FITC-labelled second antibody, a cytoplasmic pattern of anti 18-011- 
DOC immunofluorescence was observed in cultured KASMC (Figure 111-40 (A)). 
Negative control slides, from which primary antibody was omitted, remained 
unstained (Figure 111-40 (B)). 
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439 hp mimic 
298 hp 5'-flanking 
0.01 0.02 0.04 (). 0 0.10 
Attomoles of 5-flanking region 
of CYP I1131 mimic- µI 
(A) 
439 hp 
'9x bp 
(1; ) 
uimic 
'-flanking 
Figure 111-35. Competitive RT-PC'R for 5'-clanking region of 
('l'1'11131 in cultured RASMC incubated with serum-tiee 
medium with (A) or without (B) Ang III (1 NI for 48 hours. 
Increasing concentration of mimic for 5 '-flanking region of 
(_'YP 11BI increasingly inhibited the amplification 0f 
endogenous 5'-tlarlkinL rewon of C'YPI1131 cI)NA in the 
R: \SNIC. 
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Figure 111-36. The representative quantitative analysis of 
competitive RT-PCR experiment in cultured RAS MC 
incubated with serum-free medium with (A) or without (B) 
Ang II 10- M for 48 hours. The log of the ratio of the 
corrected 01) (optical density) of the target and mimic was 
plotted against the log of the attomoles concentrations of 
mimic added to the PCR reaction. Hie molar amount of target 
added to the reaction is equal to the molar amount of mimic 
when the ratio of their products is I dog ratio 1: 1 = 0). 
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Figure 111-37. Statistic analysis of competitive PCR experiment 
in cultured RASMC incubated with serum-free medium with 
\ng II 10-' NI for 48 hours. Values were calculated on the ratio 
that molar amount of target added to the reaction is equal to the 
molar amount of mimic when the ratio of their products is 1. 
Data are mcan ± S. E. M.. N=3. * indicates P<0.0 (Student's 
t-tcst). SI'M: serunm-free medium. Anse 11: angiotensin [I W- M. 
* 
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220 kf)a 
1)' kI)a 
66 kDa 
46 kDa - 
A sMMC 
+-+- 
-ill 4w -- 55 kDa 
Figure 111-38. A putative 18-( )1 I-I)O(' carrier protein 
in cultured RASMC' was analysed by immunohlutting 
using 100 tg protein from each of RASMU and 
adrenal tissue. A single immunoreactive band was 
obtained in cultured RASMU. , %-ith molecular weight 
approximately 55 kIa, similar to that obtained from 
rat adrenal tissue. SMC. rat aortic smooth muscle 
cells: A. rat adrenal tissue: +. a putative 18-OI {-I)Oý' 
carrier protein; -, negative control, from . %hich 
primary antibody was omitted. 
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Figure 111-39. As a control for specificity, primary antibody (10-5 
M) for putative 18-OH-DOC carrier protein was used for 
immunoblotting as for Figure 111-38 after first incubating with 10' M 
18-OH-DOC in PBS-T overnight at 4 ". After densitomctrv, the 
quantitative data for 18-OH-DOC-neutralised antibody (SN) were 
expressed as a percentage of the untreated control (S). Ad = adrenal 
tissues, OD = optical density. Data are mean ± S. E. M.. N=3. ** 
indicates P<0.01 (Student's t-test). 
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1. Cell culture 
The cell types that were used in these studies were first characterised hý light 
microscopy and immuno fluorescence techniques. and shown to retain their essential 
characteristics in culture. 
BAEC exhibited a monolayer. "cobble-stone" growth pattern upon reaching 
confluence, which is characteristic of bovine aorta endothelial cells (Figure 111-1) 
(Jaffe 1973, Booyse ei al. 1975. Freshney 1994d). 
BASMC and RASMC exhibited similar growth patterns, in growing out 
slowly from the original explants (Figure 111-2 (A)) in multiple overlapping layers and 
typically exhibited a hill-and-valley growth pattern upon reaching confluence (Figure 
111-2 (B)). The "hill" represents multiple layers of SMC forming a dome-like 
structure. The "valley" represents a monolayer of SMC. Although it is generally 
accepted that this growth pattern is characteristic of cultured SMC. it has been found 
that fibroblasts from the aortic adventitia sometimes exhibit a similar pattern upon 
reaching confluence. Thus the hill-and-valley growth pattern is not the sole 
determinant to characterize cultured SMC (Pang & Venance 1992). 
Cultured cells used in this work were identified and monitored using indirect 
immunofluorescence microscopy. In the case of EC. this may be achieved by 
showing positive staining of either endothelial cell-labelling factor. D1I-Ac-I. DL. or. 
as in the present study. by showing the presence of von Willebrand's factor (Pang & 
Venance 1992. Kessel 1998a, Spadafora-Ferreira et al. 2000). Immunotluorescnce 
showed a cvioplasmic pattern of distribution of this antigen in 13AEC (Figure 111-3). 
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Similarly. VSMC can be identified by the presence of either anti-smooth muscle actin 
or anti-smooth muscle myosin (Pang 1989) though actin staining is considered to he 
more reliable since myosin staining may change during the cell cycle and with culture 
conditions (Pang & Venance 1992). In these studies, the cytoplasmic localization of 
a-actin was demonstrated in cultured RASMC b immunofluorescence (Figure 111-4). 
Ater the first subculture, or passage. the primary culture resembles a cell line 
and may be propagated and subcultured several times. With each successive 
subculture components of the population with the ability to proliferate most rapidly 
will gradually predominate, and nonproliferating or slowly proliferating cells will b 
diluted out. Although some selection and phenotypic drift will continue, hýý the third 
passage the culture becomes more stable, typified by rather hardy, rapidly 
proliferating cells (Freshney 1994e). Therefore, it has become accepted that 
characterization should be repeated after at least every five passages in VSMC 
cultures (Pang & Venance 1992). For this reason, the third to fifth RASMC passage 
was used in this work. 
Because the heterogeneity in growth rate and capacity to differentiate within 
the population can produce variability from one passage to the next. cultures may vary 
significantly in many of their properties between exponential growth and stationary 
phases (Freshney 1994f). It is therefore sometimes critical to take account of the state 
of the culture both at the initiation of an experiment and at the time of sampling.. \s 
an example. it has been found that conditioned medium from confluent bovine aortic 
endothelial cells inhibited the proliferation of aortic SMC. but pre-confluence 
(exponential phase) conditioned medium stimulated proliferation (('astellot er al. 
1981). Though incubation of RASMC (Ullian el al. 1993) and human pulmonan 
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artery smooth muscle cells (HPASMC) (Morrell et al. 1999) with 10-- Mi Ang II for 
48 hours increases protein synthesis. 24 hours stimulation does not. In previous work. 
we demonstrated that conditioned medium from the second passage of (hvpoxic) 
pulmonary artery endothelial cells after 48 hours incubation stimulated the 
proliferation of pig pulmonary artery SMC (PPASMC) and the expression of bFGF in 
PPASMC (Xiao ei al. 1993a, 1993b, 1997). Because of this, in the present study . 
BAECCM was taken from 48 hour (exponential phase) cultures of second passage 
BAEC and shown, like Ang II. to stimulate the proliferation of VSMC. 
SMC can be isolated from regions along the vascular tree. Based on its size. 
location, and histology, the thoracic aorta can be easily recognized, and dissected in 
both newborn and adult rats and is an excellent source of SMC. With careful 
preparation. SMOG isolated from this source are virtually free of contamination by 
other cell types (Pang & Venance 1992). 
SMC can also be isolated from smaller vessels such as arteries of the 
mesenteric bed. However, owing to the size of these arteries, separation of tunica 
media from the intima is difficult and thus contamination with endothelial cells is not 
easily controlled. Primary cultures of SMC from mesenteric arteries contain few 
endothelial cells being lost during subculturing. shown by immunoc,, 1ochemical 
techniques (Pang & Venance 1992). 
One of the advantages of using cultured VSMC as a model to study 
mechanisms of cellular events related to hypertension is that the experimental 
conditions can be readily controlled and manipulated. However. SMC in adult arteries 
seldom undergo cell division unless they are challenged as in repair or in pathological 
conditions. It was earlier estimated that only 0.0400 of SMC in the aorta undergoes 
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mitotic activity (Lombardi et a!. 19{91). Thus, it is extremely difficult to determine the 
cycling time of VSMC in vivo. However, cultured VS`IC' represent an excellent in 
vitro model for the examination of the growth control mechanism in these cells 
without the influence of arterial blood pressure. other cellular and noncellular 
components of the vessel wall. and numerous blood-borne factors. 
2. The expression of renin in cultured BAEC 
Though elements of a tissue renin-angiotensin have been identified in the 
vascular wall of the major vessels (Unger and Gohike 1990,1992. Lindpaintner and 
Ganten 1991, Swales & Samani 1993, von Lutterotti ei al. 1994. Müller & Luft 1998. 
Kubo ei al. 1999, Takai et al. 2001, Berk 2001) there is less general agreement about 
their origin (Samani & Swales 1991, Unger & Gohlke 1992, Okamura et a!. 1992. 
Rosendorff 1996, Admiraal et al. 1999. van den Eijnden 2001). A keß example is 
renin (Taddei & Salvetti 1992). The presence of renin in the vessel wall is 
controversial, although several studies have shown renin activity in vessels (Berk 
2001). The mechanisms of vascular uptake of prorenin and renin and the possibility of 
vascular activation of prorenin has been investigated by using cultured human 
umbilical vein endothelial cells (HUVEC) (Admiraal et a!. 1999). The findings 
provided evidence for mannose 6-phosphate (M-6-P) receptor-dependent endocytosis 
of (pro)renin and proteolytic prorenin activation by vascular endothelial cells 
(Admiraal et al. 1999). Is the renin that has been located in endothelial cells indeed 
synthesised there, or is it taken up from the circulation (Dzau et al. 1993b)? If the 
former, why, it may be asked, should circulating renin evidently be so clearl%- 
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associated with vascular function? If the latter is true. however. what is the function 
of renin uptake? 
This study provides evidence that cultured bovine aortic endothelial cell 
express renin at both the protein and mRNA levels. The results presented here show 
that both prorenin and renin are contained in proliferating. second generation 
endothelial cells maintained in culture for 48 hours. as judged both by 
immunocytochemistry (Figure 111-5). in which immunoperoxidase microscopy 
confirmed the presence of immunoreactive renin within the cytoplasm of the cultured 
endothelial cells, and also the presence in immunoblotting gels (Figure 111-6) of 
immunoreactive bands with a molecular mass of approximately 37-40 kUa. In this 
work, cells were used for immunocytochemistry experiments after 48 hours in serum- 
free medium, as that reported previously (Dostal el al. 1992). Neither renin and 
prorenin have been detected in diluted and deactivated calf serum (Lilly t't al. 1985, 
Freshney 1994g) and serum-free medium (Kesseren et al. 1999). Theret'Ore the 
presence of renin in these cells is most likely to be attributable to in situ synthesis. and 
not to uptake from serum in growth media. However, it has been reported that renin 
and prorenin were detectable in calf serum and horse serum-supplemented medium 
(Kesteren ei al. 1999). Although renin immunoreactivity was present in the 
perinuclear region in neonatal rat cardiomyocytes and fibroblasts, no (pro )rcnin was 
reported to be released into the medium (Dancer et a1.1999). The lack of (pro)renin 
release in combination with the low to undetectable renin mRNA in cardiac cells was 
thought by Danser et al. (1999) not to support the concept of (pro )renin synthesis by 
these cells and the presence of immunoreactive renin might be explained by the cells 
having once have contained renn, not due to local synthesis but due to uptake from 
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the serum to which the cells were exposed prior to the serum-free period ([)anser ei 
al. 1999). Neonatal rat cardiac cells are capable of internalizing both renin and 
prorenin (van Kesteren et al. 1997). The amount of serum to which the cells «cre 
exposed, the serum source, the duration of exposure to serum. and the intracellular 
half life of internalized (pro)renin may differ between studies. and this has been taken 
to explain why under certain conditions renin still is present within cells. whereas in 
others it is not (Danser et al. 1999). 
The 2D 12 monoclonal antibodies directed against human renin. were obtained 
by the fusing of myeloma cells with spleen cells from high-responder Biozzi mice 
injected with pure human renin (Galen ei al. 1984). As usual with antibodies of this 
type, the best evidence for its specificity comes from the repeated studies in the many 
laboratories around the world that have used it. The species specificity of the 
antibodies was initially tested for inhibition of enzymatic activity, and it was shown 
that the activities of hog, mouse, dog. rabbit, and rat renin were not inhibited. 
However, 2D12 antibody was shown to stain renin in the macaque kidney by indirect 
immunofluorescence method. It was also reported that 2D12 reactive (pro)renin was 
present in human pituitary lactotroph cells and prolactin adenomas (Saint-Andre et a/. 
1989) and human pancreas (Tahmasebi et al. 1999). 
Molecular weight measurement showed that renins from various sp t ties are 
monomeric glycoproteins with molecular weight ranging from 36 kI)a to 40 kDa 
(Griending et al. 1993). Molecular weights for renin in human kidney (Yokosa%va el 
al. 1978. Yomosawa et al. 1980) and bovine pituitary (Hirose ei al. 1982) are 41 kIa 
and 36 WiL respectively. Renin mRNA from mouse SMG (Poulkn er a/. 1979. Pratt 
et u!. 1981. Morris & Catanzaro 1981). mouse kidney (Dykes et at. 1995. Poulsen er 
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al. 1980), and human kidney (Parmentier et al. 1982) were shown to encode a 40-5O 
kDa renin precursor, which was consistent with our results. A similar studs has 
reported that the stored renin isoforms in fetal and adult rat kidne` were identified 
either by silver staining or immunoblotting. showing a silver-stained band in the range 
of approximately 45 kDa (Norling et al. 1998). In fetal kidney hornovenate. the 
approximately 45 kDa band had a pI 5.3 +/- 0.1. whereas the corresponding band in 
adult samples had pI of 6.0 +/- 0.05. When Ang I generation was measured to ass& ss 
renin enzymatic activity, there was more inactive and less active renin in total kidney 
homogenate than in adult kidney homogenate. Therefore. it was speculated that these 
variations in stored renin isoforms played a role in the developmental ditlerential 
regulation of the intrarenal RAS. In renal extracts. some renin is present as 'high 
molecular weight (HMW) renin'. a heterodimeric complex of resin with the 46 kI)a 
renin-bining protein (RnBP) (Schmitz el al. 22000) now thought to 
be N-aryl-f)- 
glucosamine 2-epimerase (Takahashi et al. 1999). In fact it appears that renin is an 
inhibitor of N-acyl-D-glucosamine 2-epimerase, and the renin-RnE3p hetcrodirncr 
FIMW is an inactive form of both renin and N-acv l-U-glucosaminc 2-epimerase 
activities (Takahashi et al. 2000). 
Further evidence for renin expression in BAEC was obtained by in situ 
hybridization and by RT'-PCR, both of -which demonstrate the presence of (pro)renin 
mRNA. For in situ hybridization, the specific signals of the antis nse probe %kere 
located in the cytoplasm of cultured endothelial cells (Figure 111-7 (A)). For R 'l -f'C'R. 
a single band was detected with the size predicted. assuming homology with human 
resin, of 141 bp (Figure 111-8). 
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The general strategy was to use the mouse SMOG renin c[)NA as a molecular 
probe to study human mRNA and human renin structural gene (Soubrier ct al. 198.3). 
A comparison of nucleotide sequence of mouse and human renin cl )\, \ clones 
reveals considerable homology. The overall homology between human renal and 
mouse SMG renin is 77% at the nucleotide level in the coding region. Based on the 
high degree homology of the amino-acid and nucleotide sequence in these species 
(Soubrier ei al. 1983, Imai et al. 1983. Burnham et al. 1987. Bader et al. 1994. 
Valdenaire et a!. 1999), the probes and primers derived from human renin sequences 
were used in this work. However it should be pointed out that the nucleotide 
sequences for bovine renin has not been reported. Thus, a more direct approach to the 
questions of renin mRNA expression in bovine endothelial cells is not possible. 
However, in confirmation that the PCR products originated from total RNA and not 
genomic DNA, PCR was performed in the absence of reverse transcriptase and no 
band was obtained for either GAPDH (Figure 111-9) or renin cDNA (Figure 111-8). In 
addition, no signals were detected in negative controls, in which sections were 
hybridized with the sense probe in situ hybrization (Figure 111-7 (B) ). Thus, it may he 
concluded that bovine aortic endothelial cells in culture both synthesize and contain 
renin. This enzymatic pathway within the arterial wall may exert a local control o% er 
vascular vasoconstrictive activity which is not reflected in circulating plasma renin 
levels. 
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3. Ang 11 formation in cultured BAEC and RASMC and its effects on 
proliferation 
In addition to its systemic origin, there is abundant evidence that Ang 11 can 
also be formed by localised tissue renn angiotensin systems. ManN of these. for 
example in the reproductive tract, have been shown to have functions that are distinct 
from those of the vascular and homeostatic roles of the systemic s\ -, tem. 
The concept that Ang 11 is also generated in the vascular wall rather than in the 
circulation, has evolved slowly (Campbell 1985). Though it is known that vascular 
endothelial cells may play an important role in the vascular structural remodelling that 
occurs, for example in chronic vascular disease (Xiao et al. 1993a; h, I'oborek & 
Kaiser 1999, Sica 2000), and it is thought that Ang II may be involved (Berk et ul. 
1989, Scott-Burden et a!. 1991, I)aemen et al. 1991. Duhev et al. 1997). 1n the present 
studies, to further confirm the existence of local renin-angiotensin system 
components, the possibility that Ang II is secreted by these cells and in sufficient 
quantities to affect the proliferation of VSMC was also examined. 
The major requirements for a reliable measurement of Ang 11 are adequate 
sensitivity, specificity and precision in order to achieve the necessary accuracy; and 
appropriate sample handling in order to avoid artifacts. The lower detection limit 
(sensitivity) of Ang II assay used in this work was 3.8 pg'm1 (3.8 frnol/ml). A similar 
sensitive RIA was used to measure Ang II in conditioned medium of cardiomocytc` 
in the presence or absence of serum (van Kesteren et a!. 1999). in which the lowest 
m asurable Ang 11 concentration was 0.1-10 pg/mI (0.1-10 tmo ['ml ). Considerable 
amounts of the closely related precursor and metabolite peptides. tier example- Ang I 
and Ang III can cross-react in RIA. Cross-reaction of more than I°o with : eng 
I ma` 
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be a particular concern. particularly in the presence of low Ang 11 concentrations 
(Nussberger & Brunner 1993). The specificity of the Ang II RI: \ us4 d in this work 
was determined by measuring the cross-reactivity of several compounds at the Ie%eI at 
which 50% of the labelled Ang 11 was specifically bound (Appendix 3). In this wa% 
the cross reactivity with Ang I was 0.1%, and 67% with Anse III (appendix 3). 
Accordingly, it is generally preferable to assay Ang II by RIA after prior purification 
and/or separation from potentially cross-reacting material. However, this may involve 
unacceptable losses, particularly when, as in the present study only low 
concentrations of Ang II were anticipated. High-performance liquid chromatography 
(FIPI, C) was therefore not used. Consequently. the values obtained should kkc 
considered as relating to "immunoreactive'- (ir-)angiotensin II, which is subject to the 
inaccuracies of specificity as outlined. Nevertheless, the measure is still valid as an 
expression of RAS activity, since the most likely cross reactants are derived from this 
system. 
In addition, results of repeated measurement of the same test sample in the 
same assay (intra-assay precision) or in several separate assays ( inter-assay precision) 
should be in good agreement. The degree of such reproducibility can be expressed by 
calculated coefficients of variation (standard deviation as a percentage of the nean). 
For plasma Ang 11 assay. measured Ang 11 levels should demonstrate mean overall 
recoveries of at least 80% for each assay run. and no coefficient of variation should 
exceed 15% (Nussberger & Brunner 1993). In the present experiments, the rcco erics 
for Ang 11 RIA in CM obtained from BAEC and RA-', M(' «ere K7° ö± 4° oad the 
Ang II results were corrected for incomplete recovery. Both intra-as.. ay precision and 
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inter-assay precision (appendix 3) are less than 15° o. These data suggest that the 
precision of this assay was reasonable. 
Normal plasma concentrations of Ang II are in the low picor olar range. that is 
1-10 pg/ml (1-10 fmol/ml) in human subjects eating a regular diet. 1-20 p,! 'ml (1-20 
frnoVml) in rats and dogs, and probably in sheep and monkey also (N ussherecr x, 
Brunner 1993). Our results showed that the Ang II concentrations achieved in 
EAECCM (15.05 ± 4.67 pg /106 cells/48 hours per 10 ml) and R. \SMC'('\l (1 1.1 0 
1.8 pg /106 cells/48 hours per 10 ml) were sufficient to be physiologically significant 
(Figure III-10). This finding is consistent with that of Campbell et al. ( 1993). an 
Kais et al. (1998) and Leenen et al. (1999) in cardiac tissue. According to scv ral 
studies, serum-deprived cardiac cells release angiotensin into the culture nxdium. I he 
Ang 11 levels in the medium, however, showed huge variations, from = 10 pg/ml 11O 
fmoVml) to > 1000 pg/ml (1000 fmoVml) (Sadoshima ei al. 1993. Yama aki et u/. 
1995, Miyata et a!. 1996, van Kesteren et a!. 1999). Some of these discrepancies were 
explained by the fact that Ang 11 were sometimes measured by direct RIA. i. e. with out 
prior purification and/or separation from cross reacting material. It should also be kept 
in mind that, in view of cardiac angiotensin levels measured in VIVO Ang I. pg ( 
fmol/g) wet weight, Ang II, X20 pg/g (20 fnot g) % vet weight (Campbell er a!. 1993, 
van Kats et al. 1998, Leenen et al. 1999). even levels of 5-10 pg'nil (5-1 () fnx)l nil ) 
are eery high. since in most studies medium was collected from only 1-10 x 10)" cell.. 
with an estimated wet weight of less than 10 mg (Yonemochi e< a/. 1 98 ). 
Ang 11 was generally undetectable 1- 3.9 pgý nm1 (3.8 Imo t nil ºj in 
unconditioned medium WM) RPMI-1640 medium containing 22'o rum replacement 
(UM: the medium that had not been in contact with any cultured cells. Sec chapter 
11- 
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2.2.2. for details) (Figure 111-10). This result is consistent that rcportcd h% van 
Kesteren et al. (1999). 
Tritiated thymidine uptake is considered to reflect the S phase of the cell c\ck" 
(Jahan et al. 1996). Because the cell cycle was not ascertained by other means. it %%, aN 
assumed that at the level of cellular proliferation chosen. as judged by inspection. 
many of the total population would be at a similar phase.: corollary of this is that 
when cells are actively dividing, any additional stimulatory effect may be c xpcctcd to 
be slight. Conversely, when cells are relatively quiescent. stimulation may produce a 
greater multiple of basal levels of division, though at a much lower level of activity 
overall. Thus in general the level of thymidine incorporation seen here, though clearly 
low, reflects the relatively inactive state of the cells at the point at which the 
thymidine was added. It brings the advantage however that relative changes brought 
about by stimulation are, as a multiple of basal levels, reasonably high, and clear, and 
indeed statistically significant, as shown. Obviously this is open to considerable 
variation between individual cultures, depending on the cell cycle. Thus the 
incorporation of tritiated thymidine between experim nts, as shown in Figs. I1I -1 1. 
12.13 and 14. is indeed variable (cf Figure II-1). Within experiments. though often 
low. these values are reasonably constant. Confidence in the results is supported hý 
the clear correlations between thymidine uptake and cell numbers (ct: I. s. 111-13 and 
15). It may be concluded with confidence that not only did the conditioned medium 
from exponentially proliferating BAFC contain sting 11 in assayable amounts t Figure 
111-10) but also tritiated thvmidine incorporation into VSMM(' was incrcaud hý 
BAECCM, as well as by Ang II (Figure 111-1 1. Figure 111-13). Both of these 
stimulated increases, by BAECC M as well as by Ang II, w re inhibited b- ki. majv 
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Assay of SMC proliferation by cell number. shoved that proliferative responses in the 
presence of Ang II at a concentration of 10' M were nearly twice those of controls 
after 48 hours (Figure 111-15). The Ang 11 assays on the conditioned medium from 
RASMC suggested that VSMC themselves are one source of this hormone (Figure i II- 
10). 
The paracrine nature of the system is further demonstrated by the presence of 
mRNA coding for ATi1 receptors that was expressed predominantly in the %a'cular 
smooth muscle as detected by RT-PCR (Figure 111-16), as also shown by Dinh ei al. 
(2001). The specificity of the PCR product was tested by restriction enzyme digestion 
analysis of the amplified product (Figure 111- 17). As control. PCR for 'house keeping 
gene' rat GAPDH gene was performed and a single band was obtained (Figure 11I- 
18). These data confirm that the vascular wall is not only a target of Ang II, but also a 
site of its production. The inhibitory effect of the AT, receptor blocker, lokirtan, on 
VSMC proliferation observed here suggests that Ang 11 has a potent capacity to 
stimulate VSMC proliferation. and that this effect may be mediated hý the .\ 
I*, 
receptor. 
That Ang II acts as cellular growth factor and to contribute to atherosclerosis 
and hypertension, has of course previously been suggested (Bobik and Campbell. 
1993). However, the mode by which this effect is achieved has remained a matter of 
controversy (Newby & George 1993). While in sonic studies it has been claimed that 
there are proliferative effects in serum-deprived VS\IC (Komuro et al. 1988. Nakaki 
et at 1989, Sachindis el al. 1992), this has not been sustained by others (Geisterter ei 
al. 1988, Chua et al. 1992. Morrell et al. 1999). one suggestion is that ring t 
promotes mitogenesis, as assessed by DNA synthesis. cell count. or flow c`lometry. 
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when combined either with other growth factors (Bobik & Campbell 1993. \<«bN & 
George 1993, Dubey et a!. 1997, Berk 2001) or with minimal concentrations of : cruet 
(Jackson & Schwart 1992, Janakidevi et al. 1992). It has also been claimed that : fin,: 
II acts as a progression factor but not a competence growth factor in VS\i(' (Jahan er 
a!. 1996). meaning that Ang II has no effect on the cell cycle of G cell., halt can 
stimulate cell cycle progression from the competent G, phase to S and !1 phases. In 
other words, both competence and progression growth factors are required for cells to 
complete a cell cycle, although in some cases individual growth factors may act as 
both. In the present study, the proliferative effects of Ang II were determined on 
VSMC which had been serum deprived for 24 hours and then incubated with s& rum 
free medium with different concentrations of Ang 11. As seen already, tang II had 
significant proliferative effects (Figure 111-13). This result is consistent with the 
findings reported by Jahan et a!. (1996). However. the results do not necessarily 
indicate cell cycle progression from Go phase to the S and NI phase. (Go 
synchronization by serum deprivation was complete (100'6) in \'SNIC in primary 
culture, while it was only partial (< 20%) in passaged cells even after prolonged (72 
hours) serum deprivation (Jahan et al. 1996). It may therefore be that under such 
conditions, Ang II stimulated the cell cycle of the pre-existing G, cells to the S and \1 
phase. Therefore, this finding for VSMC in subculture is still consistent with the 
identification of Ang II as a progression growth factor. as reported by Jahan er al. 
(1996) previously. Proliferative effects of Ang 11 on \'S\i(' in the presence of t ßti 
were also demonstrated (Figure III-15). 
On the other hand. our observations showed that losartan inhibited Nasal 
VSMC proliferation, as reported by Makita et al. (1995). Although tritiated thymidinc 
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incorporation into RASMC was not significantly enhanced bý R,, \SMMCC'\i. it ý%, js 
significantly decreased in the presence of losartan (Figure 111-12). I ritiated the midine 
incorporation into RASMC incubated with SFM alone was also inhibited hN the 
presence of losartan (Figure 111-14). In addition, these results are consistent with the 
data in Figure 111-15 and Figure III-13, in which the number and tritiated thvmidine 
incorporation of VSMC treated by Ang II with losartan was significantly reduced 
compared with that of control. This mechanism may be explained by the following 
possibilities as Makita et al. (1995) suggested. First, the proliferative autocrine or 
paracrine effect of Ang II produced by the local RAS may have been blocked by 
losartan. In their experiment, the ACE inhibitor captopril inhibited the basal tritiated 
thymidine incorporation into human aortic smooth muscle cells to a maximum of 68°0 
below the control value. Second, the synergistic proliferative effect of Ang 11 with 
other growth factors in FBS may be inhibited by blocking the A f, receptor. In 
addition, incomplete Go synchronization in passaged VSMC may also suggest the 
presence of autocrine secretion of growth factors into the scrum-free medium from 
passaged VSMC. The synergistic effect of Ang II and these growth tictors on V'S%I(' 
proliferation may thus be blocked by the AT, receptor block-er. 
In summary, the findings in the present study indicate that the prolitcratke 
effect of Ang II on VSMC may play an important role in the pathogencsis of 
atherosclerosis and hypertension as a growth factor. however, the elucidation of the 
mechanism involved in VSMC growth requires further investigation. 
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4. The role of aldosterone in the proliferation of V'S%IC stimulated by Ang 11 
Since it is known that aldosterone may play a role in raising blood pressure h\ 
modulating human vascular smooth muscle tone (Pirpiris el al. 1992. Cody 1997. 
Müller 1998, Weir & Dzau 1999), the present study was undertaken to investigate the 
possibility that smooth muscle cell proliferation induced by Ang 11 may be mediated 
by aldosterone. The results showed not only that RASMC can produce 
immunoreactive aldosterone, but also that Ang II enhanced aldosterone fornation 
(Figure 111-19), in a biphasic manner, since it was unaffected at micromolar 
concentrations, though stimulated at lower concentrations. This was not well 
correlated with tritiated thymidine uptake which was nevertheless still stimulated by 
micromolar concentrations of Ang II (albeit at a somewhat Io%%er level that shown at 
0.1 µmoVl) (Figure 111-13). However, since the Ang 11 stimulated proliferation of 
these cells, as judged by tritiated thymidine uptake (Figure 111-20). was inhibited hy- 
spironolactone the results further suggest that the action of Ang II is indeed at least 
partly mediated by aldosterone (Figure 111-20). The levels of aldosterone secretion 
from intact rat zona glomerulosa cells (2-4 x 105 cells) incubated in I ml of Krebs 
bicarbonate Ringer containing glucose (200 nig ml) and bovine serum albumin (20f 
mg/ml) for 2 hours was 21.98 ± 1.56 pmoVml (Kapas et a!. 1991). AIthough the level 
of production of aldosterone in vascular cells is clearly lo%%cr than in the adrenal 
cortex, the limited space within the vessel wall could result in local aldosteronc levels 
that exceed those in the plasma (Hatakeyama cl al. 1994). A similar stud involving in 
Ang 11 and the formation of aldosterone in vessel %%all cells suggested that Ang 
II 
stimulated aldosterone synthesis in cultured hcwine aortic endothelial cells (Brilla et 
a!. 1992a). 
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The specificity of the aldosterone RIA was determined bv measuring the 
cross-reactivity of several compounds. However. the cross-reactkits of cortico"tcronc 
(<0.01%) and 18-OH-DOC (<0.02%) taken in this work is somewhat higher than that 
previously obtained by this laboratory (Figure 11-22. in house data: Appendix 4). We 
cannot explain this discrepancy and further studies need to be done. Nevertheless. the 
lack of evidence for corticosterone output still suggests that aldosterone was indeed 
the major analyte. Values for 18-OH-DOC production could not he obtained in the 
absence of a suitable RIA label, though the presence of 18-OI1-DOC is reasonable. 
Although aldosterone alone did not significantly change tritiated thvmidinL 
incorporation in RASMC (Figure 111-22). the Ang 11-induced increase in tritiated 
thymidine incorporation was significantly enhanced by aldosterone (Figure 111-21). 
The present data were consistent with those reported by U11ian et al. (1993), who 
showed an enhancement by aldosterone of Ang 11-induced protein synthesis in 
RASMC. tlllian et al. (1993) explained the aldosterone effect by the finding that the 
steroid increases Ang II receptor concentration (by preventing Ang I1-induced down- 
regulation of Ang II surface receptor). and sensitizing inositol phosphate formation. 
thereby leading to an increase in protein synthesis (t 1llian cr u/. 19922). The present 
results with aldosterone and Ang 11 in VSMC and the blocking of prolitcration hý the 
aldosterone receptor antagonist spironolactone is also consistent with this mechanism 
since Ullian et al. (1993) and Hatakeyama et a!. (1994) showed that the a1dostcrone 
antagonists spironolactone and ZK91587 may hk'ck the et1cct of Ang It on the 
mineralocorticoid receptor-mediated regulation of Ang 11 receptors. In the preunt 
experiments. the fact that spironolactone also inhibited the 
`I1-thymidinw uptake at 
non-stimulatory levels of Ang II suggests a basal level of steroid 
biosynthesis in these 
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cells (Figure III-20). That this is a mineralocorticoid receptor-mediated effiect is 
suggested by the reported specificity of spironolactone, as a mineralocurti<oiJ 
receptor antagonist (McInnes and Ramsay 1987). though it remains possible that other 
steroids or receptors may be involved, since spironolactone may not onk act as a 
potent mineralocorticoid antagonist, but also directly interfere with the bias nthcs of 
aldosterone and other corticosteroids in the adrenal cortex (Müller 1988b). Several 
reports have also suggested that spironolactone can antagonise steroids binding to 
type II (glucocorticoid) receptor (Campen & Fanestil 1982, Couette ei al. 1992) or 
indeed androgen receptors (Nirde et al. ? 001. Vinggaard ei a!. 1999). Although the 
glucocorticoid, dexamethasone. inhibited the Ang 11-stimulated protein synthesis in 
cultured RASMC (Ullian et al. 1993), incubation of cultured human fibroblasts with 
dexamethasone resulted in up-regulated binding of epidermal growth factor and 
potentiation of epidermal growth factor-stimulated mitogenesis (Baker et al. 1978). 
However, inhibition of cultured bovine VSMC replication by corticosteroids has been 
reported previously (Longenecker ei al. 1984). The relative importance of 
glucocorticoid and mineralocorticoid involved in the proliferation stimulated by Ang 
II has yet to be established. 
Some evidence suggests that freshly removed VSM(' contains I1 ti- 
hydroxysteroid dehydrogenase, which may inactivate the mineralocorticoid anti. its of 
11 ß-hydroxysteroids such as cortisol, and prevent vlucocorticoid actin ation of 
mineralocorticoid activated pathways (Funder et at 1989. Walker el al. 1991 ). As 
further evidence of the steroidogenic potential of im adrenal tissues. 
311- 
hydroxvsteroid-dehv dogenase has been demonstrated in filial and hwann calls 
(Koenig et al. 1995). but it is unclear whether 3ß-hydroxysteroid-dehydfogcn x4 
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catalyzing the conversion of pregnenolone to progesterone and 17a- 
hydroxypregnenolone to 17a-hydroxyprogesterone (cf. Figure I-16) in the adrenal 
cortex and gonads, is involved in the (at least partly) aldosterone-mediated Ang 11- 
stimulated VSMC proliferation. As evidence that this may be the case, the 30- 
hydroxysteroid-dehydogenase inhibitor trilostane was also used in this work. The Aniz 
II-induced increase in tritiated thymidine incorporation into RASMC was 
significantly inhibited by trilostane at 10'6and 10-5 M (Figure 111-23). In addition, the 
significant increase in RASMC cell number at IO-7 M Ang 11 compared with that of 
control was also inhibited by trilostane at 10'6 and 10"5 M (Figure 111-24). These 
findings suggest that it is more likely that vascular steroid participates in regulation of 
VSMC proliferation in an 'autocrine' or 'paracrine' manner rather than via the 
systemic circulation. a conclusion consistent with those of Duprez et al. (2000) and 
Berk (2001) in recent reviews. 
In short, these data provide further evidence for the close links between 
between aldosterone and Ang 11 in blood pressure regulation. 
5. CYPI IB gene expression in cultured RASMC 
With more recent descriptions of aldosterone formation in sites other than the 
adrenal, for example in the vasculature (Hatakeyama et al. 1994. Silvestre cr a1. 
1998). its biosynthetic origins need to be examined. and. in particular, the presence of 
the CYPIIB genes involved in late steps of mineralocorticoid and glucocorticoid 
synthesis in these tissues becomes of interest. It is unclear whether both CYP 11131 
CYP I1 B2 are involved. as has often appeared to be the casc in rat adrenal (Boon et of 
1996, Müller 1998). The present study examined C VP I 1131 and 
C YP 11 A2 expressk, )n 
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in cultured RASMC by RT-PCR using the primers chosen in homologous parts of the 
exon I and exon 2 regions of CYP II BI and CYP I1 B2 (Figure 11 -6). As shown in 
Figure 111-25, a 314 bp amplified product corresponding to transcripts a region 
common to CYP IIB1 and CYP I1 B2 was obtained. After purification, the R"I -P('R 
products gave a single band with the size predicted for 314 bp (Figure III-. 6 ). ýtýhý" 
sequences of the PCR product for CYP IIBI and CYP I1 B2 was 96°o and 94° o 
similar to the published sequence of CYP IIBI (Figure 111-27) and CYP I 1132 (l`igure 
111-28), respectively. The sequence obtained from analysis of PCR products in which 
differences between CYP1 I BI and -B2 are located, was in fact dominated by the 
CYP11 BI sequence (Figure 11-29). These data suggest that transcription of rRN: \ 
coding for CYP I1BI occurs in cultured RASMC. but it is difficult to be sure that this 
is true for CYP II B2. This finding is similar to a previously study (Gomez-Sanchez er 
al. 1997). Aldosterone synthase (C'YP1IB2) mRNA and activity and C'YP11HI 
mRNA has been reported to be expressed in human endothelial cells (Takcda et a!. 
1996), rat mesenteric arteries (Takeda el al. 1994) and heart (Silvcst re et at 1998). 
though the latter finding was not confirmed by Gomez-sanchef et al. (1997). 
However, in the rat adrenal, 11 P-hydro xy 1ase, the product of" the ('VP IIliI 
gene, converts 1 1-DOC to corticosterone and 18-OFl-DOC and is expressed mainly in 
the zona fasciculata of the adrenal gland (Don lik et al. 1991, Yabu er al. 1991.11O . 
Vinson 1993. Miller 1998). Aldosterone synthase. the protein product of the 
CYP1 I B2 gene, and the final enzyme in the aldosterone hios nthetic pathwa . 
hydroxylates DOC to corticosteronc. 18-OH-I)OC. 18-hydroxNcorticostcron and 
aldosterone is expressed exclusively in the in zona glomeruloki 
in the rat adrenal 
(Dornalik et al. 1991. Yabu et al. 1991. Ho & Vinson 1993. \1 
11Cr 1998). Comersch 
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in some other species, notably the bovine, a single C'VPI I E3 giv-eý, both 
glucocorticoids in the fasciculata and aldosterone in the glory rulosa (Agarr-al 
Mirshahi 1999). Clearly it is necessary to ascertain the molecular mechanism.. for 
steroid synthesis in the vasculature, and to determine whether they are similar to the 
adrenal. The finding of 1lß-hydrox}lase would seem to be insufficicnt to account for 
aldosterone production, given that, in the adrenal at least, a mimimuni of' three 
cytochrome P-450 species and one dehydrogenase/isomerase system are required I'm 
aldosterone synthesis, i. e. CYP IIA (cholesterol side chain cleavage 13450), . 1s, 3(i- 
hydroxysteroid dehydrogenase/isomerase, CYP21 (21-hydroxv last) and Cu 1' 11132 
(aldosterone synthase) (cf. Figure 1-16). Furthermore, the regulation of aldosterone 
synthesis is thought to take place at least at two of these steps in biosynthesis, namely, 
at the point of cholesterol side chain cleavage and at a late pathway stage, presumably 
involving aldosterone synthase (Vinson el al. I992a). It will be necessary in the future 
to establish whether all these steps can occur locally within the vasculature. In 
addition. it is desirable to perform RT-PCR using specific primers for ('YPI1lit. 
combined with detection of PCR products by Southern blot hybridization analysis t' or 
its demonstration (Mellon & Deschepper 1993). because this method can be used to 
detect PCR products that are not abundant enough to be detected by ethidium bromide 
staining (Ohara et a!. 1989). It has been suggested that the mRNA expression of 
CYP11 B2 is very low in heart (Silvestre et al. 1998). The cardiac C'VP11III mRNA 
was 7-fold higher than that of CYPIIB2. In this case. competitive inhibition may 
result in the predominate amplification of cDNA for CYP IB1 ww hen primers dcri%cd 
from homologous parts of CYP IIBI and CYP 11132 are used. 
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The CYPI I BI and CYPI I B2 genes are highly homologous in their amino 
acid coding region and nucleotide identity. The numbers and locations of the exons of 
these genes also exactly correspond to each other. however, the nuclcotide sequ it 
of the 5' upstream regions of CYP 11 BI and CYP 1 11322 are significantly ditlerent. 
suggesting different transcriptional regulation (Nomura ei al. 1993). Mukai et cal. 
(1991) have previously reported that CYP 11 Bl has multiple transcription initiation 
sites in at least the 200-nucleotide upstream region of the major transcription initiation 
site. The present experiments clearly demonstrated the transcription of the sequences 
183-480 bp upstream from the gene. The result suggests transcription of the 
sequences, as judged by RT-PCR (Figure 111-31) and the sequence of the Rl -PCR 
products (Figure 111-32). Moreover, RT-PCR using a second pair of primers spanning 
intron I gave a band corresponding to the 770 bp fragment from bases -4K6 
(upstream) to + 284 (exon 2) bp of CYPI I BI gene (Figure I11-30). Furthermore. 
results from competitive PCR suggest that the concentration of C'YPI 1131 mRNA in 
the RASMC maintained in 20% FBS was 0.39 ± 0.008 attomoles per 5 µg total RNA 
(Figure 111-33,34). The concentration was much lower in cells maintain d in til `1 
(0.045 ± 0.002 attmoles per 5 µg total RNA), but was nevertheless signiticantlý 
increased by Ang 11 (0.076 ± 0.006) (Figure III-3-5.36.37), suggesting that this may 
contribute to the increased synthesis of aldosterone stimulated hw Ang I I. I hes 
findings may suggest the expression of a RASMC specific CYP 11 !i1 isoform. 
Although conjectural in this case at present. there is much evidence tOr altcrnati%c 
splice sites in many other genes e. g. in rat renin (I. ee-Kirsch yet at 1999) or the 
human 
oestrogen receptor (Zhang et a!. 1996). Rl -PCR analysis for ('VP! 1RI gene (Figure 
111-25) and the fragment from bases -486 (upstream) to - 
284 (exOn 2) hp of 
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CYPI I BI gene (Figure 111-30) suggests the presence of a noel transcript of rat 
C YP 1lBI gene in cultured RASMC (Mukail et al. 1991). 
In the first place. it is remarkable that though aldosterone output On the 
adrenal the product of CYPI1B2) was detected in the VS\1(' culture medium. 
corticosterone was not, or was not detectable, although the RIA sensitivities for 
aldosterone [34 f nol (11 pg) aldosterone/assay tube] (Kapas el al. 1992) was not too 
dissimilar to that for corticosterone [88 fmol (30 pg) corticosterone assa\ tubel, 
respectively. However the values for aldosterone are still low, even in stimulated 
tubes. although it is evidently sufficient for biological action (see discussion page 
244). Because the output of steroid is slight, it remains possibly that low though 
undetectable values of corticosterone we found. In contrast. the R"I'-PCR evidence 
suggests the presence of CYP IIB1. but not convincingly for CYP 11 E32. Furthermore 
competitive PCR clearly shows that in the VSMC. it is CYP IIBI that is enhanced by 
Ang 11, when it is known not to be in the adrenal (Boon et at. 1997. Müller 1998). 
These data suggest that CYPl1BI in the vasculature may, have ditli`rent properties. 
compared with the adrenal. and it may also be that its functional significance is quit, 
different in its primary relationship to VSMC function and. quite possibly. to blood 
pressure regulation. There is now a need to clone and express the %ascular form of 
the enzyme, to determine its enzymatic activities; e. g. I1P, 18. and 19-hy dro\N-tation. 
and of course. aldosterone synthesis. Another point of interest is whether there might 
be differences between the two promoters in their responses to PKA cAMP. I akinL 
all the related data together. these findings may provid evidence for a no el pathway 
of intracellular aldosterone generation that occurs ýýxriusiýýc iý in the % uiaturt . 
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6. The expression of a putative protein carrier for 18-OH-DOC in cultured 
RASMC 
In the adrenal, exact mechanisms for the regulation of aldosterone 
biosynthesis remain somewhat enigmatic. Although the central importance of the 
CYP JI B2, aldosterone synthase, is well known (Lauber et al. 1987. Okamoto & 
Nonaka 1992), an extensive earlier literature described the "late pathway" site of 
regulation, which held that the conversion of corticosterone. or of 18-011-DO C. was 
affected by stimulation for example by angiotensin II or by a low sodium diet (Fattah 
et a/. 1977, Aguilera & Catt 1978, Aguilera et al. 1980). However, this concept 
became more difficult to sustain with the revelation firstly that CYP11132. located 
exclusively in the glomerulosa, could catalyse all of the supposed steps between IX)C 
and aldosterone (Okamoto & Nonaka 1992), and secondly that CYP 11131, the enzyme 
that gives rise to both corticosterone and 18-OH-DOC. is. in the rat adrenal. expressed 
exclusively in the fasciculata/reticularis (Ogishima et al. 1992. Ho & Vinson 1993. 
Haider et a!. 1998). Nevertheless, earlier studies had suggested that 18-011-DOC 
might be contained in a compartment. perhaps by binding to a carrier protein, that 
made it available as an aldosterone precursor (Vinson & Whitehouse 1973. 
Whitehouse & Vinson 1971. Vinson et al. 1992b, Vinson et a!. I995b). A pool of 
tissue 18-OH-DOC associated with a protein carrier has been postulated to contribute 
to this process in the rat adrenal (Vinson et al. 1995b). The present studies showed by 
western blotting (Figure 111-38,39) and immunofluorescence (Figure 111-40) that a 
very similar protein may also exist in the aldosterone-synthesising RAS\1('. The 
reasons are as follows. This antibody was raised to 18-O11-DOC coupled to 
kc, tx)kk 
limpet haetmprotein (Vinson et al. 1995b). and although cross rcactivit% to 
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mammalian protein cannot be ruled out on this basis alone. it is not generally 
considered likely. The antibody does react with 18-OH-DOC in a specific manner 
however (Vinson el al. I995b). It may be considered that immunocvtochcmistrv 
(Figure 111-40) reveals only the presence of the steroid and not a steroid-protein 
complex. However, the immunofluorescence results may still suggest the existence of 
carrier protein (or other component, though it is difficult to imagine what else it might 
be) that stabilises the steroid in the tissue section. (Hancock 1997). The further 
evidence from gel separation (Figure 111-38) strongly supports this view. Uncharged 
free steroids do not migrate on electrophoresis. The bands obtained therefore certainly 
imply association with a protein, moreover, seemingly a specific one, since only one 
band (or just occasionally two bands of very similar size) has ever been detected in 
this way. To further test the specificity of the anti-18-O11-DOC antibody, it was 
preabsorbed with excess 18-OH-DOC. This significantly reduced immunoreaction 
with the vascular component, though it was not eliminated (Figure 111-39). This may 
be because in high concentrations the free steroid tends to dimerise (Dominguez 
1965), and the dimer is not immunoreactive. Incomplete saturation has also been 
attributed to other factors in different applications (Roitt et al. 1998). 
Studies to characterise this protein are in progress. Though steroid binding 
proteins have often previously been thought to be necessary to account for intra- (or 
indeed inter-) cellular transport of steroid within endocrine glands. With the relatively 
recent exception of StAR (Stocco 2000) few candidates have been isolated (Park et a!. 
1999, Javitt et al. 2001). The identification of the inner zone antigen (IIA) as a 
putative membrane associated progesterone receptor is certainly of interest 
in this 
context. so the concept is not without support (Rata et a!. 2001). 1Io`%ever" another 
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possibility that cannot be overlooked that the 18-01-1-1)O binding protein in the 
vasculature is in fact a receptor. Although early interest in the hvpºerten, ýivc 
significance of l 8-OH-DOC in the human eventually faded (\telbý et al. 1972). there 
remains a convincing multiplicity of evidence from the Dahl strain salt st nsitwe rat 
that vascular sensitivity to 18-OH-DOC is in fact the key mediator of this 
phenomenon (Okamoto et al. 1995). The intriguing finding that CYPI 1131 is normal 
in the salt-sensitive rats, but mutated in the normotensive salt resistant Dahl rat 
(Matsukawa et al. 1993, Nonaka et al. 1998) is evidence for this concept, but has 
certainly not been fully explained. It will be interesting to examine vascular 
steroidogenesis in these animals. Clearly there is scope for much future work on this 
topic. 
In conclusion, this work provides evidence that 1) components of the renin- 
angiotensin system are expressed in the vascular wall; 2) the vascular aldosteronc may 
participate in maintaining or enhancing the effects of the vascular renin-angiotensin 
system. perhaps completing a vascular renin-angiotensin-aldosterone system; 3) the 
vascular cells are steroidogenic, and respond to Ang II stimulation. Moreover, the 
present study demonstrates for the first time that a longer fragment of the C [)1 1131 
gene than the known CYP 11 B1 gene may be transcribed in cultured VS MC and 
regulated by Ang II. 
7. Future work 
The work described in this thesis highlights several novel area. for further 
study that are relevant to understanding the angiotensin and steroid mediated 
mechanisms for VSMC proliferation. and. ultimately. hypertension. 
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In part this arises because there are aspects of these studies for «hich complete 
interpretation remains elusive. In the first place, though the requirement for the steroid 
contribution to Ang II stimulated proliferative events is clear, the identity of the 
steroid(s) involved is not absolutely established. Thus aldosteronc is only et1cctive in 
the presence of Ang II, which does not suggest it is the only means hý which : eng 11'.,, 
actions are mediated. There are probably different ways in which the specificity of 
the responses to steroid may be confirmed, but the most obvious would be to use a 
range of related and unrelated steroids for comparison with the actions of those 
known to be present. namely aldosterone and 18-h`ydrox`, deoxycorticosterone, and, at 
the same time, continuing the analysis of conditioned media for other steroids, using 
RIA and, eventually, gas chromatography-mass spectrometry (GC-MS) methods. 
The next problem that requires to be addressed is the mode of synthesis of the 
steroid(s) involved. Is aldosterone formed by the conventional pathway'' Are all of the 
enzymes present in the vasculature? As it happens, of the steroidogenic enzymes, the 
evidence presented here suggests that it is CYP 11 BI that primarily was transcribed in 
rat cultured VSMC, yet this is most usually associated with production of 
corticosterone, not aldosterone, in the rat. However, corticosterone as not abundant 
(although, seemingly, its biosynthetic companion, 18-011-DOC. was present). 
However, there are oddities about this enzyme: its RNA transcript as uncxp ctcdlý 
long, with an initation site well into the 5' region. and furthermore, it was apparently 
regulated by Ang II. Since this is not the case in the adrenal. further investigation of 
the fate of this transcript is essential. Does it code for another t erm of the protein: ' If 
so, does the expressed enzyme have different activities from ('VP i1ß1 and 
CYPI 1132? Is it able to synthesise aldosterone? \Vhat substrate does 
it utilwk'' This 
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would be a large programme: first it is necessary to characterise the full length of the 
transcript, then to determine whether any possible variant in C'A'P 1 1131 protein sire is 
possible, and finally to seek its presence in VSMC. Cellular expression. incorporating 
the steroidogenic electron transport chain, would be required to obtain a system tier 
studying its capacity to metabolise steroid. 
Finally, it will be informative to study these mechanisms in known models ()I 
hypertension in the rat. Preferably these studies should be conducted using tissue 
both from animals known to be hypertensive through mechanisms related to the R: \S 
such as the spontaneously hypertensive rat, SHR (Cheng et cal. 1998. Reaves et a!. 
1999, Jurkovicova et al. 2001), and those in which the RAS is clearly not involved, 
An important model to study here would be the Dahl rat, for which the cause of 
hypertension is clearly closely related to CYPI IBI and the formation of l8-01l-[)(X" 
(I)iPaola et al. 1997. Strehlow et al. 1999. Cicila et a!. 2001). In vie of the 
probability that an 18-O11-DOC binding protein is present in VSMC, as in the 
adrenal, this is a pressing need. 
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1. Gel buffer system for Western blotting 
The buffer system is composed of buffer used in the vcl and the running 
buffer. 
There are continuous and discontinuous buffer system. 
Discontinuous buffer system 
In discontinuous buffer systems different buffers arc present in the gel and 
electrode reservoirs. By using different buffers in the gel and in the electrode 
solutions and adding a stacking gel to the resolving gel, samples are compressed into 
a thin starting band and individual proteins are finely resolved and separated. 
SDS-PAGE buffer system is a discontinuous buffer s stem that incorporate' 
SDS in the buffer. In this system, proteins are denatured by heating them in buffer 
containing sodium dodecyl sulfate (SDS). Formulations for this system were included 
in followings: 
Discontinuous sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) preparation 
Separating gel (7.5°/o Stacking gel Wo 
Reagents polyacrylamide) p0 ly acrylamide ) 
Distilled water 5.47 ml 6.4 ml 
1.5 M Tris-HCI. pH 8.8 2.5 ml 
0.5 M Tris-HCI, pH 6.8 I5 ml 
10% (w/v) SDS 100 µl 100 µl 
AcrylamideBis (40% 1.88 ml 1 ml 
stock) 
10% ammonium persulfate 50 µl 
50 µl 
(fresh daily) 
TEMED 5µl 10 
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Continuous buffer system 
In continuous buffer system the same buffer are present, at constant p}U in thc" 
gel and electrode reservoirs. In contrast to the SDS-PAGE butler system. continuous 
non-denaturing PAGE buffer system is designed to fractionate a protein mixture in 
such a way that subunit interaction, native protein conformation, and biological 
activity are preserved. Formulations for this system were included in followings: 
Continuous non-denaturing PAGE preparation 
Separating gel (7.5% 
Reagents polyacrylamide) 
Distilled water 5.57 ml 
1.5 M tris-HC1, pH 8.8 2.5 ml 
Acrylamide/Bis (40% 1.88 ml 
stock) 
10% ammonium 50 . t1 
persulfate (fresh daily) 
TEMED 51 
2. Agarose gel electrophoresis 
Electrophoresis buffers 
0.5 M EDTA (pH 8.0) 
Dissolved 148.88 g EDTA in 780 ml deionized water and pH adjusted to 8.0 
using NaOH pellets (about 20 g). Final volume made up to 800 mL stored at room 
temperature. 
Tris-acetate (TAE) buffer (50 x) 
242 g Tris base 
57.1 ml glacial acetic acid 
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100 ml 0.5 M EDTA (pH 8.0) 
All dissolved in 800 ml deionized water. Final volume made up to 1000 ml. 
stored at room temperature and diluted 1: 50 before use. Working solution (x 1): 0.04 
M Tris-acetate and 0.001 M EDTA. 
Tris-borate (TBE) buffer (x 5) 
54gTrisbase 
27.5 g boric acid 
20 ml 0.5 M EDTA (pH 8.0) 
All dissolved in 800 ml deionized water. Final volume made up to 1000 ml, 
stored at room temperature and diluted 1: 5 before use. Working solution (x 1): 0.045 
M Tris-borate and 0.001 M EDTA. 
Preparation of agarose gel 
A aliquots (1.4g) of powdered agarose was added to 100 ml Ix TBE buffer in 
a glass bottle with a loose-fitting cap. The slurry was heated in a microwave oven 
(70% power, 3 min) until the agarose dissolved. The solution was cooled to 60°C .4 µl 
of ethidium bromide from a stock solution of 10 mg/ml in water was added to the 
solution to a final concentration 0.2 µg/ml and mixed thoroughly. After the gel as 
completely set (30-45 min at room temperature). 10 µl aliquots of sample was loaded. 
The gel was run overnight for 30-45 min at 80 volt at room temperature. 
The gels cast with low-melting-temperature agarose were chilled to 4''(' and 
run in the cold room. 
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3. Etiafuation of Ani; II RIA (data from Ang If RIA kits) 
S} NSI lI\'ITY: 
The sensitivity of the assay was measured as the lo«est measurable concentration. 
ýk hich is 3.8 pg/ml (3.8 fmoVml). 
INTRA-ASSAY PRECISION: 
Analysis of one sample (42 pg/ml; n= 10) using the same batch of antib ode . 
% coefficient of variation: 4.0%. 
INTER-ASSAY PRE'; C`ISION: 
Analysis of one sample (31 pg/ml: n= 6) using ditlerent batches ofantitx)dy . 
coefficient of variation: 5.1 %. 
S1'FC'IFIt'ITY ANI) CROSS-R[AC i'1V[I'Y: 
The specificity was determined by measuring the cross-reactivity at the point at which 
50% of the labelled Ang II was specifically bound. 
Cross reactivity with other angiotensins 
Compound % C'ru. v s Rc'aclivi1y 
Asp -11eä - 1ng II 100.0 
.. \sp'-11en5-Ang 1 
0.1 
., %sn'-Va15-: \. ng 11 
30 
tiara-Ileu8-Anv 11 0.0_ 
Vals-Ang 11 100 
llcu-Heptapeptide (: fin! III) 67 
: \ng II (-'-10) 0. - 
Ang 11 (3-8) 70 
Ang11(4-8) 91 
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A TYPICAL % RECOVERY CALCULATIONS FOR ANG 11 ASSAY: 
% Recovery data for Ang II assay 
R CPM CPM kR 
3546 126 
35 1293 
v 3544 12814. 
CPM; counts per minute; TR: total 
recovery tube; R: recovery tube; %R: % 
recovery. 
% Recovery - 
CPM Recovery Tube 
` 
1.0 nil \ 100 
CPM in total Recovery Tubes 0.4 ml 
=. 12814.5 x 
1.0 ml x 100 
35405 0.4 ml 
= 90 
4. Evaluation of aldosterone RIA (in house data) 
SENSITIVITY: 
Amount of unlabelled aldosterone that can be accurately measured (n = 40). 
2 standard deviations from the mean zero point = 34 fmol. 
INTRA-ASSAY PRECISION: 
Analysis of one sample (50 frnoles/100 µl; n= 20) using the same batch of antibod` . 
coefficient of variation: standard deviation/mean x 100 = 5° 
INTER-ASSAY PRECISION: 
Analysis of one sample (250 fuoles/100 µl: n= 20) using 
different batches of 
antibody. 
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% coefficient of variation: standard deviation/mean x 100 = 11 ° ö. 
SPECIFICITY AND CROSS-REACTIVITY: 
The specificity was determined by measuring the cross-reactivity at the point at which 
50% of the labelled aldosterone was specifically bound. 
Cross reactivity with other steroids 
Compound % Cross Reactivity 
Aldosterone 100.0 
Corticosterone < 0.001 
Cortisol < 0.001 
Cortisone < 0.001 
DHEA < 0.001 
DHEAS < 0.001 
DOC 0.002 
18-OH-B --0.001 
18-OH-DOC 0.002 
Pregnenolone < 0.001 
Progesterone < 0.001 
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